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Anaesthesia, sedation and analgesia, currently administered via injection and 
infusion, cause pain and have risk of systemic adverse effects. We have 
explored the alternative topical and transdermal formulations of anaesthetics, 
analgesics and sedatives for the treatment of peripheral neuropathic pain and 
procedural sedation. 
 
Topical delivery of amitriptyline and ketamine may provide substantial pain 
relief for peripheral neuropathic pain with improved local efficacy and less 
systemic toxicity compared to their oral and intravenous administrations. 
Firstly, an amitriptyline hydrogel with chemical penetration enhancers (CPEs) 
was developed and drug permeation studies were conducted using the in vitro 
human epidermis permeation model. Menthol 5% w/v significantly increased 
the permeation of amitriptyline 292-fold compared to the permeation of same 
drug from a hydrogel without CPEs. Meanwhile, a preliminary accelerated 
stability test indicated the formulation to be stable. An isothermal titration 
calorimetric (ITC) investigation revealed that CPE interacted with the stratum 
corneum lipids and also with the drug to form a complex. Secondly, an 
amitriptyline and ketamine hydrogel with CPEs was developed and optimised 
by binary concentration screening of all the CPEs tested. Farnesol 0.5% v/v 
achieved the highest enhancement for both amitriptyline and ketamine. The 
stability study showed that the hydrogel remained stable for 6 months when 
stored at 4°C. A LC/MS/MS assay of amitriptyline and ketamine was 
established and validated for simultaneous detection. This is the first time that 
in vivo pharmacokinetics and tissue distribution of topically applied 
amitriptyline and ketamine have been reported. The systemic plasma 
concentrations and systemic tissue distribution of the drugs were minimal. The 
drug concentrations were higher in the skin and muscle tissues, which are the 
 x 
 
targets sites for neuropathic pain. This is also the first attempt to incorporate 
CPEs into topical formulations of amitriptyline and/or ketamine. 
 
Propofol and midazolam are commonly used anaesthetics and sedatives 
respectively, with synergistic effects. They are proposed to be used for in a 
transdermal formulation procedural sedation of children. Firstly, the propofol 
organogel with 2.5% v/v limonene formulation achieved the highest in vitro 
drug permeation enhancement through the human epidermis compared to 
same gel with other CPEs. Next, midazolam was incorporated into 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles by single emulsion 
evaporation method and optimised to attain a high encapsulation efficiency of 
91.9 ± 1.7% and a high drug loading of 45.4 ± 3.0%. Following the 
characterisation and heat stability test, the midazolam nanoparticles were 
incorporated into the propofol organogel containing limonene 2.5% v/v. The 
in vitro drug release and hairless mouse skin permeation studies demonstrated 
the controlled release of both midazolam and propofol. Hence the PLGA 
nanoparticles could have formed depots on the skin surface to facilitate the 
release of midazolam. After physical and chemical stability studies over 6 
months at 3 temperatures, the midazolam nanoparticulate propofol organogel 
in PG matrix was found to be the only stable formulation when stored at 4°C. 
The incorporation of drug-loaded nanoparticles into an organogel is a novel 
delivery system of these two drugs. 
 
The ITC study of farnesol with human skin lipids revealed that farnesol 
interacted mainly with the free fatty acids, leaving the cholesterol and 
ceramides of the skin less disturbed, thus providing an explanation for the 
reports on the comparatively low dermal irritancy and higher permeation 




Our investigations on the incorporation of CPEs in amitriptyline and ketamine 
hydrogel and midazolam nanoparticulate propofol organogel demonstrate the 
potential development of alternative drug delivery systems for the treatment of 
peripheral neuropathic pain and procedural sedation.  
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Fig. 5.18 Midazolam release from midazolam nanoparticles in PG and 
ISA suspension in the presence of limonene and propofol. 
Each point on the curve represents the ratio of midazolam 
released from specific storage time over midazolam released 




Fig. 5.19 Drug contents of midazolam (MID) and propofol (PRO) in 
MNP organogel when stored at 4°C for 6 months. Each point 
on the curve represents the ratio of drug released from 
specific storage time over drug released in Day 1 (n = 3). 
 
Fig. 6.1 Solubility of lipids in propylene glycol and propylene glycol 
with 5% v/v farnesol. C16 = palmitic acid [C16:0], C20 = 
eicosanoic acid [C20:0], C24 = lignoceric acid [C24:0],  
CHO=cholesterol. Tests were done in triplicates. 
 
Fig. 6.2 Non-linear regression analyses to estimate the binding 
stoichiometry (N), the binding constant (K), and the enthalpy 
change (ΔH) with software Digitam®. (a) Titration of farnesol 
into cholesterol using propylene glycol as solvent. Tests were 
done in duplicate. (b) Titration of farnesol into eicosanoic acid 
using isopropyl alcohol as solvent N = 2, K = 779.64 m
-2, ΔH 
= 1.49 kJ/mol, ΔG = -17.16 kJ/mol, ΔS = 60.15 J/mol. Tests 
were done in triplicates. (c) Titration of farnesol into palmitic 




-2, ΔH = 6.91 kJ/mol, ΔG = -18.28 kJ/mol, ΔS = 36.69 J/mol. 
Tests were done in duplicates. (d) Titration of farnesol into 
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Anaesthesia, sedation and analgesia are performed daily in hospitals, clinics 
and homes all over the world. Parentally and orally administered anaesthetics 
and sedatives bring about systemic adverse effects especially cardiovascular 
and nervous disorders. Amitriptyline (AMI), ketamine (KET), propofol (PRO) 
and midazolam (MID) are administered mainly by injection for analgesic, 
sedative and hypnotic purposes. However, they share common adverse effects, 
such as injection pain and dizziness, and other systemic adverse effects 
particular to each drug may be reduced or alleviated by using alternative 
administration routes such as topical and transdermal delivery.  
 
1.1 Drug candidates and their clinical applications 
 
1.1.1 Amitriptyline and ketamine for neuropathic pain 
 
The International Association for the Study of Pain (ISAP) has recently 
redefined neuropathic pain as “pain caused by a lesion or disease of the 
somatosensory system” (Jensen et al., 2011), although debates over it claimed 
that the new definition might be restrictive and inaccurate (Horowitz 2012; 
Oaklander et al., 2012). In contrast to nociceptive or inflammatory pain, which 
is caused by potential tissue damaging stimuli or actual tissue damages, 
neuropathic pain is produced either by damage to, or pathological change in, 
the peripheral or central nervous system and can persist long after the 
initiating injurious event has been removed and any overt tissue damage has 
healed (Freynhagen and Bennett, 2009). Neuropathic pain may originate from 
nerve injury following numerous causes, for example, direct nerve impairment, 
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inflammation/neuritis, infections (herpes zoster, HIV), diabetes, tumours, and 
toxins (chemotherapy) (Boyce-Rustay and Jarvis, 2009). As much as 6% to 8% 
of the population is estimated to be affected by neuropathic pain, of which 5% 
may be severe (Torrance et al., 2006; Bouhassira et al., 2008). The annual 
incidence rate is almost 1% of the general population, and women as well as 
middle-aged people are more often affected (Dieleman et al., 2008). And it is a 
heavy economic burden for both patient and government since it is estimated 
that the average annual cost of pain medication per patient with diabetic 
peripheral neuropathic pain was over US$1000 (Barrett et al., 2007). Due to 
the complex and unclear mechanism of neuropathic pain, therapeutic treatment 
remains a challenge because it is often chronic and unresponsive to 
conventional analgesics such as non-steroidal anti-inflammatory drugs 
(NSAIDs) and opioids. The current therapy for neuropathic pain (Table 1.1) is 
not satisfactory as more than two-thirds of neuropathic pain patients obtain 
insufficient pain relief (Jensen et al., 2011). There are two FDA approved 
topical formulations for neuropathic pain: Lidoderm
®
 (lidocaine 5% patch) 
from Endo Pharmaceuticals and Qutenza
®
 (capsaicin 8% patch) from 
NeurogesX. However, they are only approved for postherpetic neuralgia, 
which is one type of neuropathic pain.  
 
Amitriptyline is one of the first-line treatment options in all three 
evidence-based consensus guidelines for the pharmacological treatment of 
neuropathic pain (Dworkin et al., 2010; Attal et al., 2010; Moulin et al., 2007). 
Firm clinical based evidence has demonstrated that amitriptyline is one of the 
most effective drugs for treatment of different neuropathic pain conditions 
(Coluzzi and Mattia, 2005). It can inhibit the reuptake of serotonin, 







 voltage-gated ion channels as well as the muscarinic, 
cholinergic, nicotinic, histaminergic, α2-adrenergic, opioid, and 
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N-methyl-D-aspartate receptors (Kopsky and Hesselink, 2012; Gerner et al., 
2001). Amitriptyline’s broad variety of receptor targets may explain its 
excellent efficacy, but it may also be the origin of the wide array of adverse 
effects limiting its systemic administration. The major advantages of 
amitriptyline are its low cost, long-acting local anaesthetic effects and 
beneficial effects on depression, which is a common comorbidity with 
neuropathic pain (O'Connor and Dworkin, 2009; Strumper and Durieux, 2004). 
The therapeutic plasma concentration to obtain analgesia is smaller than the 
0.3 - 0.8 μM used in treating depression, and analgesic effect occurs earlier 
than antidepressant response (Coluzzi and Mattia, 2005; Haderer et al., 2003) 
However, the systemic absorption of amitriptyline may induce anticholinergic 
adverse effects and cardiac toxicity (Dworkin et al., 2010).  
 
Table 1.1 Treatment recommendations for peripheral neuropathic pain adapted 
from recent guidelines and algorithms. Adapted from Freynhagen and Bennett 




stage of treatment 








First or second 
Third 




Second or third 
Third 
Opioids Oxycodone, morphine, tramadol, 
methadone 
Second or third 
Miscellaneous Topical lidocaine (5% patch, gel) 
Topical capsaicin (8% patch, gel) 
Cannabinoids 
Ketamine 
First or second 
Third 
Third 
Second or third 
 
Ketamine, an injectable anaesthetic, which blocks Na
+
 channels, μ-opioid 
receptors and N-methyl-D-aspartate (NMDA) receptors, has been studied for 
its potential role and already been used in an off-label manner in neuropathic 
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pain syndrome relief (de Leon-Casasola 2007). Both amitriptyline and 
ketamine have been shown to produce peripherally mediated antihyperalgesic 
and analgesic properties when administered locally in animal studies (Oatway 
et al., 2003). Topical applications of ketamine gel and ointment have been 
reported to be effective in human subjects (Ushida et al., 2002; Gammaitoni et 
al., 2000). Ketamine was also proven to relieve pain-induced depression at 
sub-anaesthetic dose (Wang et al., 2011). It was thought that ketamine may 
play a significant role in pain control as adjuvant analgesics in combination 
with other agents (Lynch et al., 2003). 
 
Topical delivery of amitriptyline can significantly decrease systemic adverse 
effects by minimising its plasma concentration while it can still be effective to 
peripheral neuropathic pain due to the peripheral-mediated analgesia 
mechanisms (Coluzzi and Mattia, 2005; Lynch et al., 2003). Recent studies 
have shown that perineural and transcutaneous amitriptyline in rats and 
humans had long-lasting local anaesthetic effects (Dualé et al., 2008). Topical 
administration also allows patients to conveniently apply the formulation 
directly to the affected areas. Both topical lidocaine and capsaicin have been 
frequently used in combination with other treatments of neuropathic pain, 
especially in localized small area neuropathic pain (de Leon-Casasola, 2007). 
However, the clinical trials of topical treatment of amitriptyline and/or 
ketamine showed ambiguous analgesic effects, which may be due to the low 
permeabilities and low potencies of amitriptyline/ketamine (Table 1.2). 
Among the trials with positive effects, an apparent dose-related efficacy as 
well as dose-related adverse effect can be observed. Therefore, approaches to 
increase and to accelerate the permeation while keeping the drug dose low are 
clinically demanded. Chemical penetration enhancers (CPEs) are the most 
extensively investigated approach to transdermal drug permeation 
enhancement because they are easy to formulate and cheap. The previous 
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studies on topical and transdermal formulations of amitriptyline and/or 
ketamine (Table 1.2) were carried out without incorporation of chemical 
penetration enhancers (CPEs). Therefore, incorporating CPEs in the 
formulation may significantly enhance the permeation of 
amitriptyline/ketamine and thus increase the concentration to therapeutic level 
in regional affected tissues. 
 
1.1.2 Propofol and midazolam for sedation 
 
Sedation is defined as “the reduction of irritability or agitation by 
administration of sedative drugs, generally to facilitate a medical or diagnostic 
procedure” (Brown et al., 2005). Sedation can be divided by the consciousness 
continuum into four stages: minimal sedation (anxiolysis) with normal 
response to verbal stimuli, moderate sedation with purposeful response to 
verbal/tactile stimulation, deep sedation with purposeful response to repeated 
or painful stimulation, and general anaesthesia in which patients are not 
arousable with even painful stimulus (Höhener et al., 2008; Mace and Murphy, 
2006). Sedatives may provide anxiolysis, sedation, amnesia, analgesia, 
increasing comfort, and decreasing requirement of opioid analgesics (Höhener 
et al., 2008; Hohl et al., 2008). Commonly performed sedations include 
procedural sedation and palliative sedation.
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Gerner et al., 
2003 
AMI 5% Cream P 1 1 g, bid 
10 yr 
 
Significant No systemic effect Liebregts et 
al., 2011 
AMI 7.5% Lecithin 
organogel 
P 1 2 ml, opd 
6 wk 
 
Significant depression relief, 
insignificant analgesic 
No adverse effect Scott et al., 
1999 
AMI 5%, 10% Cream P 2 3 ml, opd 
7 mth for 5%,  
1 wk for 10% 
 
Significant in both 5% and 10% Systemic adverse 




AMI 5% Cream P 35 Not reported Insignificant No adverse effect Ho et al., 2008 
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H 16 1.5 ml, 
once 
24 hr 
Mild and short-lasting increase of 
the tactile and mechanical 
nociceptive thresholds, significant 
decrease of cold threshold, no 
change of warm threshold 
 
No systemic effect Dualé et al., 
2008 




Cream P 20 5 ml, opd 
7 day 
Insignificant No systemic effect Lynch et al., 
2003 




Cream P 92 4 ml, tid 
3 wk 
Significant 
no difference btw groups 
Minimal Lynch et al., 
2005a 
AMI 2% & KET 
1% 
 
Cream P 28 
22 complete 
4 ml, tid 
6 mth 
Significant No systemic effect Lynch et al., 
2005b 





P 5 bid 
2 mth 
Significant No systemic effect Sandroni et al., 
2006 
AMI 3%,  




P 208 bid 
4 wk 




AMI 4% & KET 
2% (High), 
AMI 2% & KET 
1% (Low) 
 
Cream P 251 bid 
1 wk(H), then 
2 wk(H,L) 
AMI 4% & KET 2% is significant 
and optimal concentration 
<5% of H have 
detectable drug 
Everton et al., 
2007a 
AMI 4% & KET 
2% 
 
Cream H 36 4 ml, bid 
48 hr 
PK research only Sub-therapeutic 
blood level 
Everton et al., 
2007b 
AMI 4% & KET 
2% (High), 
AMI 2% & KET 
1% (Low) 
 
Cream P 250 1 wk(H), then 
2 wk(H,L) 
Significant <10% of H have 
detectable drug 
Lockhart 2004 
KET 0.25% - 
1.5% 
 
Ointment P 7 tid 
2 wk 
Efficient 3, partly efficient 1, 
inefficient 3 
Not reported Ushida et al., 
2001 
KET 1% Gel P 5 2 ml, bid 
1 wk 
 
Significant No Gammaitoni et 
al., 2000 
KET 0.5% Lecithin 
organogel 
P 23 not reported Efficient 15, inefficient 8 2 reports of skin 
irritation 




Procedural sedation is commonly performed in the emergency department to 
facilitate orthopaedic reductions, cardioversions, incision and drainage of 
abscesses, wound care, and medical device insertion as well as in outpatient 
settings (Hohl et al., 2008; Krauss and Green, 2006). The ideal sedative agent 
for procedural sedation should have a rapid onset of action and a limited 
duration of action, can in combination with short-acting narcotics, and is 
associated with few major adverse events (Hohl et al., 2008; Mace and 
Murphy, 2006). Several sedative agents are currently used for procedural 
sedation, among which propofol and midazolam are the top two commonly 
used. Registry data from Canada and the United States indicate that propofol 
is used in 25% to 84% of procedural sedation episodes, and midazolam in 15% 
to 42% (Sacchetti et al., 2007; Mensour et al., 2006; Campbell et al., 2006). 
Cohort studies, registry data, and small randomized controlled trials (RCTs) 
suggest that both propofol and midazolam are safe and effective for use in 
procedural sedation (Hohl et al., 2008). 
 
Propofol (2,6-diisopropylphenol) is a potent lipophilic anaesthetic and 
commonly used for procedural sedation, induction and maintenance of 
anaesthesia. Its application has expanded to a sedative-hypnotic agent used in 
outpatient procedures as well as in the intensive care unit (Baker and Naguib, 
2005; Marik 2004). Propofol is highly bound to proteins (97% - 99%) and can 
rapidly distribute into peripheral tissues. Sedation can be achieved with a 
plasma concentration of 1.2 - 1.9 µg/ml while higher level of plasma 
concentration at 5 µg/ml is required for anaesthetic actions (Barr et al., 2001). 
It has several mechanisms of action, all through potentiation of GABAA 
(gamma-aminobutyric acid) receptor activity, thereby slowing the 
channel-closing time, and also acting as a Na
+
 channel blocker (Marik 2004). 
Propofol is rapidly and extensively metabolized by the liver and excreted by 
the kidneys (88%). Propofol has a high metabolic clearance that ranges from 
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1.6 - 3.4 l/min in healthy adults as obtained from the product information of 
Diprivan
®
. These pharmacokinetic parameters bring about the advantages of 
propofol which are rapid onset and cessation, little accumulation and short 
duration of action, maintaining a level in the circulation similar to the levels 
achieved by inhalation anaesthetics, and minimal side effects (Takahashi et al., 
2005; Baker and Naguib, 2005). Propofol is commercially available as an 
intravenous water-in-oil emulsion as Diprivan
®
, marketed by AstraZeneca. 
Diprivan
®
 may cause pain at injection site, hyperlipidemia, emulsion 
instability, and liability of microbial contamination (Takahashi et al., 2005; 
Baker and Naguib, 2005). For alternative routes to deliver sedatives, rectal 
administration is associated with pharmacokinetic disadvantages, and nasal, 
oral or sublingual formulations are not well accepted by paediatric patients 
due to their acid pH and bitter taste (Balaguer-Fernández et al., 2010). 
 
Propofol is considered to be a promising candidate drug for transdermal drug 
delivery since: (1) the log P value is 3.80 (in datasheet of Diprivan
®
 by 
AstraZeneca); (2) it is a low molecular compound (MW 178.27); (3) it exists 
in the liquid state when above 20 °C, thereby high-concentration solutions can 
be prepared (Takahashi et al., 2005). Transdermal delivery of propofol may 
eliminate pain of injection and avoid hyperlipidaemia, and also minimise its 
systemic adverse effects. Moreover, its transdermal system can be easily 
removed to overcome the intrinsic drawback of propofol (Kerker et al., 2010). 
 
Midazolam, a short-acting sedative drug for procedural sedation and amnesia 
before medical procedures, possesses anxiolytic, amnestic, anticonvulsant and 
hypnotic properties (Blumer 1998). Several studies have shown that propofol 
and midazolam have synergistic effects in anaesthesia, sedation and hypnosis 
which can reduce the doses of both drugs if incorporated in the same 
transdermal formulation thus reducing the incidence of possible adverse 
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effects (Kerker et al., 2010; Schilling et al., 2009; Adachi et al., 2001; 
Reimann et al., 2000; Short and Chui, 1991).  
 
Midazolam’s high lipophilicity (log P reported from 2.68 to 4.33) 
(Balaguer-Fernández et al., 2010; Dagenais et al., 2009; Arellano et al., 2007), 
rapid onset of action and high effectiveness make it a good candidate for 
transdermal delivery. A preliminary study has shown that midazolam maleate 
incorporated in a solvent system of PG-ethanol-water with 5% Azone could 
increase its flux through hairless mice skin by 86-fold and achieved an 
estimated steady-state plasma concentration of 496 ng/ml, which was high 
enough to allow for a possible correction for permeation through human skin 
(Touitou 1986). Ota and his colleagues (2003) demonstrated that 5% w/v 
d-limonene in combination with ethanol and propylene glycol could facilitate 
the percutaneous delivery of midazolam through rat skin both in vitro and in 
vivo while β-citronellol, l-menthol, geraniol, and Azone showed inferior 
enhancement in vitro and merely enhancement in vivo. Balaguer-Fernández 
and her colleagues (2010) have shown that iontophoresis and azone can 
significantly enhance the permeation of midazolam through human skin in 
vitro although no synergism between these two enhancement strategies was 
found. 
 
1.2 Topical and transdermal delivery systems 
 
1.2.1 Skin structure 
 
Skin is the largest organ of the human body which accounts for more than 10% 
of body mass. It is an effective barrier and plays an essential role in protecting 
the body from various environmental insults, mainly biological and chemical. 
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Skin is composed of three major layers: the outermost avascular epidermis, the 
dermis which is vascular containing the free nerve endings that are responsible 
for pain sensation, and subcutaneous tissues (Fig. 1.1). Therefore, the target 
area for topical anaesthetic action is the dermis (Tadicherla et al., 2006). The 
epidermis can be further divided into the stratum corneum (nonviable 
epidermis) and the living epidermis (viable epidermis). The heavily 
vascularised appendages such as sebaceous glands and hair follicles originate 
in the dermis and penetrate through epidermis to reach skin surface, which 
may facilitate drug permeation and provide openings for nanoparticles to 
accumulate and release drugs directly to the deeper layer of the skin. 
 
Fig. 1.1. Skin structure. Reproduced from Lu and Flynn (2009). 
 
 
Stratum corneum is the heterogeneous outermost layer of epidermis which is a 
major barrier to drug permeation due to rigid lipid lamellar structure, 
providing a rate-limiting step in permeation process of drugs. It consists of 15 
- 25 layers of flattened, stacked, hexagonal corneocytes embedded in a highly 
organised intercellular lipid matrix (Walters and Roberts, 2002; Jepps et al., 
2012), which was first proposed by Michaels et al. (1975) and further 
developed by Elias et al. (1981) as resembling “bricks and mortar”. The 
corneocytes consist of a dense scaffolding network of keratin filaments, 
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various Natural Moisturizing Factor (NMF), and water-insoluble cells walls 
(Jepps et al., 2012) (Table 1.3).  
 
Table 1.3. Composition of stratum corneum.  
Reproduced from Lu and Flynn (2009). 
Tissue component Gross composition Percentage of 
dry weight 
Cell membrane Lipid, protein ≈ 5 
Intercellular space Mostly lipid, some protein, and 
polysaccharide 
≈ 20 
Intracellular space Fibrous protein (≈ 65 - 70%), 
nonfibrous (soluble) protein (≈ 5 - 
10%) 
≈ 75 
Overall protein Water soluble (10%), keratin (≈ 
65%), cell wall (≈ 5%) 
70 - 80 
Overall lipid - 10 - 20 
All other - Up to 10 
Water (normal 
hydration) 
- 15 - 20 
Water (fully hydrated) - Up to 300 
 
A crucial determinant of the skin barrier function is the intercellular lipid 
matrix in stratum corneum. The lipids consist mainly of a heterogeneous 
mixture of free fatty acids, ceramides and cholesterol in a roughly 1:1:1 molar 
ratio (Wertz and van der Bergh, 1998). The ceramides are the most abundant 
(40 - 50% w/w) (Wilkinson, 2008a) and diversified lipids in the intercellular 
lipids, which play an important role in skin barrier function. Nowadays at least 
11 subclasses of skin ceramides are identified and investigated (Masukawa et 
al., 2008; Masukawa et al., 2009) (Fig 1.2). In general the long chains in the 
ceramide molecules are saturated, which allows for tight lateral packing 
(Moore et al., 1997). Therefore at room temperature, ceramides exist in the 
ordered gel phase. Moreover, there is a hydrogen bonding network existing 
between ceramide headgroups both within the bilayer and between layers 
(Moore et al., 2000). These properties together confer rigidity and structural 
integrity to the stratum corneum, contributing to the formation of a highly 
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impermeable barrier. Cholesterol provides a degree of fluidity to what may 
otherwise be a rigid and brittle structure, and reduces the presence of sharp 
phase boundaries by broadening phase transitions (Wertz, 2000; Wegener et 
al., 1997). The free fatty acids, on the other hand, increase the density of the 
hydrocarbon chain packing, suggesting that they condense the lipid packing 
(Neubert et al., 1997). They also disrupt ceramide headgroup packing by 
forming hydrogen bonds with the lipid headgroups (Bouwstra et al., 2003).  
 
There have been debates over the physical structure and state of the 
intercellular stratum corneum lipids. A number of experimental-based models 
have been proposed, among which three models have been commonly cited. A 
structural and functional model for mammalian skin barrier named “single gel 
phase model” was proposed by Norlén (2001), who postulated that the 
intercellular lipid within the stratum corneum existed as a single and coherent 
lamellar gel phase (Fig. 1.3a). The proposed membrane structure was 
stabilised by the unique cocktail of lipids and their chain length distributions 
had virtually no phase boundaries, which were suggested to be mainly located 
at the lower half of stratum corneum. The single gel phase model is unique in 
that it predicted that no phase separation was present in the unperturbed barrier 
structure. It is more consistent with the continuous barrier properties of the 
stratum corneum than other theories, and can be used to explain the stratum 
corneum lipid lamellae behaviour macroscopically, such as water permeability 
of stratum corneum, intercellular lipid composition of stratum corneum, the 
absence of swelling of the stratum corneum intercellular lipid matrix on 
hydration, and the simultaneous presence of hexagonal and orthorhombic 
hydrocarbon chain packing of the stratum corneum intercellular lipid matrix at 
physiologic temperatures. Alternatively, other models propose a 
heterogeneous stratum corneum lipid matrix. In the domain mosaic model, 




Fig. 1.2. Molecular structures of the main ceramides in skin lipids. 
Reproduced from Notman and Anwar (2012). 
 
 
segregated into crystalline/gel domains bordered by fluid crystalline state 
lipids known as “grain borders" (Fig. 1.3b). This model can explain the “water 
tight” barrier property of the stratum corneum, and it can also demonstrate the 
elastic properties of the stratum corneum that permits bending and stress 
imposed on the skin surface. This mechanistic model of topical and 
transdermal drug delivery explains the structural transformation of the 
organisation of skin lipids when in contact with chemical penetration 
enhancers (CPEs). Based on “domain mosaic model”, Bouwstra and her 
colleagues (2002; 2003) developed a similar model called “sandwich model” 
(Fig. 1.3c), which depicts stratum corneum lipid membranes as one narrow  
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Fig. 1.3. Schematic diagrams of (a) Single gel phase model,  
(b) domain mosaic model and (c) sandwich model.  
Adapted from Norlén (2001) and Bouwstra et al. (2002). 
 
 




central lipid layer with fluid domains on both sides of a broad layer with a 
crystalline/gel-like structure, forming a lamellar phase with a 
“broad-narrow-broad” 13 nm periodicity. Ceramide 1 and cholesterol are 
thought to be essential to this structure, and free fatty acids could increase 
lattice density of the structure. Although the actual organisation of the skin 
lipid matrix remains unknown, these models have contributed significantly to 
the understanding of the mechanisms of chemical permeants applied on the 
skin for pharmaceutical and cosmetic purposes. 
 
1.2.2 Skin as a delivery route 
 
The penetration of substances across the skin is a complicated process 
comprising physical, chemical and biological interactions. Skin penetration 
has been extensively investigated in the fields of pharmaceutics, cosmetics, 
toxicology, and agrochemistry. The skin provides an alternative route for drug 
administration which may avoid certain undesirable effects of oral and 
parenteral administration. However, the low permeation rates and amounts of 
drugs due to the barrier function of the skin as well as the complex 
mechanisms of percutaneous absorption pose a major challenge for topical and 
transdermal drug delivery. 
 
Percutaneous absorption is generally considered to consist of three steps: 
“penetration”, which is the entry of a substance into a particular skin layer or 
structure; “permeation”, which is the penetration through one skin layer into 
another; and finally “resorption”, which is the uptake of a substance by the 
vascular system (SCCP, 2010). The postulated penetration routes for the 
diffusion of solutes across stratum corneum are the intercellular (paracellular), 




Fig. 1.4. Skin penetration routes. (1) Intercellular route through lipid lamellae; 
(2) transcellular route through the keratinocytes and lipid lamellae;  
and (3) appendageal route through the hair follicles and sweat glands. 
Reproduced from Fox et al. (2011). 
 
 
The intercellular pathway is widely accepted as the dominant route for 
lipophilic solutes to pass through the continuous but tortuous intercellular lipid 
matrix around the corneocytes, from studies on the intercellular lipids 
organisation and applied substances on delipidisation of the lipid matrix by 
microscopy and histology (Jepps et al., 2012; Pegoraro et al., 2012; Roberts et 
al., 2002). In the transcellular route, solutes partition into and diffuse across 
both corneocytes and intercellular lipid lamellae. The process of repeated 
diffusing across both hydrophobic and hydrophilic environments is highly 
unfavourable for most solutes and therefore the intercellular route is the 
preferred route of administration for most investigated molecules (Pegoraro et 
al., 2012). However, recent studies support the view that transcellular route is 
important for highly and moderate hydrophilic drugs (Chen et al., 2010; 
Mitragotri 2003; Yu et al., 2003; Peck et al., 1994). With the aid of chemical 
penetration enhancers (CPEs), electric field, ultrasound, photoacoustic waves 
and microneedle, the transcellular route is being investigated by many 
hydrophilic solutes (Mitragotri 2003; Stahl et al., 2012). Hydrophilic solutes 
can also penetrate into the stratum corneum via the appendageal route. Skin 
appendages such as hair follicles, sebaceous glands and sweat glands provide 
alternative routes for diffusing solutes, which circumvent the stratum corneum 
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(Wilkinson, 2008b). One orifice of hair follicle has a diameter of 50 - 100 m 
and together they can occupy 0.1% of the surface area of the skin in 
low-density areas and up to 10% in high density areas, such as those on the 
face and scalp (Roberts et al., 2002). The openings lead down to an epithelial 
surface which has a much thinner stratum corneum layer, and the outer root 
sheath is considered to play an important role for the permeation of highly 
hydrophilic substances, especially in iontophoresis treatment (Essa et al., 
2002). The hair follicles have also been investigated as the target for topical 
and transdermal micro/nanoparticles delivery (Pegoraro et al., 2012; Prow et 
al., 2011; Cerv and Vierl, 2010; Baroli, 2010). Nanoparticle-mediated drug 
delivery into the epidermis and dermis without modification of the skin barrier 
is rare, and there is no conclusive evidence to support that particles larger than 
20 nm in diameter can penetrate across stratum corneum into viable tissue 
(Prow et al., 2011). Non-deformable nanoparticles in the range of 50 - 5000 
nm in diameter may not penetrate across the stratum corneum but can stay in 
the deeper hair follicles (Cerv and Vierl, 2010; Nohynek et al., 2007). As a 
result, hair follicles may act as a reservoir for the accumulation and deposit of 
nanoparticles with an increasing local concentration of drug released from the 
nanoparticles, thus facilitating drug permeation into the stratum corneum via a 
high thermodynamic driving force.  
 
Unlike other biological membranes, the stratum corneum lacks active transport 
and facilitated transport processes, as the corneocytes are anucleated and 
keratinised, therefore cannot produce the specialised transmembrane protein 
domains needed for active or facilitated transport (Bouwstra et al., 2003). It is 
assumed that the mechanism of transport through the stratum corneum is by 
passive diffusion driven by the thermodynamic force arising from the greater 
concentration of chemical on the surface of the skin, as expressed by Fick's 
first law of diffusion adapted to percutaneous absorption: 
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Flux(J) = (P*D*ΔC)/h                                     (1.1) 
The parameters are: J is the unit flux, P is the partitioning coefficient between 
the stratum corneum and the vehicle, D is the diffusion coefficient or 
diffusivity within the intercellular lipids in the stratum corneum, ΔC is the 
concentration gradient across the skin, and h is the skin thickness. Fick's first 
law of diffusion relates the diffusive flux to the concentration under the 
assumption of steady state and an infinite sink condition inside the membrane, 
and the driving force is a gradient of chemical potential. The assumption of the 
steady state and the sink condition makes the concentration gradient of ΔC to 
be a time-independent value. 
 
Equation 1.1 is the foundation of absorption profile, representing the 
cumulative amount of substance penetrating the skin with time. A commonly 
derived pattern of absorption profile in in vitro study is under infinite dose 
conditions (Fig. 1.5), in which the amount/concentration of chemical present 
on the skin surface effectively remains constant or the amount/concentration 
decrease is considered negligible. However, if the experimental time is long 
enough, this infinite dose condition is not a realistic scenario for most skin 
exposure to chemicals. A finite dose condition (Fig. 1.6) is more 
representative of dermal exposure occurring in in vivo experiments when a 
discrete quantity of chemical, applied to the skin surface, gradually depletes 
with time (Pugh and Chilcott, 2008). 
 
In order to establish the absorption profile as well as the rate and degree of the 
penetration across skin in a quantitative manner, percutaneous absorption 
measurements are indispensable with possible standardization and 
optimization. As drug efficacy and safety are important considerations for the 
patients, percutaneous absorption measurements should be reproducible and 
reliable, as found in numerous recommendations, guidelines and protocols 
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(Brain et al., 2002). The percutaneous absorption measurements comprise 
mainly in vitro and in vivo methods. In vitro methods are used extensively in 
industry and academia. The advantages of in vitro methods are cheap, 
avoiding animal sacrifice, providing direct measurements and can be precisely 
controlled as the only variable is the skin. However, disadvantages are also 
obvious: it cannot simulate the physiology environment in that little 
information on the metabolism, distribution, onset of therapeutic action, and 
effects of blood flow on permeation can be obtained (Brain et al., 2002). The 
commonly used apparatuses are Franz diffusion cells (or static diffusion cells) 
and flow through diffusion cells. The latter is an automated version of the 
former apparatus, which maximises the sink conditions as the fluid is 
continually replaced using a peristaltic pump. The permeation tests are usually 
carried out at 32°C with duration of 24 - 48 hr. Other in vitro methods include: 
skin-stripping, Attenuated Total Reflectance-Fourier Transform Infrared 
(ATR-FTIR) Spectroscopy, artificial (cultured) skin, autoradiography, 
Laser-Scanning Confocal Microscopy (LSCM), and using synthetic artificial 
membranes (Pendlington, 2008). In vivo methods include those on animal 
subjects and those on human volunteers. Animal studies are substitutes for 
clinical trials since it is not always ethically or practically possible to conduct 
pharmacokinetic studies in humans. However, there are intrinsic drawbacks of 
animal models. For example, small laboratory animals, such as rats, mice, and 
rabbits, lack sweat glands, but have more hair follicles than human skin. Thus 
a combination of laboratory animal and human in vivo investigation is 
necessary for evaluation of drug delivery systems. In many studies, 
extrapolation between in vitro and in vivo penetration is reasonably accurate 
unless the drug undergoes extensive dermal metabolism in vivo (Brain et al., 
2002). Therefore, a commonly applied investigational method in the 
development of topical and transdermal drug delivery systems is to perform in 
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vitro study with human skin and in vivo study on laboratory animals before 
performing clinical trials. 
 
Fig. 1.5. A typical absorption profile under infinite dose condition.  
The curve has 2 phases: a lag phase (A) and a steady state (B).  
The gradient of this line can be used to calculate the steady state flux (Jss; 




). Lag time (tL) is often calculated by linear 
extrapolation of the steady state back to the x-axis. 
 
 
Fig. 1.6. A typical absorption profile under finite dose condition.  
The curve has 3 phases: a lag phase (A), a pseudo-steady-state (B) and a 
plateau phase (C). The gradient of phase B can be used to estimate the 




Percutaneous absorption is a phenomenon intertwined by a variety of 
biological, physical and chemical processes. The interactions between solutes, 
vehicles, intercellular lipids, corneocytes and possible penetration enhancers 
(CPEs) that determine solute permeability and diffusivity are probably 
complex and multifactorial, and the sum of all these factors will contribute to 
the percutaneous absorption (Grice et al., 2010). These factors can be divided 
into four major aspects: skin, drug, vehicle, and drug application (Table 1.4), 
some of which will be discussed in greater detail in the following chapters. 
 
Table 1.4. Factors may influence percutaneous absorption.  
Adapted from Grice et al. (2010), Brain and Chilott (2008), Roberts et al. 
(2002) and Surber and Davis (2002). 
 Influencing factors 
Skin 1. microflora, 2. pH, 3. sweat and sebum, 4. temperature, 5. 
blood flow, 6. disease compromised and damaged skin, 7. 
different body sites, 8. appendages, 9. skin metabolism, 10. 
stratum corneum reservoir, 11. race, 12. age, 13. inter-individual 
difference 
Drug 1. lipophilicity (log P), 2. molecular weight and size, 3. 
hydrogen bonding donor and acceptor number, 4. solubility, 5. 
charge 
Vehicle 1. vehicle matrix, 2. excipients, 3. chemical penetration 
enhancers, 4. particle (if any) type and size, 5. volatility 
Application 1. skin treatment, 2. occlusion, 3.loss and change of vehicle, 4. 
dose and area applied, 5. application duration and frequency  
 
 
1.2.3 Transdermal delivery and topical delivery 
 
Transdermal drug delivery system, developed since the 1970s, treats systemic 
diseases by achieving therapeutic systemic drug levels with the application of 
drugs to the skin. The first commercially available product was a scopolamine 
patch that was approved by the FDA in 1979. Today, there are various 
transdermal delivery systems on the market for drugs like estradiol, fentanyl, 
lidocaine, clonidine, nitroglycerine, and testosterone. Compared to the oral 
 24 
 
route, transdermal delivery avoids the first-pass effect, drastic pH changes as 
well as the presence of food and enzyme; and it can also minimise systemic 
adverse effects and inter-patient variation (Parhi et al., 2012). Compared to 
parenteral administration, transdermal delivery is non-invasive, convenient, 
with good patient compliance and can be self-administered, may achieve 
prolonged drug level in blood, and economical especially in developing 
countries (Prausnitz and Langer, 2008; Barry, 2004). Moreover, it can provide 
sustained release (up to one week) which other administration routes may not 
achieve.  
 
However, the major challenge for transdermal drug delivery is that only a 
limited number of compounds can be selected as candidates to be administered 
by this route. With current transdermal delivery methods, the ideal drug 
candidates should be small molecules (typically < 500 Da), having low 
melting points and good solubility properties, and possessing moderate 
lipophilicities with log P value around 2 (Hadgraft 1999; Hinz et al., 1991). 
The molecular weight and log P values of 4 candidate drugs in this study are 
listed in Table 1.5, which shows that they are potential applicable in 
transdermal delivery. Besides having these chemical properties, the drug 
candidates should be highly potent (a dose of milligrams per day or less) with 
a low clearance in dermal, muscle and plasma (Prausnitz and Langer, 2008). 
Moreover, it is difficult to deliver hydrophilic drugs and macromolecules like 
peptides, proteins, DNA and siRNA using traditional transdermal techniques.  
 
Table 1.5. Molecular weights (MW) and log P values of 4 candidate drugs. 
The data were from SciFinder Web
®
 and original product information. 














Advances in transdermal drug delivery systems have been categorised by 
Prausnitz and Langer (2008) into three generations of development. The first 
generation is characterised by traditional transdermal patch with the passive 
diffusion as the main delivery mechanism, as found in most transdermal 
products on the market. In the second generation, permeation enhancing 
techniques, for example, chemical penetration enhancers, supermolecular 
structures like microemulsions, liposomes, nanoparticles and dendrimers, 
iontophoresis, magnetophoresis, thermophoresis, and noncavitational 
ultrasound are incorporated (Brown et al., 2006). The third generation 
techniques enable stronger disruption of the stratum corneum, and thereby 
more effective, especially in delivering macromolecules, while still protecting 
deeper tissues, among which novel chemical enhancers and their combinations, 
electroporation, cavitational ultrasound, microneedles, thermal ablation and 
microdermabrasion have all shown a great potential for more targeted 
enhancement. Another categorisation system of transdermal drug delivery 
enhancing techniques was introduced by Barry (Fig. 1.7), which is categorised 
by mechanisms of enhancement and is commonly cited by textbooks. 
 
Considering the advances in transdermal delivery techniques, a large number 
of new products are in development, such as for pain management, namely 
opioids and non-steroidal anti-inflammatory drugs (Tanner and Marks, 2008). 
However, the success of novel drug delivery technologies must result in a 
good balance of the safety and efficacy of the drug as well as the portability, 
user-friendliness and cost-effectiveness of the product for the potential market. 
 
Topical delivery is different from transdermal delivery, as it is achieves drug 
levels in local tissues far in excess of those that can be achieved by other 
means of administration. Therefore, low systemic drug level brings about rare 
systemic toxicities and its plasma concentration is difficult to measure. Most 
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topical delivery systems comprise semisolid formulations while most 
commercialised transdermal delivery systems are presented as transdermal 
patches.  
 
Fig. 1.7. Techniques for enhancing transdermal delivery.  
Adapted from Barry (2005). 
 
1.3 Chemical penetration enhancers 
 
Although transdermal and topical drug delivery systems have been recognised 
as promising systems for systemic or local delivery of drugs with many 
advantages, the application of transdermal and topical delivery systems to a 
wide range of drugs is limited due to the significant skin barrier function. In an 
attempt to overcome the skin impermeability and to enhance the drug 
permeation, a variety of approaches and techniques have been developed and 
invented, which have been discussed in Section 1.2.3. Among these methods, 
the most commonly applied is the use of chemical penetration enhancers 
(CPEs) (Ahad et al., 2009).  
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Almost 400 chemicals, termed chemical penetration enhancers (or chemical 
permeation enhancers), have been found to interact with the skin and disrupt 
its highly ordered lipid bilayer structure thus increasing the transport of drug 
molecules across the skin (Karande and Mitragotri, 2009). The major 
advantages of CPEs are that they are inexpensive, easy to formulate and do not 
need specific and complex devices so that the products can be administered by 
patients. CPEs can be categorised into several classes according to their 
chemical structures, such as hydrocarbons, fatty acids, alcohols, esters, amides, 
surfactants (anionic, cationic, nonionic and zwitterionic), azones, polyols, 
pyrrolidones, sulfoxides, terpenes, urea and its derivatives, cyclodextrins, 
phospholipids, as well as water, which is considered to be the most natural 
penetration enhancer (Kanikkannan et al., 2005; Williams and Barry, 2004). 
Besides the traditional CPEs, novel CPEs like a 16-amino-acid peptide 
penetratin (Cohen-Avrahami et al, 2012), a sugar ester sucrose laurate 
(Okamoto et al., 2011), a pore-forming peptide magainin (Kim et al., 2007), 
capsaicin derivatives, transkarbam (Parhi et al., 2012) have also been reported. 
 
CPEs enhance permeation of drug by a variety of complex mechanisms as 
seen in Fig. 1.8. They can increase drug permeability by enhancing its 
thermodynamic activity in the formulation, e.g., by raising solubility or 
causing supersaturation of the drug in the formulation. They can increase drug 
diffusivity and solubility in the stratum corneum. And they can directly exert 
their effect on stratum corneum structure by acting on the intercellular lipids 
and/or corneocytes (Karande and Mitragotri, 2009; Moser et al., 2001). As 
most CPEs interact with the intercellular lipids, they can be divided broadly 
into two categories: they either extract lipids from the skin thereby creating 
diffusion pathways for the drug to permeate through, or partition themselves 
into the lipid bilayers thereby disrupting the highly ordered lipid lamellae and 




Fig. 1.8. Some actions of penetration enhancers on human stratum corneum.  
(a) Action at intercellular lipids - ways by which penetration enhancers attack 
and modify the well-organised intercellular lipid domain of the stratum 
corneum. (b) Action at desmosomes and protein structures - dramatic 
disruption by enhancers (particularly potent solvents) as they split the stratum 
corneum into additional squames and individual cells would be clinically 
unacceptable. (c) Action within corneocytes - swelling, further keratin 
denaturation and vacuolation within individual horny layer cells are less 
drastic but would usually be cosmetically challenging.  




et al., 2004). The major concerns of applying CPEs are their safety and 
efficacy as well as the inability to reach the ideal or required enhancement for 
permeation of most drugs. Increased permeation enhancement typically 
correlates with increased skin irritation and sensitization, thus limiting their 
enhancing abilities (Karande and Mitragotri, 2009; Prausnitz and Langer, 2008; 
Brown et al., 2006). Use of combinations of instead of single CPEs has been 
thought to be a safer and more effective approach, and a ternary combination 
may exhibit the best cost to benefit ratio (Arora et al., 2010). With the advent 
of high-throughput screening method of CPE combinations (Karande et al., 
2004) and revelation of the mechanisms of permeation enhancement by CPEs, 
the use of CPEs in formulation development has become increasingly rational.  
 
Terpenes and terpenoids are popular CPEs with high enhancement efficacies, 
reversible effects, low toxicities and irritancies at low concentrations (1-5%), 
while some of these compounds have been designated as generally recognised 
as safe (GRAS) by the US FDA (Ahad et al., 2009; Kang et al., 2007a). 
Terpenes can be classified by the numbers of isoprene (C5H8) units, for 
example, monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), and 
triterpenes (C30), which consist of terpene carbon skeletons. And they can also 
be classified by their functional groups (i.e. alcohols, esters, ketones, and so 
on) in the molecules or the presence of cyclic rings (i.e. acyclics, monocyclics, 
bicyclics, and so on). Many factors influence the penetration enhancing 
potencies, such as lipophilicity, molecular weight, chirality, boiling point and 
energy of evaporation (Aqil et al., 2007). In general, smaller terpenes with 
higher lipophilicities, lower boiling points and lower energies of vaporization 
are good permeation enhancers; and hydrocarbon terpenes are probably 
effective for lipophilic drugs and oxygen containing terpenes may be effective 
for hydrophilic drugs (Aqil et al., 2007; Kanikkannan et al., 2005). However, 
different perspectives have been reported by other researchers. Kang and his 
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colleagues (2007b) found that the lipophilicity of terpenes was positively 
correlated with permeation enhancement of CPEs; El-Kattan et al. (2000) 
indicated that the permeation of hydrophilic drugs was better enhanced by 
lipophilic terpenes, while Ghafourian et al. (2004) argued that enhancement by 
terpenes are different with drugs of different lipophilicities. Meanwhile, many 
terpenes, such as menthol, cineole, farnesol, and limonene, have been used for 
permeation enhancement of both hydrophilic and lipophilic drugs when they 
are judiciously selected and combined with solvents (Ahad et al., 2009; Sapra 
et al., 2008). However, the enhancing potencies seem to be drug specific or at 
best may be predictive for a group of drugs with similar physicochemical 
properties, mainly log P values, molecular weights and solubilities (Williams 
and Barry, 2004).  
 
Terpenes, usually mixtures of essential oils, have a long history in 
aromatherapy and traditional medicines for sedation, analgesia and hypnosis. 
It has been demonstrated that some terpenes may have local analgesic or 
sedative effects as well as aid the analgesics in performing stronger and longer 
effect by acting as CPEs in transdermal and topical formulations. The most 
commonly applied terpene in topical formulations, especially pain relieving 
products, is menthol, as it has cooling analgesic and local anaesthetic effects 
that are derived from its influence on transient receptor potential cation 
channel subfamily M member 8 (TRPM8) receptors and is a penetration 
enhancer that increases the skin permeation of the drug substances (Cal 2008; 
Patel et al., 2007). Eugenol, widely used for its anaesthetic and analgesic 
action in dentistry, has been explored for the local analgesic effect and CPE 
potential in topical drug delivery systems (Pramod et al., 2010). Germacrene D 
in Senecio rufinervis essential oil has been characterised for its analgesic 
activity (Mishra et al., 2010). A recent review over analgesic-like activity of 
essential oils constituents found that 43 terpenes and terpenoids exhibited 
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antinociceptive activity via different mechanisms of action in mouse/rat pain 
models (de Sousa 2011). Limonene was reported to be a selective antagonist 
for adenosine A2A receptors which may induce sedative effects (Park et al., 
2011) while carvone was thought to induce sedation (de Sousa et al., 2007). In 
summary, the incorporation of terpenes into the transdermal and topical 
formulations of analgesics and sedatives may have a synergistic effect when 
incorporated in formulations with analgesic and anaesthetic drugs. 
 
1.4 Gel formulation 
 
Currently for transdermal and topical delivery, semisolid formulations are 
preferred because they remain in situ and deliver the drug over extended 
period of time (Walters and Brain, 2002). Therefore, many commercial 
formulations are ointments, creams, or gels.  
 
A gel is a semisolid system in which a liquid phase is trapped within an 
interlocking, three-dimensional polymeric matrix of a natural or synthetic 
polymer (Lu and Flynn, 2009). A high degree of physical or chemical 
cross-linking of the polymer is present in the gelling system. Both by weight 
and volume, gels are mostly liquid in composition and thus exhibit densities 
similar to those of their constituent liquids. Gels are usually less greasy than 
ointments and creams, and they have greater patient compliance. And as gels 
generally do not comprise two immiscible phases of opposite lipophilicity like 
creams and ointments, gels are thermodynamically more stable. 
 
Hydrogel is a network of polymer chains that are water-insoluble, sometimes 
as colloidal gel, in which water or biological fluids are the dispersion media. 
Due to their physical properties (high water content, soft, and pliable 
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consistence), hydrogels possess a degree of flexibility quite similar to that of 
human tissue, which have been used for different administration routes 
(Cerchiara and Luppi, 2005). They can be used as reservoirs in topical and 
transdermal drug delivery of hydrophilic and ionic drugs as well as 
macromolecules, which can be delivered by iontophoresis, electroosmosis, 
electroporation and microneedles (Cerchiara and Luppi, 2005; Valenta and 
Auner, 2004). 
 
Organogel is composed primarily of a low molecular weight or polymeric 
organogelator dissolved in organic solvents. In the organic solvent, the binding 
forces of gelation are primarily dipolar interactions, intermolecular hydrogen 
bonds or metal-coordination bonds, which differ from those in the hydrogel. It 
has advantages including the capacity to incorporate both hydrophilic and 
lipophilic drugs, thermoreversibility, high degree of stability to moisture and 
temperature, and the ability to control the rate of drug release (Lim et al., 
2008). Moreover, an important merit of organogel is that many typical 
organogel components are chemical penetration enhancers, for example, fatty 
acids, surfactants, alcohols, terpenes and propylene glycols (Vintiloiu and 
Leroux, 2008).  
 
1.5 Nanoparticlate drug delivery systems 
 
Nanotechnology, or nanoscience, has become a rapidly growing field with 
applications in many areas ranging from electronics to pharmaceutics. 
Nanomaterials such as nanoparticles, nanorods, nanowires, nanosheafs, 
nanotubes and nanomeshes have been developed with extraordinary physical 
and chemical properties as a result of their nanosize effects due mainly to the 
increased surface area and the quantum effect (Stevanović and Uskoković 
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2009; Thassu et al., 2007). These nanomaterials are generally less than 100 nm 
in all three dimensions. Nanoparticles in nanotechnology refer to particles 
having diameters between 1 - 100 nm, while for pharmaceutics and cosmetics, 
nanoparticles are particles of diameters between 1 - 999 nm, which will 
usually be above 100 nm (Baroli 2010). Most current nanomaterials could be 
categorised into 4 types: carbon-based materials, metal-based materials, 
polymers/dendrimers, and composites, among which polymers/dendrimers 
have been preferred for pharmaceutical applications (Lü et al., 2009).  
 
Nanoparticulate drug delivery systems (NPDDSs), which are developed with a 
combination of nanotechnology and drug delivery system (DDS), have been 
explored to enhance the delivery of drugs. NPDDSs can target and release 
therapeutic molecules in defined regions of the body. Many NPDDSs provide 
both hydrophobic and hydrophilic environments, which facilitate the 
solubilities of a drug as it transits through the body and its barriers before 
reaching its target sites of action. Moreover, NPDDSs can increase drug 
bioavailability by encapsulating the drug in a protective environment so that 
smaller doses of drug can be administered (Pathak et al., 2007).  
 
In 2005, the U.S. FDA approved the intravenously administered 130-nm 
albumin nanoparticles loaded with paclitaxel (Abraxane
TM
) for cancer therapy, 
which became the first of many new products containing nanoparticulate 
systems (Gupta 2006). NPDDSs have been applied for a wide range of 
therapeutics from cancer treatments to some over-the-counter (OTC) 
preparations. The advantages of NPDDSs are shown in Table 1.6. However, 
the GMP production of nanoparticles with well-defined properties may be 
expensive and the challenge of manufacturing scale-up of nanoparticles 




Table 1.6. Advantages of nanoparticulate drug delivery systems in formulation 
applications. Adapted from Pathak et al. (2007). 
1. Addressing the drug-delivery problems 
- Solving the issues related to solubility 
- Overcoming the poor bioavailability of the drugs 
- Reducing fed/fasted variability 
- Decreasing pharmacokinetic variability 
2. Finding solutions with nanoparticulate drugs 
- Technology advances 
- Reduction in particle size of the poorly water-soluble drugs 
- Increased surface area of the active agent 
3. Benefits for faster dissolution 
- Greater bioavailability 
- Smaller drug doses 
- Diminished toxicity 
- Decreased dosing variability 
4. Pharmacodynamic factors: Applicable to peptides and other drugs 
- These can be formulated as receptor-specific 
- These can be more resistant to unspecific degradation 
- They can deliver the drug in encapsulated form to delay the 
degradation, set a depot form for prolonged signalling, and increase the 
treatment efficacy as compared to substitution of the natural form of 
peptide 
 
1.5.1 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
 
Polymeric nanoparticles are extensively used for the nanoencapsulation of 
bioactive compounds. Biodegradable polymeric nanoparticles are generally 
preferred for their characteristics, such as providing controlled or sustained 
release, being biocompatible and biodegradable, non-toxic, nonthrombogenic, 
nonimmunogenic, and may be applicable to both small molecules and 
macromolecules (Kumari et al., 2010). A number of polymers have been 
investigated for formulating biodegradable nanoparticles, such as synthetic 
polymers, namely polylactic acid (PLA), polycaprolactone (PCL) and 
poly(lactic-co-glycolic acid) (PLGA), and natural polymers, namely cellulose, 
gelatin, alginate and chitosan. PLGA is a copolymer synthesised by means of 
random ring-opening copolymerization of two different monomers, glycolic 
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acid and lactic acid. It is one of the most commonly used biodegradable 
polymeric biomaterials for the development of nanomedicines as its hydrolytic 
products are biodegradable metabolite monomers both in the body and on the 
surface of the skin (Fig. 1.9). Since the body can effectively deal with these 
two monomers by metabolism in the Krebs cycle, there is minimal systemic 
toxicity associated by using PLGA for drug delivery or biomaterial 
applications (Kumari et al., 2010). Moreover, the safety of PLGA has been 
buttressed by its US FDA and European Medicines Agency (EMA) approvals 
of drug delivery systems for parenteral administration (Danhier et al., 2012). 
 
Fig. 1.9. Hydrolysis of PLGA. 
 
 
In nanotechnology, the most widely used PLGA composition of 50:50 has the 
fastest biodegradation rate of the D,L-lactide/glycolide polymers that is  
degradation in about 50–60 days in vivo (Mundargi et al., 2008). There is no 
report so far about the degradation profile of PLGA on human skin surface. 
 
The synthesis of PLGA nanoparticles can be divided into bottom-up and 
top-down techniques. The bottom–up technique employs a monomer as a 
starting point, such as emulsion or microemulsion polymerization, interfacial 
polymerization and precipitation polymerisation; while the top-down 
technique applies pre-formed PLGA polymers by which nanoparticles are 
synthesised, such as emulsion evaporation, emulsion diffusion, salting out and 
nanoprecipitation (Astete and Sabliov, 2006). One of the most commonly used 
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and simplest methods is single emulsion evaporation method for lipophilic 
drugs which is an oil-in-water (o/w) process or double emulsion evaporation 
method for hydrophilic drugs which is a water-in-oil-in-water (w/o/w) process. 
Generally, in single emulsion evaporation method, PLGA and the drug are 
first dissolved in a water-immiscible, volatile organic solvent (e.g., 
dichloromethane), This polymer-drug-solvent solution or suspension is then 
emulsified in a stirrer/sonicator/homogenizer with appropriate power and 
temperature conditions in a large volume of aqueous solution in the presence 
of an emulsifier such as polyvinyl alcohol (PVA) to yield an o/w emulsion. 
PVA is the most commonly used stabiliser in the emulsion evaporation 
method. Followed by solvent removal by either evaporation or extraction to 
harden oil droplets, the solid nanoparticles obtained are then collected by 
centrifugation or filtration with one or more times of wash to get rid of the 
drug on the surface of the nanoparticles. These nanoparticles are then 
resuspended and lyophilised to obtain final nanoparticulate powder 
(Cohen-Sela et al., 2009; Song et al., 2008; Mainardes and Evangelista 2005). 
For the double emulsion evaporation method, the primary w1/o emulsion is 
first formed followed by the secondary w1/o/w2 emulsion. Other steps and 
conditions are similar to those of the single emulsion evaporation method. In 
summary, the emulsion evaporation method can be used for most drug 
candidates (single emulsion method for hydrophobic drug and double 
emulsion method for hydrophilic drug and macromolecules), and is easy to 
scale up with high yield of nanoparticles. However, a lack of monodispersity 
for the nanoparticles was found, especially when using a sonicator in the 
emulsification process (Astete and Sabliov, 2006). 
 
The PLGA nanoparticles are characterised by its size, size distribution, surface 
charge, morphology, drug loading, drug encapsulation efficiency, recovery 
rate and drug release profile. Size and size distribution can be measured by 
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dynamic light scattering, static light scattering, ultrasonic spectroscopy, 
turbidimetry, and filtration (Haskell 2006). Dynamic light scattering records 
the variation in the intensity of scattered light on the microsecond time scale 
(Chu and Liu, 2000). The technique is well developed with several advantages 
including fast measurement, no calibration needed and high sensitivity 
(Haskell 2006). However, test sample suspensions should be diluted to a 
certain concentration to avoid artifacts, demanding a number of dilutions for 
an unknown or new sample. The surface charge of PLGA nanoparticles can be 
characterised by zeta potential using the same dynamic light scattering 
apparatus. The higher absolute value of zeta potential indicates the higher 
surface charge of nanoparticles, thus the nanoparticles are less likely to 
aggregate. The morphology, as well as size, of PLGA nanoparticles is usually 
characterised by scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM), which provide a way to directly observe 
nanoparticles (Haskell 2006). However, the beam heating effect caused by 
SEM or TEM may generate surface local heating to the PLGA nanoparticles 
and change their structures and morphologies; therefore, high voltage should 
be avoided (Stout et al., 2011; Egerton et al., 2004). Drug loading, 
encapsulation efficiency and recovery rate are three parameters used to 
describe how successfully the drug has been incorporated into the 
nanoparticles. Achieving a high drug loading, encapsulation efficiency and 
recovery rate must be balanced with other desired characteristics, such as 
stability and release profile of nanoparticles. The release process of PLGA 
nanoparticles involves the release of compound from the surfaces and inner 
parts of the nanoparticle matrix as well as the structural changes of the entire 
nanoparticle. Then the in vitro release study of nanoparticles is typically 
performed using a dialysis membrane instead of a filter membrane with 




1.5.2 Nanoparticles and the topical and transdermal routes 
 
Nanoparticles have been increasingly applied in the topical and transdermal 
delivery systems to facilitate drug percutaneous absorption (Prow et al., 2011). 
Fig. 1.10 shows the potential sites for targeting nanoparticles, which include 
skin surface, skin furrows and hair follicles. Few studies have shown that 
PLGA nanoparticles penetrated the dermis of rat skin in vivo by iontophoresis 
(Tomoda et al., 2012a; Tomoda et al., 2012b); and through hairless mouse skin 
and human skin in vitro with the microneedle pre-treatment (Zhang et al., 
2011; Zhang et al., 2010). Other studies of topical and transdermal PLGA  
 
Fig. 1.10. Schematic diagrams of sites in skin for nanoparticle delivery. 
Topical nanoparticle drug delivery takes place in three major sites: stratum 
corneum (SC) surface (a), furrows (dermatoglyphs) (b), and openings of hair 
follicles (infundibulum) (c). The nanoparticles are shown in green and the 
drug in red. Other sites for delivery are the viable epidermis (E) and dermis 





NPDDSs showed no obvious evidence that PLGA nanoparticles had 
penetrated into the viable layers of the skin. Recent reviews of topical and 
transdermal NPDDSs argued that rigid nanoparticles with parameters over 20 
nm are very unlikely to penetrate the viable layers of skin both in vitro and in 
vivo (Pegoraro et al., 2012; Prow et al., 2011; Cerv and Vierl, 2010; Baroli, 
2010). It is unlikely for non-deformable PLGA nanoparticles with diameters 
of usually more than 100 nm to conquer the stratum corneum barrier. 
Therefore, PLGA nanoparticles may not deliver the drug into the skin in the 
form of nanoparticles, but they may enhance drug permeation by forming 
nanoparticle aggregations and thereafter drug reservoir in skin furrows and 
hair follicles, or forming some kind of nanoparticle “coating” to achieve 
sustained release (Cerv and Vierl, 2010). Other studies demonstrated drug 
permeation enhancement by combining PLGA nanoparticles with massage 
pre-treatment (Lademann et al., 2007) and by oleic acid surface modification 
of PLGA (Shah et al., 2012), thereby showing the potential of PLGA 
nanoparticles as a drug reservoir for the enhanced and sustained release of 
drugs on the skin surface. 
 
1.6 Isothermal titration calorimetry 
  
Isothermal titration calorimetry (ITC) is a physical technique used to 
quantitatively determine the thermodynamic parameters, mainly enthalpy 
changes, of physical and chemical interactions initiated by the addition of 
titrant to titrand at a constant temperature (Fig. 1.11) (Roselin et al., 2010; 
Kang et al., 2006). ITC has major advantages of high sensitivity (some at the 
nanowatt range), stable conditions at several fixed temperatures, 
non-destructive to samples, and fast equilibration after reloading the sample 
and changing the temperature at which measurements are carried out (O’Neill 
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and Gaisford, 2011; Privalov and Dragan, 2007). ITC has a variety of 
application areas, for example, ligand binding studies, dissolution and sorption 
measurements, estimation of the stability of chemical substances and technical 
products, and measurements of metabolic reactions in living cellular systems 
(Wadsö et al., 2001). Kang and his co-workers (2006) have shown that a 
chemical enhancer azone could selectively interact with the components of 
stratum corneum lipids by hydrogen bond. Although most of the applications 
of ITC are centred on macromolecules, it remains a useful approach to 
investigate interactions between small molecules (Freyer and Lewis, 2007). 
 
Many studies have been carried out on penetration enhancement mechanisms, 
but few used ITC to unravel the interactions between small molecules. For a 
ternary interaction system of drugs, CPEs and stratum corneum lipids, 
interactions between stratum corneum lipids and CPEs are usually overlooked, 
but could provide valuable insights. 
 
Fig. 1.11. A representative diagram of a typical power compensation ITC. 




1.7 Objectives and hypotheses 
 
The overall objective of this thesis is to develop topical/transdermal 
formulations that may provide desired therapeutic effects while overcoming 
the systemic adverse effects of the drugs when administered by oral and 
parenteral routes. Meanwhile, the thesis also aims to explore preliminary 
mechanisms of percutaneous absorption.  
 
1.7.1 Amitriptyline and ketamine hydrogel for neuropathic pain 
 
The major objective is to develop a topical formulation of amitriptyline and 
ketamine hydrogel with CPEs for peripheral neuropathic pain which may 
achieve high local tissue concentrations and minimal systemic exposure of 
amitriptyline and ketamine. 
The specific objectives are to: 
- Develop a hydrogel formulation incorporated with amitriptyline, ketamine 
and CPEs. 
- Test the enhancement of CPEs in the hydrogel by in vitro permeation 
studies through excised human epidermis and hairless mouse full skin. 
- Profile the pharmacokinetic parameters and tissue distribution of both 
drugs in rats after application of amitriptyline ketamine hydrogel. 
- Establish the HPLC assay of simultaneous detection of both amitriptyline 
and ketamine. 
- Establish and validate the plasma and tissue extraction methods and 
LC-MS-MS assay of both amitriptyline and ketamine. 
- Validate the stability of the finalised formulation by rheological tests, drug 
content analysis and microcalorimetry test. 
- Probe into the possible interaction between drug and CPE through 




These are preclinical studies of formulations containing amitriptyline and 
ketamine prior to clinical investigations. 
 
1.7.2 Midazolam nanoparticulate propofol organogel for sedation 
 
The major objective is to develop a transdermal formulation of midazolam 
nanoparticulate propofol organogel with CPEs for procedural sedation which 
may achieve substantial skin permeation of midazolam and propofol.  
The specific objectives are to: 
- Develop midazolam-PLGA-nanoparticulate preparation method and to 
achieve high drug loading and encapsulation efficiency with optimization. 
- Characterise midazolam-PLGA-nanoparticles with various parameters. 
- Develop midazolam PLGA nanoparticulate propofol organogel with CPEs. 
- Assess the stability of the midazolam PLGA nanoparticulate propofol 
organogel at different temperatures for 6 months with rheological tests, 
drug content analysis and SEM profiles. 
- Establish and validate the HPLC assay of simultaneous detection of both 
propofol and midazolam. 
- Probe the in vitro release profile and in vitro permeation profile of 
midazolam PLGA nanoparticulate propofol organogel through hairless 
mouse skin. 
 
The study has been conducted on a laboratory scale and would need further 
scale-up studies for manufacturing supplies, clinical trials or applications.  
 
1.7.3 Isothermal Titration Calorimetry (ITC) study 
 
The specific objectives are to: 
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- Explore change of solubilities of stratum corneum lipids in PG in the 
presence of farnesol. 





Topical delivery of amitriptyline and ketamine hydrogel with CPEs for 
peripheral neuropathic pain can achieve high local tissue concentrations and 
minimal systemic exposure of amitriptyline and ketamine. 
 
Transdermal delivery of MNP organogel with CPEs for procedural sedation 
can achieve substantial skin permeation of midazolam and propofol. 
 
Farnesol may have some type of inter-molecular interaction with the stratum 




2. Amitriptyline hydrogel 
 




Amitriptyline hydrochloride (98%) (AMI), (-)-menthol (99%) (MEN), 
(+)-limonene (98%) (LIM), hydroxypropylmethylcellulose (HPMC) (typical 
MW 120,000; viscosity 100,000,000 cps in 2 wt% solution in water, 20°C), and 
propylene glycol (PG) (99.5%) were obtained from Sigma (Steinheim, 
Germany). Acetonitrile (HPLC grade) was purchased from Tedia (Ohio, USA). 
Milli-Q water (18 MΩ-cm; Millipore, USA) was used in the preparation of 
aqueous solutions and HPLC mobile phase. Chemicals were of at least reagent 
grade and all materials were used as received. 
 
2.1.2 Preparation of human epidermal membrane 
 
Abdominal skins of one Chinese female adult and one Malay female adult were 
obtained with their informed consent after plastic surgery. Full-thickness skin 
with epidermis facing downwards was immersed in 60°C water for 2 minutes 
(Lim et al., 2006). Then the epidermis was carefully peeled off and stored in a 
freezer at -80°C until use. The epidermis was thawed prior to permeation 
studies in 1 × PBS solution. 
 
2.1.3 Amitriptyline hydrogel preparation 
 
Amitriptyline hydrogel was prepared with 50% v/v water, 35% v/v ethanol, 5% 
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v/v PG, and 2% w/v amitriptyline hydrochloride. The mixture was then stirred 
at 300 rpm with HMPC added slowly during stirring. The stirring was kept for 
around 8 hr until a homogeneous transparent gel was formed. Amitriptyline 
hydrogels containing different enhancers, namely menthol and/or limonene, 
were formulated as shown in Table 2.1. Solubilities of menthol and limonene 
were increased in hydrogel by adding 1% v/v Tween 20 or Tween 80. 
 
Table 2.1. Composition of enhancers and solubilisers in hydrogels.  













1a 0 0 1.5 0 
1b 0 0 1.5 1 Tween 20 
1c 5 0 1.5 1 Tween 20 
1d 0 5 1.5 1 Tween 20 
1e 2.5 2.5 1.5 1 Tween 20 
Permeation  
test 2 
2a 0 0 1.8 0 
2b 0 0 1.8 1 Tween 80 
2c 1 0 1.8 1 Tween 80 
2d 1.5 0 1.8 1 Tween 80 
2e 2 0 1.8 1 Tween 80 
2f 2.5 0 1.8 1 Tween 80 
2g 5 0 1.8 1 Tween 80 
  
2.1.4 In vitro skin permeation study 
 
Flow-through type diffusion cells were used for permeation studies with the 
methods adapted from Kang et al. (2007a). Excised human epidermis was 
mounted between donor and receptor compartments with stratum corneum side 
up. Excess skin was trimmed off to minimise lateral diffusion. The circular skin 
area available for drug permeation was 0.785 cm
2
. The receptor solution of 1 × 
PBS solution containing 10% v/v methanol and 1% v/v antibacterial 
antimycotic solution was allowed to flow through the receptor compartment. 
The receptor solution was thoroughly degassed for 15 min to avert the 
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formation of bubbles beneath the epidermis. One gram of amitriptyline 
hydrogel was placed into the donor cell and covered with Parafilm
®
 and 
aluminum foil to minimise evaporation and contamination. Assembled 
diffusion cells were maintained isothermally at 32°C by a heater/circulator 
(Haake, Germany). The receptor solution was pumped by a 16-channel 
peristaltic cassette pump (Ismatec, Switzerland) continuously at 0.75 ml/hr 
through the receptor compartment and drained into sample tubes. Cumulated 
receptor liquid samples were taken every 6 hours for HPLC assay. 
 
2.1.5 In vitro amitriptyline hydrogel release study 
 
The release of amitriptyline from the hydrogel was carried out according to in 
vitro skin permeation study (described in 2.1.4) except that Nylon filter 
membrane (0.45 m, Whatman, England) was used instead of human epidermis 
and that samples were taken every hour in 0 - 6
th









 hr with a flow rate of 3.5 ml/hr of the receptor 
solution. Hydrogels 2b and 2e were used in release study. 
 
2.1.6 Determination of drug concentration 
 
Drug concentrations were determined using reversed phase HPLC method. A 
Hitachi LaChrom L-2000 HPLC system and an Agilent Hypersil ODS column 
(4.0 × 250 mm; 5 μm) were used. The gradient elution and detection wavelength 
were 1.2 ml/min and 254 nm, respectively. The mobile phase consisted of 
solution 1 (1% w/v ammonium acetate at pH 4.0) and 2 (acetonitrile). The 
starting ratio was 45% for solution 1 and 55% for solution 2, after which the 
proportion of solution 2 increased linearly to 85% in 12 min, and then back to 
the initial composition, followed by a 10-min equilibration. The column 
temperature was set at 45°C. Mean peak area ratios of amitriptyline were 
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linearly related to the drug concentrations for the samples containing 1 - 5000 
μg/ml (r2 = 0.999). 
 
2.1.7 Permeation parameters 
 
Permeation parameters are interpreted from a cumulative drug per unit skin area 
versus time plot (Lim et al., 2006). The gradient and x-intercept of the linear 
portion of the plot yield steady-state flux (Jss) and lag time (tL) accordingly. 
Permeability (KD/L) is given by the ratio of Jss to drug concentration C0 in the 
donor solution. Diffusion parameter (D/L
2
) gives the mobility of the drug solute 
in the skin, and partition parameter (KL) reflects the distribution of the drug 
between the skin and the donor solution. Enhancement index (EI), a ratio of 
permeabilities in the presence and absence of penetration enhancers, measures 
the enhancement in drug penetration.  
The transdermal application area can be estimated by using equation (2.1) 
(Vaddi et al., 2002): 
A= Css×Clp / Jss                                              (2.1) 
Css is the steady state plasma concentration of amitriptyline. Css of amitriptyline 
in the treatment of neuropathic pain was reported to be 36 ± 29 ng ml
-1
 
(Eisenach et al., 1997). Clp is plasmatic clearance of amitriptyline, which is 




 (Brunton et al., 2006).  Jss is the steady state flux of the 
transdermal formulation. 
 
2.1.8 Formulation stability study 
 
The amitriptyline hydrogel with highest permeation enhancement was 




2.1.8.1 Physical consistency test 
 
Brookfield viscometer LVT (Middleboro, MA, USA) was used to test the 
viscosity changes. The viscosity of the hydrogel was measured at two different 
shear rates in triplicates. Data at Day 0 and Day 30 of the accelerated test were 
compared.  
 
2.1.8.2 Chemical stability test 
 
Hydrogel samples were extracted and tested for drug concentration at Days 0, 7, 
15, and 30. The recovery rate was defined as the drug concentration after 
storage versus the drug concentration at Day 0. One gram of hydrogel was 
accurately weighed and dissolved in 100 ml volumetric flask with Milli-Q water, 
and was stirred for 30 min. The resultant mixture was filtered through 0.45-μm 
Nylon membrane filter and injected into the HPLC system. The amount of 
amitriptyline hydrochloride was estimated from the standard curve as described 
in Section 2.1.6. 
 
2.1.8.3 Microcalorimetry test 
 
The physicochemical stability of the hydrogels was determined with the thermal 
activity monitor (TAM) from Thermometric AB (Jarfalla, Sweden). One gram 
of hydrogel 2e was pipetted into a 4 ml glass ampoule and capped. The ampoule 
was placed in the measuring cylinder of TAM at 40°C for 26 days. The control 








2.1.9 Drug-enhancer interaction study 
 
The possible molecular interaction between amitriptyline and menthol was 
determined by isothermal titration calorimetry (ITC) technique. The machine 
performing the study was thermal activity monitor (TAM) from Thermometric 
AB (Jarfalla, Sweden) (the same as described in Section 2.1.8.3) with 4 ml 
stainless steel ampoules. Samples were prepared in the solvent system used in 
amitriptyline hydrogel formulation with two major solvents of 58.8% v/v water 
and 41.2% v/v ethanol. Amitriptyline and menthol solution was prepared at 
concentrations of 6.37 mmol l
-1
 and 0.18 mmol l
-1
, respectively. Amitriptyline 
solution of 0.12 ml was titrated consecutively into 2.7 ml of menthol solutions 
by 15 aliquots. The menthol solution was stirred with a turbine at 60 rpm. The 
reference ampoule was loaded with 2.7 ml water-ethanol solution. The system’s 
temperature was maintained at 36.94°C. ITC data were analysed by Digitam
®
 
software (Scitech Software, Sweden) supplied with TAM2277. 
 
The thermodynamic parameters include the enthalpy change ΔH, binding 
stoichiometry N, and binding constant K and were estimated from the 
non-linear regression analysis procedure of Digitam
®
. Free energy change ΔG 
and entropy change ΔS were calculated according to: 
ΔG= –RTlnK= ΔH–TΔS                                      (2.2) 
R is the gas constant, 8.314 (J mol K
-1
), and T is the temperature (310.15 K). 
 
2.1.10 Statistical analysis 
 
Statistical analysis was performed using Minitab software. One-way analysis of 
variance (ANOVA) with Tukey’s comparison ascertained the effects of CPEs 
present in hydrogels on the permeation of amitriptyline across human epidermis. 
The level of significance was taken as p < 0.05. 
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2.2 Results and discussion 
 
2.2.1 Enhancement effects of menthol and limonene 
 
Amitriptyline hydrochloride (AMI) (molecular weight = 313.87 g mol
−1
) is 
ionised in physiological environment (pH 7.4) with a pKa of 9.49. Amitriptyline 
is considered free soluble in water and can dissolve in cold water in a 1:1 
volume ratio and form a viscous solution (data not shown here). As the main 
barrier of skin is stratum corneum which is composed of fatty acids, ceramides 
and cholesterol, charged molecules can hardly penetrate the lipid barrier 
without permeation enhancement techniques. Meanwhile, the common 
permeation pathways for hydrophilic drugs through hair follicles and sweat 
glands only offer limited permeation capacity. 
 
The profiles of permeation test 1 are shown in Fig. 2.1. The flux values and 
other permeation parameters are given in Table 2.2. Fluxes of amitriptyline with 
terpenes were significantly different from control with or without Tween 20 (p 
< 0.05). Tween 20 was added to increase the solubility of 5% terpene in the 
hydrogel system. Tween 20, a non-ionic surfactant and also a penetration 
enhancer, significantly increased the flux of amitriptyline by 3.5 fold as 
compared to the control formulation without Tween 20. 
 
However, the enhancement achieved by Tween 20 alone is almost negligible 
when compared to the enhancement achieved in the presence of terpenes. The 
formulations of 5% menthol alone and the combination of 2.5% menthol and 







Table 2.2 Permeation parameters of amitriptyline in hydrogel containing 5% 


























1a  0.34 ± 0.05 31.10 ± 0.51 0.54 ± 0.01  0.17 ± 0.03  0.32 ± 0.05     - 
1b  1.18 ± 0.19  5.69 ± 0.11 2.93 ± 0.06  0.59 ± 0.10  0.20 ± 0.04   3.5 
1c 92.82 ± 3.89 11.47 ± 1.47 1.47 ± 0.19 46.41 ± 1.95 31.99 ± 5.03 273.0 
1d 15.04 ± 3.94  6.43 ± 1.90 2.77 ± 0.91  7.52 ± 1.97  3.05 ± 1.59  44.2 
1e 79.57± 24.46 10.00 ± 3.27 1.82 ± 0.71 39.78 ± 12.23 22.86 ± 7.48 234.0 
 
Fig. 2.1 Time course of cumulative amitriptyline hydrochloride (AMI) 
permeated through 0.785 cm
2
 of human epidermis with or without terpene.  
Each point represents mean ± S.D. (n = 3). 
 
 
Menthol, a terpene penetration enhancer, is often used to increase the 
permeation of drugs with a wide range of lipophilicities in transdermal and 
topical formulations, such as imipramine hydrochloride, indomethacin, 
antipyrine, and testosterone (Fujii et al., 2003; Jain et al., 2002; 
Kaplun-Frischoff and Touitou, 1997). Its enhancing efficacy is due to several 
mechanisms of interactions with the skin lipid matrix. Obata and his colleagues 
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(Obata et al., 2010) proved that l-menthol could interrupt the rigid 
microstructure of intercellular lipids in stratum corneum in a positive 
concentration-dependent manner at its low concentration range (0 - 1%). 
Detailed mechanism of lipid interruption was investigated by Jain and his 
co-workers (2002) who indicated that menthol could break hydrogen bonds 
where a network was formed between ceramide head groups found abundantly 
in stratum corneum. A study using computational methods also supported that 
hydrogen bonding was involved in the interactions between oxygen-containing 
terpenes, such as menthol, and model drugs (5-fluorouracil, hydrocortione, 
diclofenac sodium and estradiol) (Drakulić et al., 2008). Terpene penetration 
enhancers may create micro-pores in the intercellular lipids through which both 
ions and polar drugs may pass (Cornwell and Barry, 1993). This is likely the 
major pathway for the permeation of ionised drug into the skin which agrees 
with the observation of the considerable increase of amitriptyline permeation 
with menthol in our study. In addition, it was suggested by Fujii and his 
co-workers (2003) that menthol can increase permeation of ethanol which will 
also cause a solvent drag effect on the permeant.  
 
In the in vitro release study using Nylon filter membranes, both hydrogels with 
and without 2% menthol provided sustained release of amitriptyline within 48 
hr (Fig. 2.2). It was observed that the release rates of the amitriptyline hydrogels 
with and without 2% menthol were not significantly different (p > 0.05). This 
indicates that menthol did not interact with the hydrogel matrix or Nylon filter 
membrane and minimally modified the release of amitriptyline. As menthol 
caused greater percutaneous permeability and diffusivity of amitriptyline, the 
enhancement action of menthol occurred in the presence of the stratum corneum. 
Therefore, the penetration enhancing effect of menthol is probably due to one or 




Menthol could also significantly decrease the lag time of amitriptyline 
permeation (p < 0.05), although limonene performed better (Table 2.2). In view 
of the partition parameter (KL), menthol significantly increases the partitioning 
of amitriptyline by 100 fold, while the increase of diffusion parameters is 
moderate. This also provides evidence that menthol could have facilitated 
penetration of amitriptyline from the hydrogel vehicle through human 
epidermis by increasing partitioning. 
 
Fig. 2.2 Time course of cumulative amitriptyline hydrochloride (AMI) 
permeated through 0.785 cm
2
 of 0.45 m Nylon filter membrane with or 
without menthol. Each point represents mean ± S.D. (n = 3). 
 
 
The high enhancement efficacy achieved by 5% menthol could probably be due 
to its oxygen-containing and hydroxyl group containing structure, which could 
form hydrogen bond with the skin lipid layer and possibly with the permeant, 
amitriptyline. Many studies suggest that alcohol terpenes (e.g. menthol), ketone 
terpenes and oxide terpenes, which are hydrophilic, are more effective in 
enhancing the permeation of hydrophilic drugs; whereas hydrocarbon terpenes 
(e.g. limonene) and cyclic ether terpenes, which are lipophilic, are more 





Limonene is reported to be very effective in enhancing the transport of 
lipophilic drugs such as haloperidol, indomethacin and hydrocortisone (Lim et 
al., 2006; Williams and Barry, 2004; El-Kattan et al., 2000). Limonene can also 
enhance the transdermal permeation of some hydrophilic drugs, such as 
ondansetron hydrochloride and acyclovir sodium (Jukanti et al., 2011; 
Krishnaiah et al., 2008). In our study, 5% limonene can significantly increase 
the permeability of amitriptyline through human epidermis for 44.2 fold (p < 
0.05), which is higher than most data reported in literature mentioned above. 
Our findings showed that limonene can be an effective terpene penetration 
enhancer for some hydrophilic drugs. Moreover, limonene significantly 
decreased the lag time to 6.43 ± 1.90 hr compared to the control of 31.10 ± 0.51 
hr, which indicates that limonene significantly modified the diffusivity of 
amitriptyline into the lipid layers. This decrease in lag time was also reported in 
another study by Chandrashekar and Hiremath (2008).  
 
Numerous studies have shown that mixtures of CPEs, which are combinations 
of chemicals either in the same group or from different groups, may achieve 
higher permeation enhancement than the individual CPE. Therefore, such 
combination-derived synergy may offer not only an increase in permeation, but 
also a decrease in the irritancy potential as each CPE is applied at lower 
concentration than when it is used alone. Synergy can be quantified by a 
mathematical parameter, S, indicative of the “extent of interaction” between 
two CPEs and be calculated using the following equation by Karande et al. 
(2004): 
  
    
  
    
          
                                            (2.3) 
    
  
 is the enhancement ratio obtained with a formulation containing two 
permeation enhancers A and B at a total concentration of Y% w/v and X weight 
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fraction of A.   
  and   
  are the enhancement ratios obtained with pure 
components A and B respectively at the same total concentration Y (Karande 
and Mitragotri, 2009). 
 
With the enhancement indices (EI) of 234.0, 273.0, and 44.2 for 2.5% MEN + 
2.5% LIM, 5% MEN, and 5% LIM (Table 2.2), respectively, it can be 
calculated that S between menthol and limonene is 1.48. With a value greater 
than 1, S indicates a positive synergy between menthol and limonene. However, 
the S value is adjacent to 1, and the permeability of 5% MEN and 2.5% MEN + 
2.5% LIM is insignificantly different (p > 0.05). Thus, the synergy between 
menthol and limonene did not yield higher percutaneous permeation 
enhancement and lower irritancy. Moreover, the poor solubility of limonene in 
aqueous system would lead to an unstable hydrogel formulation. Therefore, in 
the subsequent formulations, only menthol was used as it achieved sufficient 
high flux and could be formulated in hydrogel system.  
 
2.2.2. Enhancement effects of menthol at different concentrations 
 
Because the stratum corneum consists of keratinised dead cells, moderate 
disruption of its structure does not cause irritation. However, CPEs are usually 
not selective towards stratum corneum lipids, and after they permeate through 
stratum corneum they may affect the viable cells in the epidermis and even the 
dermis, thereby inducing irritation by interstitial release of cytokines and 
triggering other inflammatory responses (Karande et al., 2004). Thus, terpene 
enhancers are generally incorporated in topical and transdermal formulations at 
a concentration not exceeding 5% w/w due to risk of adverse effects upon 
repeated application on human skin.  
 
Considering the insignificant difference in the fluxes of formulations with 5% 
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and 2.5% menthol as described in Section 2.2.1, the concentration of menthol in 
the formulation was reduced to decrease the irritancy potential of the 
formulation while retaining a relatively high percutaneous enhancement 
efficacy.  
 
Fig. 2.3 Time course of cumulative amitriptyline hydrochloride (AMI) 
permeated through 0.785 cm
2
 of human epidermis with different concentrations 
of menthol (0 - 5% w/v). Each point represents mean ± S.D. (n = 3). 
 
 
Table 2.3. Permeation parameters of amitriptyline in hydrogel containing 0 - 5% 
w/v menthol through human epidermis. Each value represents the mean ± S.D. 

























2a   0.32 ± 0.03 21.10 ± 1.23 0.79 ± 0.05  0.26 ± 0.02  0.32 ± 0.01 - 
2b   3.83 ± 0.04 11.83 ± 0.02 1.41 ± 0.01  3.06 ± 0.03  2.17 ± 0.03  11.8 
2g 151.88 ± 24.08 11.86 ± 0.91 1.41 ± 0.10 75.94 ± 12.04 54.16 ± 10.12 292.1 
2f 138.90 ± 18.63 12.14 ± 1.35 1.38 ± 0.16 69.45 ± 9.32 50.67 ± 9.08 267.1 
2e 153.38 ± 10.74 10.13 ± 0.76 1.65 ± 0.12 76.69 ± 5.37 46.51 ± 3.09 295.0 
2d 119.68 ± 6.56  9.07 ± 3.23 2.03 ± 0.83 59.84 ± 3.28 32.77 ± 12.31 230.2 




Judging from data in Fig. 2.3 and Table 2.3 of 5%, 2.5% and 2% menthol 
hydrogels, the cumulative amounts and fluxes of amitriptyline were not 
significantly different (p > 0.05). T-test comparison between hydrogels with 2% 
and 1.5% menthol, and t-test between hydrogels with 1.5% and 1% menthol of 
the cumulative amount of and flux of amitriptyline showed significant 
differences for both variables. Therefore, the percutaneous enhancement of 
menthol for amitriptyline was concentration-dependent in the range of 0 - 2%. 
And from 2% to 5%, the enhancement of menthol reached a plateau. Krishnaiah 
and his colleagues (2002) demonstrated a similar enhancement phenomenon 
when the permeation of nicardipine hydrochloride increased as the 
concentration of menthol increased from 0 to 8% w/w and then reached a 
plateau at 8 to 12% w/w. With this finding, the concentration of menthol in 
hydrogel was reduced from 5% to 2%, thus lowering risk of irritancy and the 
cost of the formulation.  
 
Therefore, the CPE content was set at 2% menthol in the final formulation of 
amitriptyline hydrogel and the flux obtained was 153.38 g cm-2 hr-1. Using the 
equation (2.1), the estimated transdermal application area is 9.7 cm
2
 for a 60 kg 
patient to reach the therapeutic efficacy of amitriptyline, which is clinically 
accepted.  
 
Human skin is not a simple homogeneous barrier as indicated by Fick’s Laws, 
and some permeation parameters such as permeability coefficient may vary 10 
fold between skin samples (Williams and Barry, 1991b). Skin from a Chinese 
donor was used in the permeation test 1 (Fig. 2.1) and skin from a Malay donor 
was used in the permeation test 2 (Fig. 2.3). The cumulative amount of 
amitriptyline using control gel with no Tween (1a/2a) was around 1.5-fold 
higher through Malay skin than through Chinese skin. The fluxes of both skins 
were the same. However, the permeability and diffusivity of Malay skin was 
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1.52-fold and 1.46-fold more than Chinese skin, respectively, while the lag time 
of Chinese skin was 1.47-fold more than Malay skin. Therefore, the 
enhancement index (EI) in permeation test 2 (Table 2.3) is generally higher than 
in permeation test 1 (Table 2.2) using a hydrogel with the same menthol 
concentration. Another reason for the difference may be that Tween 80 (EI = 
11.8) used in permeation test 2 (2b) is more potent in enhancing amitriptyline 
permeation than Tween 20 (EI = 3.5) applied in permeation test 1 (1b).  
 
2.2.3. Enhancement effects of other components in the formulation 
 
Ethanol is commonly applied in many topical and transdermal formulations. It 
is also commonly employed as a co-solvent with water as it permeates rapidly 





when with water (Williams and Barry, 2004). It is reported that menthol and 
ethanol worked synergistically to significantly enhance the flux of tetracaine 
across mouse skin in vitro and concurrently illustrated the shortest anaesthesia 
onset time, the longest anaesthesia duration and the strongest anaesthesia 
efficacy in human volunteer studies (Fang et al., 2008). 
 
Propylene glycol (PG) has been extensively studied as a co-solvent or a 
penetration enhancer in topical and transdermal drug delivery systems. Many 
studies have shown the synergistic actions of PG when used with other 
penetration enhancers. Synergistic effects between terpenes and PG have also 
been shown with PG as the vehicle, such as the enhancement efficacies of 
carveol, carvone, pulegone and 1,8-cineole rose approximately 4-fold. This was 
explained by improved partitioning of the enhancers into the stratum corneum 
(Williams and Barry, 2004). 
 
Non-ionic surfactants are usually considered to have minor permeation 
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enhancement effect in human skin. However, in our study, 1% v/v Tween 20 
(1b) achieved an EI of 3.5 and 1% v/v Tween 80 (2b) of 11.8, indicating that 
Tween 20 is a moderate permeation enhancer and Tween 80 is an efficacious 
penetration enhancer in the enhancement of hydrophilic drugs in aqueous 
vehicles. And our findings are supported by a report that 0.5% w/w Tween 80 
increased the permeation of diltiazem hydrochloride in HPMC gel through 
human skin by 5 times compared to the control (Karakatsani et al., 2010). 
Therefore, Tween 80 is an efficacious enhancer in enhancing hydrophilic, freely 
soluble drugs released from an aqueous vehicle through human skin. 
 
2.2.4. Formulation stability 
 
The amitriptyline hydrogels were subjected to accelerated stability tests at 40°C 
for 30 days (26 days for microcalorimetry test). The relative humidity was 
roughly controlled using beaker filled with water in the oven. The formulation 
in the permeation test 1 with Tween 20 showed obvious phase separation by the 
end of Week 2. Then Tween 80 was used as the subsequent solubiliser and 
phase separation was not observed after the accelerated stability test.  
 
2.2.4.1. Physical consistency 
 
As shown in Table 2.4, the viscosity of the amitriptyline hydrogel decreased 
significantly (p < 0.05) after 30 days at 40°C. We postulated that the decrease in 
the viscosity may be due to the absorption of moisture by PG, a humectant, in 
the formulation which was not stored in an air-tight container. However, the 
data obtained from microcalorimetry test and the drug content analysis as 
shown in Sections 2.2.4.2 and 2.2.4.3 suggested that the formulations were 
stable. The significant changes in viscosity could probably be due to the 
inaccurate operation and the systematic error of the machine as the Brookfield 
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viscometer required a minimum 100 ml of gel per test. The minimal volume of 
100 ml used led to fluctuations of the measurements from the marginal effect 
and the turbulence compared to tests using a larger volume. 
 
Table 2.4. Viscosity changes of amitriptyline hydrogel before and after an 
accelerated stability test. Each value represents the mean ± S.D. (n = 3). 








6 4.77 ± 0.08 4.25 ± 0.13 
3 5.39 ± 0.02 4.87 ± 0.12 
 
2.2.4.2. Chemical stability 
 
From Fig. 2.4, the amitriptyline drug content remained relatively constant 
between 97.5% and 102.5%. And the HPLC analysis of gel extraction at Day 30 
showed no additional peak besides the existing peak seen at Day 0. These 
findings indicate that amitriptyline degradation in the hydrogel at 40°C over 30 
days was minimal. Therefore, there was no significant drug degradation of 
amitriptyline.  
 
Fig. 2.4. Recovery rate of amitriptyline from hydrogel along the 30-day 




2.2.4.3. Microcalorimetry tests 
 
When there are physical or chemical reactions, heat is either generated or 
absorbed, which can be monitored by isothermal titration calorimetry (ITC) 
technique (Kang et al., 2006). The thermal activity monitor (TAM) calorimeter 
used in our study could detect heat change as low as 1 microwatt. As shown in 
Section 2.2.4.2, amitriptyline is chemically stable under the accelerated 
condition. So the possible changes of the gel would be the physicochemical 
changes of the excipients in the formulation.  
 
Fig. 2.5. Static TAM run for amitriptyline hydrogel containing 2% (w/v) 
menthol at 40°C over 26 days. The upper curve was the test sample, and the 
lower curve was the control. 
 
 
From Fig. 2.5, no obvious peak was detected by the TAM calorimeter indicating 
that the amitriptyline hydrogel was stable under the accelerated condition over 
26 days.  
 
According to the International Conference on Harmonization (ICH) Tripartite 
guidelines, the predictive factor for chemical stability at 25°C is 5, i.e. 30 days 
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at 40°C corresponds to 150 days at 25°C. Therefore, the final formulation of 
amitriptyline may possibly be stable for 150 days at 25°C. 
 
2.2.5. Drug-enhancer interaction study 
 
Fig.2.6 is a representative graph of the triplicate ITC tests of titrating 6.37 mmol 
l
-1
amitriptyline into 0.18 mmol l
-1
 menthol. It reveals that heat was released 
during the titration process and the reaction between menthol and amitriptyline 
was exothermic. The control study was conducted by titrating pure 
water-ethanol solution into the amitriptyline solution, and the heat of the control 
experiment was deducted from the titration study in non-linear regression 
analysis. 
 
Fig.2.6. ITC result of 6.37 mmol l
-1






Fig. 2.7 shows the non-linear regression analyses using the average values of 
raw data triplicates to estimate the thermodynamic parameters of the titration. 




 and the binding 
constant was 5.24×10
4
. According to equation (2.2), the entropy change was 
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. When ΔH is negative and ΔS is positive, the 
process is spontaneous. The stoichiometry number was 1, indicating that one 
menthol molecule interacted with one amitriptyline molecule. The result shows 
that the reaction is entropy-driven because |ΔH| < |TΔS|. This indicates that 
hydrophobic interactions, instead of van der Waals interactions, possibly 
occurred between menthol and amitriptyline molecules (Bouchemal 2008).  
 
Fig.2.7. Non-linear regression analyses to estimate the binding constant K, the 
binding stoichiometry N, and the enthalpy change ΔH with software Digitam®. 
The energy (integral) of each peak as in Fig. 2.6 was plotted as a function of the 




The ITC results offer an explanation that the permeation enhancement effect of 
menthol was not only due to its interaction with the stratum corneum 
constituents but could be due to the complex formation with the permeant 






The preparation and optimisation of a topical formulation of amitriptyline 
hydrochloride with potential efficacy for neuropathic pain was reported. 
Menthol could be an efficacious penetration enhancer for the permeation of 
amitriptyline hydrochloride as shown by in vitro permeation tests through the 
human epidermis and 2% w/v menthol was sufficient to achieve the needed flux. 
Limonene and Tween 80 were also suitable penetration enhancers for 
amitriptyline hydrochloride. The final formulation of hydrogel was found to be 
stable using an accelerated test over 30 days. From the ITC study, the 
permeation enhancement mechanism of menthol showed that menthol formed a 





3. Amitriptyline and ketamine hydrogel 
 
There is a clinical need to develop a topical delivery system of both 
amitriptyline and ketamine, which are proven therapeutics, into a hydrogel 
formulation for the treatment of peripheral neuropathic pain. CPEs are 
incorporated to achieve high local concentrations and low systemic exposure. 
This chapter first describes the optimisation and stability tests of the 
amitriptyline and ketamine hydrogel formulation, then leads to the in vivo 
pharmacokinetics and tissue distribution studies and the development and 
validation of LC/MS/MS method. This is the first attempt to incorporate CPEs 
into topical formulations of amitriptyline and/or ketamine. 
 




The following chemicals were purchased from Sigma (Steinheim, Germany): 
Amitriptyline hydrochloride (98%) (AMI), ketamine hydrochloride (98%) 
(KET), (1R, 2S, 5R)-(-)-menthol (99%), (R)-(+)-limonene (98%), (±)-phytol 
(97%), nerolidol (98%), (R)-(-)-carvone (98%), nerol (97%), (-)-menthone 
(90%), β-citronellol (95%), (±)-linalool (95-97%), sodium dodecyl sulfate 
(SDS) (98.5%), oleic acid (99%), hydroxypropylmethylcellulose (HPMC) 
(typical MW 120,000; viscosity 100,000,000 cps in 2 wt% solution in water, 
20°C), and propylene glycol (PG) (99.5%). Farnesol (97%) was purchased from 
TCI chemical company (Kyoto, Japan). Myristyl lactate (93%) was a gift from 
Chemic Laboratories (Canton, MA, USA). Acetonitrile (HPLC grade) was 
purchased from Tedia (Ohio, USA). Milli-Q water (18 MΩ-cm; Millipore, USA) 
was used in the preparation of aqueous solutions and HPLC mobile phase. 
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Chemicals were of at least reagent grade and all materials were used as 
received. 
 
3.1.2 Preparation of amitriptyline and ketamine hydrogel  
 
Amitriptyline and ketamine hydrogels were prepared with different chemical 
permeation enhancers (CPEs) at two concentrations, i.e. a high concentration 
at 5% (v/v or w/v) (CPE-H) and a low concentration at 0.5% (v/v or w/v) 
(CPE-L). The formulations were shown in Table 3.1. The mixture was then 
stirred at 600 rpm with HMPC added slowly during stirring. The hydrogel was 
stirred for about 8 hr until a homogeneous transparent gel was formed, and 
used within 12 hr as freshly made. 
 























50 35 5 5 2 1 0.2 1.8 
CPE-L 
(0.5%) 
52.5 37 0.5 5 2 1 0.2 1.8 
 
3.1.3 Simultaneous determination of amitriptyline and ketamine by 
HPLC 
 
A Dionex UltiMate 3000 HPLC system and a Phenomenex Luna 3u C18 
column (50 × 2.0 mm; 3 m) were used. Gradient elution was set at 0.5 ml/min. 
The determination wavelengths were 254 nm for amitriptyline and 218 nm for 
ketamine with simultaneous detection by diode array detector. The mobile 
phase consisted of 70% (v/v) 50mM ammonium acetate (pH 6.0) and 30% (v/v) 
acetonitrile. The column temperature is 45°C. Mean peak area ratios of 
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amitriptyline and ketamine were linearly related to the drug concentrations for 
the samples containing 1 - 250 μg/ml (r2 = 0.9998). 
 
3.1.4 Sample treatment and simultaneous determination of amitriptyline 
and ketamine by LC/MS/MS 
 
After thawing, the tissue samples were cut into pieces of about 0.2 g each, and 
then minced with a pair of scissors. The mince was carefully weighed and 
saline was added to form 0.25 g/ml suspension. The suspensions were 
subjected to homogenisation using the Sonic Dismembrator Model 500 (Fisher 
Scientific Inc., Pittsburgh, PA, USA) at 30% amplitude for 30 sec. The 
homogenates or plasma samples (0.1 ml) were added to 5 l internal standard 
(imipramine dissolved in acetonitrile, 100 g/ml for skin and muscle and 8 
g/ml for other tissues and plasma) and 395 l acetonitrile, and then subjected 
to vortex for 1 min followed by centrifugation at 13000 rpm for 10 min. The 
supernatants were extracted for LC/MS/MS analysis. 
 
The LC/MS/MS analysis was performed using the Agilent Series 1200 HPLC 
system (Agilent Technologies, Palo Alto, CA, USA) equipped with a vacuum 
degasser (G1379B), a binary pump (G1312A), an autosampler (G1329A) and 
a thermostated column compartment (G1316A), and the 3200 QTRAP
®
 
LC/MS/MS systems (Applied Biosystems Inc., Toronto, Canada) supplied 
with electrospray ionisation (ESI) source (ESI-MS/MS) and an on-line 
nitrogen generator system. All the instrumental control and data processing 
were performed using Analyst Software
®
 version 1.4.2 (Applied Biosystems 
Inc., Toronto, Canada). A Phenomenex Luna 3u C18 column (50 × 2.0 mm; 3 
m) was used and the mobile phase consisted of 70% (v/v) 10 mM ammonium 
acetate (pH 6.0) and 30% (v/v) acetonitrile. The column temperature was 60°C. 
The flow rate was 0.25 ml/min. The injection volume was 10 l. The mass 
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spectrometer was operated using ESI source in positive ion mode (ESI+) with 
multiple reaction monitoring (MRM). The precursor and product ions 
transition for amitriptyline, ketamine, and imipramine were 278.3→233.1, 
238.3→125.0, and 281.3→86.2, respectively. 
 
The LC/MS/MS analysis method was validated for intra-day and inter-day 
accuracy and precision, recovery and matrix effect, all of which were 
measured for high, medium and low levels of quality control samples. To 
determine intra-day accuracy and precision, a triplicate analysis of samples 
was performed on the same day. The inter-day accuracy and precision were 
assessed by analysis of three batches on different days. The extraction 
recovery was determined by comparing the analyte/internal standard peak area 
ratios obtained from extracted tissue homogenates and plasma samples with 
those originally dissolved with biological matrix extract. The matrix effect 
was determined by comparing the analyte/internal standard peak area ratios 
dissolved with blank matrix extract against those dissolved with acetonitrile. 
Each effect was measured in triplicate. 
 
3.1.5 In vitro permeation study 
 
In vitro permeation of amitriptyline and ketamine hydrogels were carried out 
according to in vitro skin permeation study (method described in Section 2.1.4) 
except that hairless mouse dorsal skin was used with a flow rate of 0.65 ml/hr of 
the receptor solution. The skins were obtained from euthanised 12-week female 
hairless mice and stored at -80°C before the fat and connective tissues were 
carefully removed and checked for any broken site before use. The samples 





3.1.6 In vivo study 
 
All in vivo experiments are conducted with strict compliance to the Guidelines 
on the Care and Use of Animals for Scientific Purposes (National Advisory 
Committee for Laboratory Animal Research, 2004) of Singapore. The animal 
handling protocols were reviewed and approved by the Institutional Animal 
Care and Use Committee of the National University of Singapore (NUS). The 
male Sprague-Dawley rats (300 - 350 g) used for in vivo studies were 
maintained on a 12-hr light/dark cycle in a specific pathogen free animal 
facility (temperature: 22 ± 1°C, humidity: 60 - 70%). The rats had free access 
to food and water throughout the study.  
 
3.1.6.1 Pharmacokinetic study 
 
Five male Sprague-Dawley rats were used for the pharmacokinetic study. 
Jugular vein cannulation surgery was carried out on the day before the 
pharmacokinetic study. A polyethylene tube (I.D. 0.58 mm, O.D. 0.965 mm, 
Becton Dickinson, Sparks, MD, USA) was placed into the right jugular vein 
through surgical implant under isoflurane anaesthesia. This cannula was used 
for blood sampling, and 0.3 ml heparin-saline (10 IU/ml) was used to flush the 
cannula after blood sampling. Drug administration was performed under 
isoflurane anaesthesia. Hair within the measured area of 15 cm
2
 was carefully 
removed from the abdominal portion using an electrical hair clipper. One gram 
of amitriptyline and ketamine hydrogel was applied on the area, which was 
then covered by Tegaderm
®
 films (3M, Neuss, Germany). Surgical plastic 
tapes were used to fix the Tegaderm
®
 films, and a rat jacket was put on to 
avoid any bite or scratching of the site of application of the gel and the 
covering films. The gel was applied for 6 hr. After which, the rat was lightly 
anaesthetised and the rat jacket, plastic tapes and Tegaderm
®
 films were 
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removed. Then the gel exposed skin areas were washed with saline and 
swabbed with three layers of gauze pads three times. Serial blood samples 
(100 l/sample) were collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 
24, 30 and 36 hr after topical administration. Blood samples were immediately 
centrifuged at 3000 g for 10 min. The harvested plasmas were collected and 
stored at -80°C until LC/MS/MS analysis. 
 
3.1.6.2 Tissue distribution study 
 
Fifteen male Sprague-Dawley rats were used for the tissue distribution study. 
The gel application and removal methods were the same as described in 
Section 3.1.6.1. Five time-points (1.5, 4.5, 7, 11, 20 hr) were set and three rats 
were sacrificed at each time-point to harvest blood and tissues including skin, 
muscle, heart, lung, spleen, kidney, intestine, liver and brain. All these 
samples were immersed immediately in an ice bath at the end of each 
collection interval and then stored at -80°C until required. 
 
3.1.6.3 Pharmacokinetic calculations 
 
All pharmacokinetic calculations were performed with the software of 
WinNonlin standard version 5.0.1 (Scientific Consulting Inc., Apex, NC, 
USA). 
 
3.1.7 Characterisation of rheological parameters  
 
The rheometer (HAAKE RheoStress RS600, Thermo Electron Corporation, 
Waltham, Massachusetts, USA) was used to determine rheological parameters 
of fresh (12-hr-old) amitriptyline and ketamine hydrogel. All measurements 
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were performed at 32 ± 0.2ºC.  
 
3.1.8 Stability study 
 
With the final formulation, amitriptyline and ketamine hydrogels were 
prepared and stored at 4°C for 6 months. Physical and chemical studies were 
performed on different time intervals. 
 
3.1.8.1 Rheological stability of amitriptyline and ketamine hydrogel 
 
The amitriptyline and ketamine hydrogels were tested at predetermined time 
intervals by amplitude sweep tests using rheometer and the conditions 
described in Section 3.1.7 to obtained parameters relating the stability, i.e., 
elastic modulus (G’), viscous modulus (G’’) and yield value. The tests were 
carried out at Day 0, Day 14, Month 1, Month 3 and Month 6 in triplicate. 
 
3.1.8.2 Chemical stability of amitriptyline and ketamine hydrogel 
 
Hydrogel of 100 mg was carefully weighed and suspended with 
acetonitrile:water (50:50 %v/v) to form 0.10 g/ml suspension. After vortex for 
10 min and centrifugation at 13000 rpm for 10 min, the supernatants were 
subjected to HPLC tests for simultaneous detection of amitriptyline and 
ketamine contents. The tests were carried out at Day 0, Day 14, Month 1, Month 
3 and Month 6. Any chemical instability was indicated by a significant change 
of amitriptyline or ketamine concentration in the supernatant beyond ±5% 




3.1.9 Statistical analysis 
 
Statistical analysis was performed using Minitab software. One-way analysis of 
variance (ANOVA) with Tukey’s comparison was used in group comparisons. 
The level of significance was taken as p < 0.05. 
 
3.2 Results and discussion 
 
3.2.1 In vitro CPE optimisation study 
 
Since the enhancement efficacy of CPEs in the formulation is drug-specific 
and few studies have been conducted on the permeation enhancement of 
amitriptyline or ketamine, there is a need to screen a CPE or a combination of 
CPEs to achieve a drug permeation that is high enough for the local 
therapeutic effect. The structures and crucial physicochemical properties of all 
the thirteen CPEs are shown in Fig. 3.1 and Table 3.2. Ten terpenes are chosen 
to represent the major structural classes of commercially available terpenes in 
purified forms. And the three amphiphilic CPEs chosen are non-terpene CPEs 
generally reported to have good enhancing efficacies.  
 
The in vitro permeation study results are shown in Fig. 3.2 and Table 3.3. The 
bars in the figures are sequenced with the right hand side possessing highest 
flux and lowest lag times using the better data among the 2 concentration 






Fig. 3.1. Classification and molecular structures of thirteen CPEs. 
 
 
Table 3.2. Molecular weights (MW) and log P values of 13 CPEs. The data 
were from SciFinder Web
®
 and original product information. 
CPEs MW Log P 
(R)-(+)-limonene 136.24 4.55 
(-)-menthol 156.27 3.22 
(R)-(-)-carvone 150.22 2.27 
(-)menthone 154.25 2.76 
nerol 154.25 2.94 
citronellol 156.27 3.24 
linalool 154.25 2.80 
nerolidol 222.37 4.68 
farnesol 222.37 4.83 
phytol 296.53 8.23 
SDS 288.37 4.42 
oleic acid 282.46 7.42 




Fig. 3.2. Steady-state fluxes and lag times of amitriptyline and ketamine 
permeated through 0.785 cm
2
 of hairless mouse skin. Each bar represents mean 
± S.D. (n = 3). Fluxes of amitriptyline (a) and ketamine (b) in different gels. 












There are several findings that can be derived from Fig. 3.2. Firstly, the ten 
terpenes are more efficient than the three amphiphilic CPEs (oleic acid, SDS 
and myristyl lactate) for both amitriptyline permeation flux (p < 0.01) and 
ketamine permeation flux (p < 0.05). Comparing the fluxes either at 0.5% or 5% 
concentration, the three amphiphilic CPEs are generally less efficient than 
terpenes except limonene. Limonene is the only hydrocarbon terpene tested 
with other 9 terpenes all possessing polar functional groups. The low 
enhancing efficacy of limonene on amitriptyline and ketamine agrees with 
some studies that sesquiterpene and monoterpene enhancers with polar 
functional groups generally produce higher permeation enhancement of 
hydrophilic permeants (Cornwell and Barry, 1994; Williams and Barry 1991b). 
As for the lag times, there is no significant difference between terpenes and 
amphiphilic CPEs, which may indicate that they both reduced the lag time 
significantly by interacting with the stratum corneum. Oleic acid is an 
FDA-approved CPE shown in various in vitro studies to be a promising skin 
penetration enhancer for both hydrophilic and hydrophobic drugs and has been 
widely used in commercial formulations (Shah et al., 2012; Lee et al., 2011; 
Moreira et al., 2010). However, oleic acid demonstrated only moderate 
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enhancing efficacy when compared to the high EI values achieved with 
terpene CPEs. The terpene CPEs, especially sesquiterpenes, showed the most 
permeation enhancement of amitriptyline and ketamine. 
 
Table 3.3. Hairless mice skin permeation parameters of amitriptyline and 
ketamine in hydrogel containing 0.5% or 5% w/v CPEs.  






















control - 0.91±0.05 30.05±0.27 - 5.56±1.52 17.16±1.20 - 
Tween 80 0.1% 1.02±0.04 15.31±0.42 1.12 8.59±0.02 16.74±0.60 1.55 
carvone 
0.5% 8.45±3.10 11.43±3.27 9.30 13.20±1.13 10.06±1.48 2.38 
5% 58.57±14.40 5.06±2.45 64.49 117.96±25.22 3.57±1.11 21.23 
citronellol 
0.5% 15.72±2.30 17.66±2.38 17.31 27.10±6.42 13.97±0.58 4.88 
5% 79.69±37.05 3.22±0.90 87.75 122.06±35.08 4.78±1.15 21.96 
farnesol 
0.5% 92.70±32.57 8.94±3.09 102.07 128.04±25.82 2.82±0.08 23.04 
5% 97.34±22.83 10.19±2.98 107.18 128.48±0.37 3.51±0.05 23.12 
limonene 
0.5% 1.68±0.34 11.12±2.19 1.85 15.14±6.30 14.47±2.13 2.72 
5% 4.43±2.08 16.72±1.45 4.88 38.17±18.27 13.43±0.78 6.87 
linalool 
0.5% 15.37±5.53 10.33±1.06 16.92 35.21±15.39 11.92±1.15 6.33 
5% 74.57±9.73 2.99±0.83 82.11 115.18±1.05 10.42±1.95 20.73 
menthol 
0.5% 5.80±0.99 19.94±1.33 6.38 41.39±6.56 14.45±0.87 7.45 
5% 48.81±1.85 6.96±0.24 53.75 104.68±4.28 14.86±1.22 18.84 
menthone 
0.5% 8.10±2.78 12.08±3.56 8.92 14.15±5.24 11.16±2.50 2.55 
5% 74.68±28.85 9.99±1.68 82.23 117.89±46.64 3.81±1.31 21.21 
myristyl 
lactate 
0.5% 30.13±10.49 14.52±0.45 33.17 68.43±14.26 8.80±1.35 12.31 
5% 26.87±11.73 13.79±2.19 29.59 79.59±12.21 7.15±1.37 14.32 
nerol 
0.5% 9.82±3.77 7.72±1.43 10.81 24.08±8.38 15.76±1.81 4.33 
5% 71.70±21.52 8.85±0.60 78.94 132.15±30.77 2.63±0.92 23.78 
nerolidol 
0.5% 29.74±4.21 18.78±3.84 32.75 68.12±11.23 11.63±0.77 12.26 
5% 72.04±15.64 12.59±0.30 79.32 126.49±9.85 3.46±1.31 22.76 
oleic acid 
0.5% 22.64±13.94 17.07±2.32 24.93 57.95±26.20 14.96±2.01 10.43 
5% 14.54±0.79 17.24±1.11 16.01 44.36±1.47 15.47±0.82 7.98 
phytol 
0.5% 27.54±3.10 9.11±1.40 30.32 54.97±14.93 12.85±2.01 9.89 
5% 26.96±0.12 23.93±0.34 29.68 84.90±8.47 17.22±1.44 15.28 
SDS 
0.5% 20.02±7.39 15.02±1.75 22.04 43.66±23.02 10.29±1.93 7.86 




Secondly, among all the CPEs tested, 5% CPEs are generally more efficient 
than 0.5% in the enhancement of both amitriptyline and ketamine permeations 
(p < 0.01). Few reports about the effect of CPE concentrations on skin 
permeation of drugs are available (Nokhodchi et al., 2007; Nokhodchi et al., 
2003). It may be time-consuming and much animal tissue would be needed if 
the CPEs were tested at several concentrations. Therefore, 0.5% and 5% were 
selected to form a binary comparison system to investigate the trends of 
concentration-dependent enhancing effect of each CPE on the permeation of 
amitriptyline and ketamine. From Table 3.3 and Fig. 3.2, as a general rule, the 
5% CPEs showed higher flux than 0.5% CPEs. However, in terpene CPEs, 
farnesol in amitriptyline and ketamine permeation and phytol in amitriptyline 
permeation are exceptions to this rule. Moreover, amphiphilic CPEs do not 
conform to this rule either. The above mentioned exceptions showed 
insignificant differences in fluxes between the formulations with 0.5% and 5% 
CPEs, indicating that their permeation enhancing efficacies may not be 
concentration-dependent in the range of 0.5 - 5% and there may be a plateau 
or a highest point in the concentration-efficacy curves. Farnesol was reported 
to show an outstanding enhancing efficacy at very low concentration of 0.25% 
for diclofenac (Nokhodchi et al., 2007). In the permeation study of lorazepam, 
the enhancing effect of surfactants dropped beyond 1% w/w which was related 
to the interaction of micelle and drug (Nokhodchi et al., 2003). The 
differences of the concentration-efficacy profiles of different CPEs may be 
due to the different skin lipid interaction mechanisms, thereby the optimal 
concentration of each CPE for each drug require further experimentation.  
 
Thirdly, comparing the 4 structural subgroups of CPEs, the sesquiterpenes at 
0.5% were more efficient than cyclic (p < 0.05) and linear monoterpenes (p < 
0.05) for both drugs, and amphiphilic CPEs at 5% are less efficient than linear 
monoterpenes (p < 0.05) and sesquiterpenes (p < 0.05) for both drugs. The 
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differences in lag times were insignificant among the groups. Sesquiterpenes 
0.5% showed higher enhancing efficacy possibly due to their long carbon 
chains and structural similarities to the lipid constituents of the stratum 
corneum which would have interrupted the skin structure at low concentration 
and were more efficient than monoterpenes. Amphiphilic CPEs, especially 
surfactants, had insignificant difference between 0.5% and 5% and showed 
inferior efficacy at 5% when compared to sesquiterpenes and linear 
monoterpenes. The permeation enhancement of surfactants at low 
concentration is usually attributed to the ability of the surfactant molecules to 
penetrate the skin and increase drug permeability. On the other hand, 
solubilisation of the permeant by surfactants micelles decreased the 
thermodynamic activity of the permeant thus decreasing the driving force of 
the drug absorption. Therefore, the overall enhancing effect of a surfactant on 
the transdermal drug is the combination of the influence of two opposing 
effects, which could explain the lack of concentration-dependent enhancing 
efficacy of amphiphilic CPEs in our study (Nokhodchi et al., 2003). 
 
Fourthly, CPEs exerted more enhancement effects on amitriptyline than on 
ketamine both at 0.5% (p < 0.05) and at 5% (p < 0.01). After application of 
CPEs, the EI for amitriptyline is generally 3 - 5 fold of EI for ketamine. As the 
data were obtained through the same hydrogel, the same piece of skin and the 
same analysing procedure, the EI differences may only originate from the 
differences between amitriptyline and ketamine. The enhancing efficacies and 
mechanisms of CPEs depend on the physicochemical properties of the 
permeants. The log P values and molecular weights are two commonly 
considered parameters for both permeants and CPEs. Although both 
categorised to the moderate lipophilic drugs (log P = 2 - 5), amitriptyline is 
more lipophilic than ketamine (Table 3.2) and has a larger molecular weight. 
The moderate lipophilic drugs may permeate into skin mostly via passive 
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diffusion pathway with the help of CPEs which interrupt the skin barrier by 
interacting with skin lipids and drugs. It is suggested in Chapter 2 that 
amitriptyline could possibly have formed a complex with menthol via 
hydrophobic interactions. Therefore, it can be postulated that with a higher 
lipophilicity, the drug is more likely to form complex with the lipophilic 
terpene CPEs via hydrophobic interactions, thereby being dragged into the 
stratum corneum at a higher rate. But this postulation should be limited to the 
comparison of permeants with similar structures and functional groups 
because the possible hydrogen bonds or other interactions between drugs and 
CPE or skin lipids may influence the CPE enhancing mechanism and efficacy. 
 
Finally, in vitro models of hairless mouse skin and human epidermis yielded 
different results when comparing the different CPE enhancing efficacies. The 
control gel with 2% amitriptyline and 1% ketamine without CPE achieved a 
steady-state flux of 0.91 ± 0.05 g cm-2 hr-1 for amitriptyline through hairless 
mice skin, while the control gel with 2% amitriptyline without CPE achieved 
0.32 ± 0.03 g cm-2 h-1 through human epidermis (Section 2.2.2). Assuming 
that ketamine did not enhance permeation of amitriptyline, human epidermis 
was 2.84 fold less permeable to amitriptyline than hairless mice skin. Due to 
the epidermal anatomical and physiological differences (e.g., skin thickness, 
number of cell layers, sebaceous secretions), species-species extrapolation of 
dermal absorption data was found to be difficult (Magnusson et al., 2001). 
Rodents’ skin has more hair follicles and fewer sweat glands than that of 
human, while the thickness of the stratum corneum is uniform, hence the 
permeation pathway of drugs of different lipophilicities through the skin will 
differ (Magnusson et al., 2001). In spite of these differences, in vitro studies 
were performed to compare the rate of drug absorption by skins from different 
species. It is reported that the rat/human ratios of percutaneous absorption 
rates varied from 1.7 to 5.8 with a mean value of 3.1 (Barber et al., 1992). The 
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percutaneous absorption rate of hairless mice skin was also shown to be 
linearly correlated with that of human skin in vitro although there was not 
enough data to provide the average mouse/human ratio of percutaneous 
absorption rates (Wasdo et al., 2009). We found that without CPE the hairless 
mouse/human ratio of percutaneous absorption rates was 2.84, and the ratio 
changed with the incorporation of CPEs. Hydrogels with 5% menthol and 5% 
limonene achieved EI values of 55.75 and 4.88 through hairless mice skin, 
respectively. In contrast, 5% menthol and 5% limonene achieved much higher 
EI values of 292.1 and 44.2 though human epidermis, respectively. Although 
there is dermis in full thickness hairless mice skin but no dermis in human 
epidermis which could cause different permeation resistance to the permeants, 
it is possible that CPEs may have different enhancing mechanisms and 
efficacies due to the structural differences in the epidermis among species. 
Further studies should be performed to test whether there is any 
structure-activity relationship model to explain the different effects of CPEs 
on animal or human skins for a specific drug in vitro. 
 
Considering all the above points, 0.5% farnesol was used in later studies since 
it was among top 2 of the 13 CPEs in both flux and lag time of both 
amitriptyline and ketamine. Farnesol and other CPEs with high EI values share 
an important structural feature that might be the reason behind the higher 
enhancement activity: the presence of hydroxyl and ketone groups that are 
capable of hydrogen bonding. They may form possible complex with skin 
lipids and drugs as shown in Section 2.2.5 on amitriptyline-menthol 
interaction. Another common feature of CPEs with high EI is that they are 
generally linear terpenes which may cause extensive lipid disruption in the 
stratum corneum. However, farnesol did not reduce the lag time of 
amitriptyline and ketamine significantly compared to other terpene CPEs. This 
could be due to the relatively low permeability of farnesol resulting in a 
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relatively long time of distribution across the stratum corneum and effects on 
permeation of the drug. A similar delay onset was reported by Nokhodchi et al. 
(2007).  
 
As the synergistic effects exist among CPEs, the best enhancer (0.5% farnesol) 
and the next best terpene enhancer (5% menthone) and the best amphiphilic 
enhancer (0.5% oleic acid) were tested for possible synergism. It can be seen 
from Fig. 3.3 and Table 3.4 that the combinations of farnesol and menthone or 
oleic acid did not yield any synergistic effect in the permeation of both 
amitriptyline and ketamine. Since the combinations did not show any additive 
effect, it is likely that farnesol had the same penetration enhancing mechanism 
as menthone and oleic acid, and hence their enhancing effects were 
competitive. This may be buttressed by the fact the farnesol, menthone and 
oleic acid are all categorised as fluidising CPEs. 
 
Table 3.4 Hairless mice skin permeation parameters of amitriptyline and 
ketamine in hydrogel with CPEs and their combinations.  




















Oleic acid 0.5% 
Menthone 5% 
Farnesol 0.5% + 
oleic acid 5% 
Farnesol 0.5% + 
menthone 5% 
92.70±32.57 8.94±3.09 102.07 128.04±25.82 2.82±0.08 23.04 
22.64±13.94 17.07±2.23 24.93 57.95±26.20 14.96±2.01 10.43 
74.68±28.85 9.99±1.68 82.23 117.89±46.64 3.81±1.31 21.21 























Fig. 3.3. Steady-state fluxes and lag times of amitriptyline and ketamine 
permeated through 0.785 cm
2
 of hairless mouse skin with CPEs and 
combinations. Each bar represents mean ± S.D. (n = 3). (a) Fluxes of 






Therefore, in the subsequent stability study and in vivo studies, we chose 0.5% 
farnesol as the sole CPE due to its high efficacy. However, the other 
constituents in the formulation such as ethanol, PG and Tween 80 could have 
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provided synergistic or additive enhancing effects with farnesol, such that the 
final EI was the compound EI of all the components in the hydrogel 
formulation. 
 
3.2.2 Rheological characterisation 
 
Rheological parameters are applied to characterise and to modify the rheology 
of the semisolid system, especially for the consideration of long term stability 
and spreadability. A typical result of amplitude sweep analysis of amitriptyline 
and ketamine hydrogel is shown in Fig. 3.4. The G’ (elastic modulus) and G’’ 
(viscous modulus) values are stable in the range of 1 to 70 Pa for shear stress. 
So the G’ and G’’ values are estimated by the average values of points in this 
range. The yield value is the crossover point of G’ and G’’, which is calculated 
by the RheoWin® software. 
 
Fig. 3.4. A typical result of an amplitude sweep analysis of amitriptyline and 





The flow curve of amitriptyline and ketamine hydrogel is demonstrated in Fig. 
3.5. It can be seen that when the shear rate increases, the viscosity drops 
significantly, which is called “shear-thinning”. Shear-thinning is a desirable 
property of semisolid formulations to achieve good spreadability and good 
“skin feel”. The flow curve also demonstrates a plastic behaviour of the 
amitriptyline and ketamine hydrogel, indicating that the hydrogel network 
exhibited resistance to an external force before it started flowing. During 
storage, amitriptyline and ketamine hydrogel may maintain its plastic 
behaviour, which is a desirable characteristic of the consistency of topical 
formulations. 
 
Fig. 3.5. Flow curve of amitriptyline and ketamine hydrogel 
 
3.2.3 Stability study 
 
3.2.3.1 Rheological stability of amitriptyline and ketamine hydrogel 
 
Changes in rheological behaviours can indicate the kinds of instability in the 
semisolid system. G’, G’’ and yield value are used as three parameters to 
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indicate the physical stability of the semisolid system. It is shown in Fig. 3.6 
that after 6-month storage at 4°C, the 3 parameters of amitriptyline and 
ketamine hydrogel remained stable. Therefore, it can be postulated that the 
final formulation of amitriptyline and ketamine hydrogel would be physically 
consistent over 6 months when kept at 4°C. 
 
Fig. 3.6. Rheological stability of amitriptyline and ketamine hydrogels 
at 4°C over 6 months. 
 
 
3.2.3.2 Chemical stability of amitriptyline and ketamine hydrogel 
 
It is demonstrated in Fig. 3.7 that after 180-day storage at 4°C amitriptyline 
and ketamine contents in the hydrogel were insignificantly changed. Besides, 
no new peak appeared in the HPLC analysis graphs when compared with the 
Day 0 analysis. Therefore, it can be concluded that amitriptyline and ketamine 




Fig. 3.7. Drug contents of amitriptyline (AMI) and ketamine (KET) in 
amitriptyline and ketamine hydrogel when stored at 4°C for 6 months.  
Each point on the curve represents the percentage of drug content at the 
specific time-point compared to that on Day 0. 
 
 
3.2.4 In vivo studies 
 
3.2.4.1 LC/MS/MS assay development 
 
The LC/MS/MS in the MRM mode provided a highly selective method for the 
determination of amitriptyline, ketamine and imipramine (I.S.). The analytes 
were easily protonated and generated positive product ions. They were 
identified at m/z 278.3 for [amitriptyline + H]
+
, 238.3 for [ketamine + H]
+
 and 
281.3 for [I.S. +H]
+
. The retention times were approximately 8.7, 2.8 and 8.4 
min, respectively. Typical chromatograms resulting from the analysis of 
various plasma samples are shown in Fig. 3.8. No endogenous substance or 
chemical components were observed to interfere with the drugs and internal 








Fig. 3.8. Typical MRM chromatograms of amitriptyline (channel 1), ketamine 
(channel 2) and imipramine (channel 3) (IS). 
 
 
3.2.4.2 LC/MS/MS assay validation 
 
The calibration curves of the peak area (y) to the concentration (c, ng/ml) were 
constructed from six standards using 1/x weighted linear least-square 
regression model. The calibration curves, correlation coefficients and linear 
ranges of amitriptyline and ketamine in plasma and each tissue are listed in 
Tables 3.5 and 3.6, respectively. The calibration curves showed good linearity 
in the corresponding ranges for both drugs. The calibration curves for all 
matrices demonstrated good linearity (r
2
 > 0.996) over the concentration 
ranges. 
 
The lower limits of detection (LLOD) of amitriptyline and ketamine in 
different matrices were 0.5 - 2 ng/ml and 0.1 - 0.5 ng/ml, respectively, which 
were sufficient for studies of pharmacokinetics and tissue distribution after 





Table 3.5. Standard curves, correlation coefficients and linear ranges of 
amitriptyline in different matrices. 






Plasma y = 0.00102 × c + 0.0242 0.9961 2-100 
Skin y = 0.000111 × c + 0.0281 0.9972 100-100000 
Muscle y = 0.000107 × c + 0.0811 0.9984 10-4000 
Heart y = 0.00104 × c + 0.0232 0.9993 2-1000 
Intestine y = 0.00131 × c + 0.00532 0.9958 2-1000 
Brain y = 0.00108 × c + 0.0124 0.9988 2-1000 
Spleen y = 0.00118 × c + 0.00738 0.9971 2-1000 
Lung y = 0.000963 × c + 0.0238 0.9979 2-1000 
Kidney y = 0.00128 × c - 0.00593 0.9971 2-1000 
Liver y = 0.00112 × c + 0.0237 0.9983 2-1000 
 
Table 3.6. Standard curves, correlation coefficients and linear ranges of 
ketamine in different matrices. 






Plasma y = 0.00124 × c + 0.0135 0.9977 2-100 
Skin y = 0.000142 × c + 0.00889 0.9989 100-100000 
Muscle y = 0.000112 × c + 0.0013 0.9990 10-4000 
Heart y = 0.00111 × c + 0.0211 0.9995 2-1000 
Intestine y = 0.00164 × c - 0.00747 0.9971 2-1000 
Brain y = 0.0014 × c + 0.0142 0.9989 2-1000 
Spleen y = 0.00126 × c + 0.00975 0.9973 2-1000 
Lung y = 0.00116 × c + 0.0156 0.9985 2-1000 
Kidney y = 0.00129 × c - 0.0033 0.9970 2-1000 
Liver y = 0.00144 × c + 0.00447 0.9991 2-1000 
 
The extraction recoveries and matrix effect data are shown in Tables 3.7 and 
3.8 for amitriptyline and ketamine, respectively. The data suggests that the 
acetonitrile deproteinisation and extraction method resulted in no appreciable 
matrix effect for both drugs and the internal standard. The acceptance criteria 
of accuracy (mean recoveries and matrix effects between 85 and 115%, at 




The accuracy and precision assessed by QC samples at different 
concentrations are shown in Tables 3.7 and 3.8 for amitriptyline and ketamine, 
respectively. The intra-day precision and accuracy were ≤ 10.8 and ≤ 7.6% for 
amitriptyline and ≤ 9.8 and ≤ 7.6% for ketamine, respectively. The inter-day 
precision and accuracy were ≤ 8.8 and ≤ 7.6% for amitriptyline and ≤ 9.4 and 
≤ 6.0% for ketamine, respectively. The results indicate that the methods used 
were accurate and reproducible for the determination of amitriptyline and 
ketamine in rat plasma and tissues.  
 
3.2.4.3 Pharmacokinetic study 
 
Topical delivery aims to achieve high drug concentration in local tissues and 
low systemic absorption. The main advantage of topical and transdermal 
formulations is that they usually demonstrate a smoother drug 
concentration-time profile with markedly less fluctuation between maximum 
and minimum plasma concentrations, compared with the oral and intravenous 
administrations. Plasma concentration-time profiles for most of the 
transdermal systems are characterised in terms of Cmax (maximal plasma drug 
concentration), half-life (time needed for half the dose to be removed from the 
body), AUC0–t (area under the time concentration curve from time 0 to time t) 
and AUC0–∞ (area under the time concentration curve from time 0 to infinity). 
 
The plasma concentration-time profiles of amitriptyline and ketamine after 
topical application of hydrogel are shown in Fig. 3.9 with the pharmacokinetic 
parameters listed in Table 3.9. The Cmax of amitriptyline and ketamine are 32.4 
and 27.2 ng/ml, respectively. Cmax occurs due to: (a) slight depletion in driving 
force of drug; (b) variation due to plasma assay/sampling; and (c) other 
reasons such as circulation variation. For any of these, Cmax provides a 
practical estimate of Css (steady-state plasma concentration) (Farahmand and
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Table 3.7. Precision, accuracy, extraction recovery and matrix effect of amitriptyline in plasma samples and tissue homogenates of rats (n = 3). 
Samples QC conc Intra-day Inter-day Extraction recovery Matrix effect 








Mean ± S.D.% R.S.D. %  
Plasma    4 10.2 98.0 6.0 95.7  88.8 ± 3.9 4.4  86.3 
   20 5.7 103.9 2.1 102.4  96.8 ± 1.1 1.1  85.4 
   40 6.9 98.2 4.2 97.2  97.1 ± 3.1 3.1  99.3 
  100 2.2 101.9 2.4 100.6  96.6 ± 2.2 2.2  92.5 
         
Skin   100 8.1 98.4 3.3 98.7  88.5 ± 4.1 4.7 101.2 
  4000 5.2 97.9 8.8 101.4  95.6 ± 3.1 3.3 103.9 
 100000 3.8 100.5 6.7 96.7  96.3 ± 7.6 7.9 107.1 
         
Muscle   10 1.1 95.6 1.6 98.8  89.9 ± 7.4 8.3  87.8 
  400 3.1 104.3 2.7 103.9  95.3 ± 6.5 6.8  87.1 
 4000 7.4 97.3 1.8 97.7 102.1 ± 0.9 0.9  85.5 
         
Heart    4 10.8 107.6 3.4 104.8  86.5 ± 3.8 4.4 116.1 
   100 4.7 103.9 8.0 101.4  99.6 ± 9.3 9.3 108.3 
  1000 3.4 103.0 6.0 100.3 103.3 ± 5.1 4.9 109.1 
         
Intestine    4 3.6 95.8 5.0 95.6 101.4 ± 5.0 4.9 110.2 
   100 4.4 97.8 3.5 100.3  99.4 ± 2.0 2.0 110.9 
   1000 1.2 97.9 1.2 99.6 100.7 ± 6.0 5.9 102.4 
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Samples QC conc Intra-day Inter-day Extraction recovery Matrix effect 








Mean ± S.D.% R.S.D. %  
Brain    4 8.0 99.9 7.5 99.8 100.3 ± 6.6 6.6  86.2 
   100 1.7 98.0 1.3 99.5  99.6 ± 2.1 2.1 103.4 
  1000 3.9 99.6 3.9 96.2 100.1 ± 1.1 1.1 103.9 
         
Spleen    4 3.3 95.6 2.8 97.0  85.7 ± 6.4 7.4  84.6 
   100 5.2 99.6 1.7 96.1  87.1 ± 2.5 2.9  99.3 
  1000 0.6 97.1 2.3 98.1  90.3 ± 1.0 1.2 102.2 
         
Lung    4 9.1 99.5 3.8 92.4  87.3 ± 3.7 4.3  93.9 
   100 2.3 103.8 2.2 99.9  95.3 ± 3.3 3.4  91.0 
  1000 2.3 103.4 3.4 99.9  95.7 ± 2.2 2.3  97.4 
         
Kidney    4 8.0 97.5 7.5 99.8  86.8 ± 8.9 10.2 98.0 
   100 6.1 99.9 3.7 96.2  95.7 ± 4.1 4.3 92.1 
  1000 2.9 100.4 2.1 100.2  96.1 ± 1.3 1.3 90.2 
         
Liver    4 6.3 105.0 6.4 104.8  93.3 ± 5.5 5.9 83.3 
   100 4.8 97.9 4.0 96.4  91.6 ± 5.9 6.5 92.1 




Table 3.8. Precision, accuracy, extraction recovery and matrix effect of ketamine in plasma samples and tissue homogenates of rats (n = 3). 
Samples QC conc Intra-day Inter-day Extraction recovery Matrix effect 








Mean ± S.D.% R.S.D. %  
Plasma    4 4.6 92.4 4.1 94.0  91.8 ± 6.7 7.3  85.7 
   20 4.1 98.2 2.6 96.1  99.9 ± 3.6 3.6  99.3 
   40 1.6 100.2 3.4 100.8  99.8 ± 5.7 5.8 111.2 
  100 2.2 101.8 1.5 100.0  99.5 ± 3.8 3.8 108.8 
         
Skin   100 7.4 102.1 1.9 104.0  88.9 ± 5.0 5.7  98.1 
  4000 2.0 95.3 1.3 96.1  88.6 ± 8.4 9.5  96.0 
 100000 2.3 94.4 1.6 96.1  91.2 ± 8.7 9.5  99.9 
         
Muscle   10 5.5 96.3 9.4 98.2  87.7 ± 5.9 6.7  85.6 
  400 4.4 104.0 5.9 98.4  90.1 ± 4.9 5.5  86.5 
 4000 2.9 104.8 2.4 101.8  88.5 ± 6.0 6.7  89.1 
         
Heart    4 7.0 101.4 4.0 101.8  92.4 ± 9.3 10.0 115.8 
   100 4.4 101.8 3.4 101.5  96.3 ± 5.1 5.3 106.1 
  1000 3.9 101.4 2.3 102.3 100.6 ± 4.5 4.4 103.8 
         
Intestine    4 4.9 95.9 2.5 98.0  95.3 ± 4.0 4.2  83.5 
   100 4.8 102.8 6.5 103.2  97.4 ± 6.7 6.9  87.1 
  1000 3.1 99.5 1.8 99.2 99.2 ± 6.3 6.4 88.7 
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Samples QC conc Intra-day Inter-day Extraction recovery Matrix effect 








Mean ± S.D.% R.S.D. %  
Brain    4 2.7 98.4 0.6 101.1 100.1 ± 3.2 3.2  84.0 
   100 4.0 99.4 2.1 98.5  98.5 ± 3.5 3.6  85.9 
  1000 2.1 96.4 3.2 95.6 100.0 ± 2.9 2.9  87.7 
         
Spleen    4 8.7 103.2 3.5 104.4  86.9 ± 7.7 8.9  83.6 
   100 3.4 98.9 1.2 100.3  92.1 ± 5.3 5.7  98.4 
  1000 3.5 100.5 4.7 102.7  92.5 ± 4.0 4.3 105.6 
         
Lung    4 5.9 102.6 1.7 101.9  97.3 ± 1.8 1.8 107.4 
   100 5.6 94.4 2.6 97.5  98.9 ± 3.1 3.2  98.2 
  1000 1.2 97.4 2.0 98.8  98.3 ± 1.4 1.4 106.4 
         
Kidney    4 9.8 99.8 6.8 98.9  91.5 ± 5.6 6.2 101.0 
   100 3.4 99.8 6.2 100.8  98.3 ± 4.7 4.7  98.6 
  1000 1.8 98.3 4.6 103.8  99.0 ± 2.0 2.1  87.7 
         
Liver    4 6.5 100.7 3.1 102.7  92.5 ± 4.3 4.7 105.5 
   100 3.3 99.2 0.8 97.3  94.5 ± 5.7 6.0 114.3 




Maibach, 2009). The reported therapeutic plasma concentration of 
amitriptyline for neuropathic pain was 36 ng/ml (Eisenach et al., 1997), which 
was lower than those needed for depression at 50 - 125 ng/ml (Breyer-Pfaff et 
al., 1982). The therapeutic plasma concentration of ketamine for analgesia was 
100 - 150 ng/ml (Owen et al., 1987). The plasma concentration after topical 
administration of amitriptyline and ketamine hydrogel in our study was lower 
than the therapeutic concentrations of both drugs, indicating that the drugs 
may not achieve systemic therapeutic effect. The result will be lower systemic 
toxicity since the toxicity is dependent on plasma and tissue concentrations. 
The plasma concentration of a drug is usually associated with its dose in the 
topical and transdermal formulation and the deviation is less pronounced when 
compared with oral route of administration. Therefore, another advantage that 
topical and transdermal drug delivery possesses over oral dose regimens is 
avoiding the variability associated with the gastrointestinal tract such as 
effects of pH, motility, transit time and food intake (Farahmand and Maibach, 
2009). 
 
Table 3.9. Pharmacokinetic parameters of amitriptyline and ketamine hydrogel 
























Plasma half-life of amitriptyline was reported to be 2.78 - 3.88 hr in rat 
(Rutkowska et al., 1999; Miyake et al., 1990), while the plasma half-life of 
ketamine was found 44 min in rat and 79 min in man (Idvall et al., 1980). The 
Table 3.9 shows that the half-life of amitriptyline and ketamine following 
topical application are 19.4 and 6.6 hr, respectively, which are 5 - 7 fold and 9 
fold compared to that after intravenous administration. The longer half-life of 




Fig. 3.9. Plasma concentration time profiles following topical administration 
of (a) amitriptyline and (b) ketamine hydrogel to Sprague-Dawley rats for 6 h.  








as well as the skin reservoir effect, which results in a sustained release of both 
drugs and low frequency of gel application. In this study, the aim of removing 
the hydrogel at 6
th
 hr was to investigate possible reservoir effect of 
amitriptyline and ketamine in the immediate skin and muscle tissues. It can be 
seen from Fig. 3.9 that following the removal of the gel at 6
th
 hr, the plasma 
concentration of amitriptyline rose until 8
th
 hr and then decreased slowly while 
the plasma concentration of ketamine also had a much longer elimination 
phase than those obtained after i.v. and oral administration. Large amount of 
both drugs accumulated in the skin during hydrogel application time (Fig. 3.10) 
may cause the sustained release of the drugs from the skin into the plasma and 
other tissues. It should be noted that amitriptyline demonstrated a more 
distinguished reservoir effect than ketamine as its plasma concentration kept 
rising after gel removal for at least 2 hr. This may be due to the higher 
lipophilicity and larger molecular weight of amitriptyline, which may result in 
its lower diffusivity (Cross et al., 2003) and permeability in the lipophilic 
stratum corneum causing a more prominent formation of skin depots (Suh et 
al., 1997).  
 
As there were existing pharmacokinetic data on oral and intravenous 
administration of amitriptyline and ketamine on rats, the normalised AUC data 
can be used for comparison. The AUC0-t of amitriptyline and ketamine in our 
study are 668.2 and 362.4 ng h/ml with doses of 120 and 60 mg/kg, 
respectively. The dose normalised AUC0-t of oral and i.v. amitriptyline are 876 
and 15600 ng hr/ml (Miyake et al., 1992). The dose normalised AUC0-t of oral 
and i.v. ketamine are 1175.5 and 30888 ng hr/ml (Shimoyama et al., 1999; 
Edwards et al., 2002). It can be calculated that the bioavailability of 
amitriptyline in rat is low (5.6%) after oral administration. The data for 
ketamine are from 2 different studies, so that it can only be estimated that 




obvious that the AUC values of amitriptyline and ketamine in topical 
administration of rat (4.3% and 1.2%, respectively) are lower than those after 
oral administration, which suggests that the amount of drugs delivered into 
systemic circulations by topical delivery is lower than oral administration. As 
the Cmax after topical application is lower than that after oral administration, 
the topical delivery of these drugs may lower the risk of systemic toxicity. 
 
The single-dose pharmacokinetic profile for transdermal delivery usually 
includes three distinct periods: (1) the time until plasma concentrations are 
achieved (lag time); (2) the plateau at constant steady-state plasma 
concentrations; and (3) a declining phase after removal of the patch or 
semisolid formulation. The last phase may be prolonged due to the presence of 
skin reservoir effect and the pharmacokinetic characteristics of the drug 
(Berner and John, 1994). However, not all topical and transdermal systems can 
show the steady-state plateau, which may be attributed to insufficient drug 
input or insufficient application duration. We did not achieve the Css in our 
pharmacokinetic study as the hydrogel application was over only 6 hr. The 
application time was set at 6 hr to reflect the usual gel application time of less 
than 8 hr. Assuming the clearance is linear, we can use equation 3.1 to predict 
the steady-state plasma concentration Css (Berner and John, 1994): 
Css = Jss / Cl                                           (3.1) 
The Jss is the steady-state transdermal permeation flux and the Cl is the total 
systemic clearance.  
The Jss values of amitriptyline and ketamine were 92.70 and 128.04 mg/cm
2
/hr 
from the in vitro permeation study, respectively (Table 3.3). And with the 
reported clearance data of both drugs, it can be predicted that the steady-state 
plasma concentrations of amitriptyline and ketamine are 257.5 and 291.0 
ng/ml, respectively. The current Cmax of both drugs are generally 1/10 of the 




possible Css. However, it would be impractical to achieve the predicted Css 
because the hydrogel application may not remain on skin surface for more 
than 8 hr thus the drug on the skin surface would be depleted in several hr. 
Moreover, it would be unnecessary to achieve the Css since the target site of 
action for the hydrogel formulation is the peripheral nerves at the dermal and 
muscle tissues. Low systemic plasma concentration and low distribution of 
drug to other tissues are desired for reduced systemic toxicity.  
 
3.2.4.4 Tissue distribution study 
 
In the pharmacokinetic study (Section 3.2.4.3), we showed that amitriptyline 
and ketamine have minimal systemic effects and therefore not likely to trigger 
systemic adverse effect with sustained release. The toxicity and the local tissue 
efficacy were evaluated by the tissue distribution study. 
 
The tissue distribution data and the calculated tissue/plasma ratio data are 
shown in Fig. 3.10. The distribution profiles of amitriptyline and ketamine are 
consistent with the lipophilic nature of the molecules since drug 
concentrations in tissues tested are higher than those in plasma over the first 
few hours (p < 0.01).  
 
Fig.3.10. Distribution of amitriptyline and ketamine in plasma and tissues of 
rats at various time-points following topical application of hydrogel (left 





















In the tissue distribution study, plasma and tissue samples were collected at 
time-points that were different from those in the pharmacokinetic study. The 
plasma concentrations of two drugs obtained from the tissue distribution study 
were consistent with the plasma concentration-time profiles from the 
pharmacokinetic study.  
 
Both drugs showed rapid distribution to skin with high concentrations of 60 - 
80 g/g tissue at 1.5 hr after topical application. The ketamine contents in the 
skin were in the same range from 1.5 hr to 7 hr, indicating that the skin was 
saturated with ketamine at 1.5 hr. Meanwhile the content of amitriptyline in 
the skin reached the maximum at 7 hr and decreased with a slower speed than 
ketamine. With the skin reservoir effect mentioned earlier, the elimination rate 
of drug in the skin is influenced by blood circulation in the dermis, drug 
diffusion into muscle and the lipophilicities of the drugs. Since ketamine is 
less lipophilic than amitriptyline, it demonstrated less skin reservoir effect and 
faster elimination rate in the skin, which is mostly due to the lipophilic stratum 
corneum. Significant concentration gradients of both drugs were observed 
between skin, muscle and plasma after topical administration of hydrogel. The 
skin/plasma ratio drops from around 10000 at 1.5 hr to around 4000 at 4.5 hr 
and remained unchanged. This may be caused by the decrease of the skin 
diffusivity of the drugs with the depletion of CPE. The high concentrations 




depot for the drugs to diffuse into neighbouring muscle tissues and more 
importantly analgesic effect to nerves in the dermis.  
 
Fig. 3.11. Distribution of amitriptyline and ketamine in rat skin at various 
time-points following topical application of hydrogel at centre, 1 cm and 2 cm 
from gel application area.  
 
 
It is not known if drugs delivered in the skin will diffuse away from the 
application site or into deeper tissues. The drugs’ concentrations were tested in 
the skins of the application site, 1 cm from the rim of the application sites, and 
2 cm from the rim of the application sites. It can be seen from Fig. 3.11 that 
the drug concentrations in the skin drops about an order of magnitude per 1 cm 
away from the gel application site, indicating that the lateral diffusion of drugs 
in the skin was not distinct. This means that the majority of the drugs have 
permeated into the muscle below the skin and eliminated by the circulation in 
the muscle and dermis. This would be an advantage in alleviating the skin 
irritation and other toxicity symptoms caused by the topical formulation. 
 
The high concentrations (around 1 g/g) and tissue/plasma ratios of both drugs 
in the muscle may provide substantial analgesic effect to the local nerves. The 
lipophilicity differences of amitriptyline and ketamine demonstrated 
differences on Tmax in the muscle tissue as amitriptyline reached highest 
concentration after removal of the gel while ketamine reached highest 




muscle/plasma ratio of both drugs indicate the rapid removal of drugs from 
muscle tissues by systemic circulation. This result thus demonstrates the 
possibility of targeting drugs via topical delivery to local tissues without 
affecting high plasma concentrations.  
 
The brain ketamine levels for hypnosis and ataxia are 25 and 8 - 10 g/g tissue 
in rat (Marietta et la., 1976). The substantial low brain concentration of 
ketamine (< 20 ng/g) avoided the severe adverse effects which usually occur 
after p.o. and i.v. administration, such as illusion. The brain/plasma ratio was 
reported to be maintained at 6.5:1 after intravenous administration of ketamine 
(Cohen et al., 1973), while in our study it was less than 1. This indicates that 
only trace amount of ketamine was redistributed to the brain tissues after 
entering the systemic circulation following topical administration. In this study, 
the maximum concentration of amitriptyline (116 ng/g) was reached until 7 hr. 
Compared to the i.v. (1.75 mg/kg) and i.p. (17.5 mg/kg) administration of 
amitriptyline in rat which were 5167 ng/g at 15 min and 3476 ng/g at 30 min 
(Glotzbach and Preskorn, 1982), the concentration of amitriptyline in the brain 
after topical administration was low. Therefore, it can be postulated that the 
topical application of amitriptyline and ketamine hydrogel would cause 
minimal effects on the brain. 
 
The amitriptyline content was high in intestine and low in kidney. This may be 
because amitriptyline is eliminated via nonrenal route and a significant 
intestinal first-pass effect of amitriptyline occurred following oral 
administration in rats (Bae et al., 2009). The ketamine content was low in 
intestine and high in kidney as it is eliminated via renal route. A significant 
increase in the kidney/plasma ratio after 10 hr of application of the gel 




ratio may raise the chances of renal toxicity as ketamine has been indicated to 
affect the urinary system (Yeung et al., 2009). 
 
The other tissues of heart, lung, spleen and liver all showed low concentrations 
(< 20 ng/g) and low tissue/plasma ratios (< 3) of ketamine, indicating that 
ketamine in this topical formulation is unlikely to cause toxicity within these 
vital organs. Amitriptyline was found to be low in heart and liver tissues, but 
relatively high in spleen (Cmax = 193 ng/g) and lung (Cmax = 522 ng/g) tissues. 
It has been reported that amitriptyline caused a dose-dependent lung injury 
(Svens and Ryrfeldt, 2001). Therefore, there is a need to investigate the effects 
of the duration of application, and dose of topical amitriptyline and ketamine 
hydrogel. 
 
The tissue distribution profile is dependent on the route of administration. For 
example, after i.v. administration of amitriptyline, the majority of the drug 
(68%) was localised in the lung, and the liver contained only 1%; but after i.g. 
administration, the lung and the liver contained similar amounts of the drug, 
38% and 24%, respectively (Rutkowska et al., 1999). To the best of our 
knowledge, this is the first investigation on tissue distribution of amitriptyline 




This is the first reported study to develop a topical formulation of amitriptyline 
and ketamine hydrogel with the incorporation of CPEs for the treatment of 
peripheral neuropathic pain. After the optimisation of the hydrogel 
formulation, 0.5% v/v farnesol was chosen as the CPE in the final formulation. 




stable after 6-month storage at 4°C. The LC/MS/MS assay was established and 
validated for simultaneous detection of amitriptyline and ketamine. The 
pharmacokinetic and tissue distribution studies demonstrated that topical 
application of the hydrogel resulted in minimal systemic plasma concentration 
and systemic tissue distribution while achieving high drug concentrations in 
skin and muscle tissues, which are the target sites for neuropathic pain. Further 
pharmacodynamic study has to be performed to establish the analgesic 
efficacy and further toxicity studies has to be carried out, especially on lung 
and kidney. With an effective topical delivery system of amitriptyline and 
ketamine hydrogel, the drugs can be delivered directly to the site of pain. 
Furthermore, the lack of clinically significant systemic exposure may lead to 
minimal systemic adverse effect and minimal drug-drug interactions. 
Therefore, the topical formulation of amitriptyline and ketamine hydrogel has 
the potential to be utilised as either monotherapy or as part of a polypharmacy 
regimen with oral systemic agents to achieve a better benefit/risk ratio in 







4. Propofol organogel 
 
Commercially available parenteral formulations of propofol may cause serious 
adverse effects. There is a clinical need for non-invasive administration of 
sedatives in paediatric patients. This chapter describes the incorporation of 
propofol in the organogel vehicle with CPEs and demonstrates its transdermal 
permeation by in vitro study on human excised epidermis. 
 




Propofol (PRO) (97%), (+)-limonene (98%), farnesol (95%), carvone (98%) 
and propylene glycol (PG) (99.5%) were obtained from Sigma (Steinheim, 
Germany). Dibutyllauroylglutamide (GP-1) was obtained from Kishimoto 
Sangyo Co. Ltd (Japan). Acetonitrile (HPLC grade) was purchased from Tedia 
(Ohio, USA). Milli-Q water (18MΩ cm; Millipore, USA) was used in the 
preparation of aqueous solutions. Chemicals were of at least reagent grade and 
all materials were used as received. 
 
4.1.2. HPLC analysis 
 
Drug concentrations were determined using HPLC method with the same 
HPLC and column described in Section 2.1.6. The detector wavelength was 
272 nm. The mobile phase was a 60:40 v/v ratio of acetonitrile (ACN) and 
deionised water. Flow rate was 1.0 ml/min at 40°C and injection volume was 




ACN:water. Mean peak area ratios of propofol were linearly related to the 
drug concentrations for the samples containing 0.1 to 50 µg/ml (r
2 ≥ 0.999). 
 
4.1.3 Test solutions of in vitro experiments preparation 
 
Pure liquid propofol and the donor solutions containing 5 - 90% v/v PG and 10 
- 95% v/v propofol were prepared to investigate the enhancing effects of PG 
on the permeation of propofol across excised human epidermis. These 
solutions were completely mixed using a vortex mixer. 
 
4.1.4 Preparation of organogel 
 
Organogels containing 20% v/v propofol and CPEs (Table 4.1) were prepared 
using 5% w/v GP-1 as the gelator. Measured amounts of propofol, CPEs and 
GP-1 were mixed and placed in an oven at 100°C for 30 min to allow for 
dissolution. Three times of mild shake (5 sec per time) were performed to 
ensure the homogenous of the hot solution. The resulting drug solution was 
then cooled to room temperature, and a pale-yellow gel was formed.  
 
Table 4.1. Formulations of organogels. 
Organogels 
 Composition (% v/v) 
PG FAR LIM CAR PRO 
PG 80 - - - 20 
PG-FAR 77.5 2.5 - - 20 
PG-LIM 77.5 - 2.5 - 20 
PG-FAR-LIM 77.5 1.25 1.25 - 20 
PG-CAR 77.5 - - 2.5 20 
 
4.1.5 Preparation of human epidermis 
 




obtained with their informed consent. The preparation procedure is similar to 
Section 2.1.2.  
 
4.1.6 In vitro permeation study using human epidermis 
 
Refer to Section 2.1.4. 
 
4.1.7 Permeation parameters 
 
Refer to Section 2.1.7. 
 
4.1.8 Statistical analysis 
 
Statistical analysis was performed using Minitab software. One-way analysis 
of variance (ANOVA) with Tukey’s comparison ascertained the effects of PG 
concentration and type of CPEs present in organogel on the permeation of 
propofol across human skin. The level of significance was taken as p < 0.05. 
 
4.2 Results and discussion 
 
4.2.1 Enhancement of propylene glycol on transdermal permeation of 
propofol 
 
Fig. 4.1 and Table 4.2 show the in vitro permeation profile of propofol through 
human epidermis in 48 hr with propofol solutions containing different 
concentrations of PG. It is demonstrated that 70% v/v and 90% v/v PRO 




μg, respectively. Amount of cumulative propofol decreased when PG 
concentration increased beyond 30% v/v or less than 10% v/v. The decrease in 
penetration enhancement at higher concentrations of PG was similar to other 
studies reported by Yamato et al. (2009). Possible explanations for the decrease 
in permeation of propofol with increasing PG concentrations include: (1) PG as 
a humectant has a dehydration effect on the skin, leading to lower skin 
permeability; (2) high viscosity of PG reducing the penetration of propofol; (3) 
higher affinity of propofol for PG which may contribute to the reduced drug 
permeation (Ross and Shah, 2000).  
 
Fig. 4.1. Cumulative amounts of propofol permeated through human epidermis. 
 
 
Fig. 4.2 shows the enhancement index of propofol when PG alone was used as a 
co-solvent type permeation enhancer. Compared with the control of pure 
propofol, 30% v/v PG - 70% v/v PRO yielded the greatest enhancement, with 
enhancement index of 5.7. A similar report by Yamato et al. (2009) indicated 
that the highest cumulative permeation across rat skin was observed after the 





Table 4.2. Human epidermis permeation parameters of propofol in solutions 

















100 12.82±1.19 0.69±0.06 0.72±0.06 - 
95 38.65±5.97 0.82±0.15 0.90±0.14 1.19 
90 77.89±5.63 2.55±0.18 2.97±0.21 3.69 
70 78.96±25.10 3.92±1.25 5.87±1.87 5.67 
50 44.74±9.10 2.11±0.01 4.41±0.01 3.04 
10  7.68±1.65 0.34±0.04 3.56±0.77 0.49 
 
 
Fig. 4.2. Enhancement index of permeation of propofol in PG solution. 
 
 
PG, a co-solvent type enhancer, effectively increased the permeation of 
propofol across human epidermis at concentrations below 50% v/v. Possible 
mechanisms include: (1) ability of PG to penetrate and transport lipophilic drug 
via solvent drag effect; (2) solvation of keratin within the stratum corneum by 
competition with water for the hydrogen bond sites and the intercalation in the 




and Barry, 2004). The enhancements of PG on other lipophilic drugs, such as 
anti-estrogens and tenoxicam, were also reported by Funke et al. (2002) and 
Larrucea et al. (2001). 
 
4.2.2 Enhancement of organogel on transdermal permeation of propofol 
 
Although 30% v/v PG - 70% v/v PRO yielded the highest enhancement index 
(Section 4.2.1.), the organogel did not solidify even with the addition of 20% 
w/v GP-1. Fig. 4.3 shows that 20 - 60% v/v of PG with 5% w/v GP-1 did not 
form a solid or semisolid gel network at 5% w/v GP-1. However, 70% v/v PG - 
30% v/v PRO appeared as a flowing semisolid when cooled to room 
temperature while 80% v/v PG - 20% v/v PRO gave rise to a solid organogel 
network. Therefore the subsequent organogels were prepared using the ratio of 
80% v/v PG - 20% v/v PRO although it had a lower permeation enhancement 
than 70% v/v PG - 30% v/v PRO. 
 
Fig. 4.3. Appearance of propofol formulations with 20 - 90% v/v PG and 5% 
w/v GP-1. 
    
20%PG-80%PRO 30%PG-70%PRO 40%PG-60%PRO 50%PG-50%PRO 
    




4.2.3 Enhancement of chemical penetration enhancers on transdermal 
permeation of propofol 
 
It is demonstrated in Fig. 4.4 and Table 4.3 that organogel containing only one 
enhancer, 2.5% v/v limonene, achieved higher enhancement than farnesol and 
carvone organogels. Lim et al. (2006) reported that limonene may have a 
greater enhancement efficacy due to multiple possible mechanisms that could 
increase the permeability of propofol. These mechanisms include increased 
propofol solubility within the stratum corneum, the partial extraction of stratum 
corneum lipids and the limonene-PG synergism. In addition, Aqil et al. (2007) 
suggested that lipophilic terpenes such as limonene are more potent enhancers 
for lipophilic drugs such as propofol and midazolam (Femenía-Font et al., 
2005). Carvone was also found to be the least effective in comparison with 
other terpene enhancers for promotion of permeation of lipophilic drugs from a 
gel by Williams and Barry (2004).  
 
Fig. 4.4. In vitro permeation of propofol from organogel preparation  






Table 4.3. Human epidermis permeation parameters of propofol in organogel 
containing 2.5% w/v CPEs. Each value represents the mean ± S.D. (n = 3). 














(EI) PRO PG Enhancer 
100 0 0  12.82±1.19  0.69±0.06  0.72±0.06 - 
80 20 0 219.77±34.00 12.77±4.85 66.87±25.40 45.46±17.3 
77.5 20 2.5% LIM 430.48±7.75   10.44±1.23 54.66±6.44 37.16±4.38 
77.5 20 2.5% FAR 295.68±12.36  8.16±1.44 42.74±7.55 29.05±5.13 




422.05±28.86 11.67±0.28 61.12±1.46 41.55±1.39 
 
 
As observed from Fig. 4.4, the flux within 24 hr of permeation study is higher 
than the flux obtained at 48 hr. This trend was observed obviously both in 2.5% 
v/v LIM organogel and 1.25% v/v LIM + 1.25% v/v FAR organogel. The initial 
high flux value could be attributed to the synergism between limonene and PG. 
However, since limonene might reach its maximum enhancement in 24 hr, PG 
activity may be the major contributor in the enhancement after 24 hr. Further 
studies are needed to prove this postulation. 
 
Comparing the cumulative amount of propofol in the control organogel 
formulation in Table 4.3 to cumulative amounts of propofol of PG-propofol 
solutions in Table 4.2, there was a significant increase in propofol permeation in 
organogel compared to the solutions, indicating that the propofol organogel 
vehicle is more effective in enhancing propofol permeation than the PG 
solution. Apart from the gelation structure of the organogel, the gelator GP-1 
may play an essential role in drug permeation enhancement.  
 
GP-1 is a highly lipophilic (log P = 5.02) molecule with long alkyl chains. The 
possible mechanism of GP-1 enhancement may be alteration of the lipid domain 




between the hydrophobic tails of the lipid bilayer, thus upsetting the packing 
and increasing the fluidity of the membrane, thereby allowing easier permeation 
of propofol (Williams and Barry, 1991b).  
 
 










4.2.4 Clinical application 
 
The current pediatric dosing regimen for i.v. propofol for procedural sedation is 
1 mg/kg followed by 0.5 mg/kg every 3 to 5 min as needed for sedation 
(Micromedex). Assuming a 15-kg 6-year-old child requiring 0.5 mg/kg every 4 
min, it would require 127.5 mg/hr. Hence an application area of about 0.7 m
2
 is 
required to achieve the therapeutic level with the use of 1.25% v/v LIM - 1.25% 
v/v FAR organogel (using the highest flux obtained at 24 hr). However, this 
application area is impractical and the long lag time to achieve therapeutic 
plasma concentration also poses a challenge. Combinations of more potent 
CPEs using other formulations techniques would be needed for further 




PG has a significant permeation enhancing effect of propofol both in 
PG-propofol solution and organogel. Limonene, farnesol, and carvone can also 




formulation in transdermal propofol delivery is organogel containing 2.5% v/v 
limonene, which achieved the highest cumulative permeated propofol in 48 hr, 
approximately 34-fold compared to 100% propofol. Nevertheless, the 







5. Midazolam nanoparticulate propofol (MNP) organogel 
 
Since propofol and midazolam are the two most commonly used sedatives, 
there is a clinical need to develop a transdermal delivery system of both drugs 
into an organogel formulation with CPEs to obtain a systemic sedative effect on 
paediatric patients for procedural sedation. This is the first attempt to 
incorporate drug-loaded nanoparticles into an organogel to form a 
nanoparticulate organogel system. And this is also the first in vitro and in vivo 
study in concurrent delivery of propofol and midazolam. This chapter first 
describes the preparation, characterisation and optimisation of 
midazolam-loaded nanoparticles, then demonstrates the in vitro and in vivo 
studies of MNP organogels with its stability validated. 
 




Propofol (97%), (+)-limonene (98%), polyvinyl alcohol (PVA) (MW 
30000-70000), dichloromethane (HPLC grade), and propylene glycol (PG) 
(99.5%) were obtained from Sigma (Steinheim, Germany). 
Poly(D,L-lactic-co-glycolic acid) (PLGA) (PURASORB
®
 PDLG 5002) was 
obtained as a gift sample from Purac Asia Pacific Pte Ltd. (Singapore). 
Dibutyllauroylglutamide (GP-1) and isostearyl alcohol (ISA) (99%) were 
obtained from Kishimoto Sangyo Co. Ltd (Japan). Midazolam (99.8%) was 
purchased from Yichang Humanwell Pharmaceutical Co., Ltd (China). 
Acetonitrile (HPLC grade) was purchased from Tedia (Ohio, USA). Milli-Q 
water (18MΩ cm; Millipore, USA) was used to prepare the aqueous solutions. 






5.1.2 Nanoparticulate preparation 
 
The midazolam-loaded PLGA nanoparticles were prepared by an oil-in-water 
single emulsion evaporation technique. The organic phase consisting of 
different amounts of PLGA polymer and midazolam was dissolved in 10 ml 
dichloromethane. The mixture was suitably stirred to ensure that all materials 
were dissolved. The aqueous phase contained PVA solution, which was 
adjusted to pH 8.0 by sodium hydroxide solution. The organic phase was 
slowly added into the aqueous phase and emulsified by sonication using a 
microtip probe sonicator (Vibra cell 
TM
, Sonics and Materials Inc., New Town, 
CT, USA) in pulse mode with a 30W energy output. The formed o/w emulsion 
was stirred at 700 rpm by a magnetic stirrer for 8 hr to evaporate the organic 
solvent. The nanoparticles were recovered by centrifugation at 7000 rpm for 20 
min (Beckman, Avanti J-25, New York, USA) and washed three times with 
Mili-Q water in order to remove the surface adsorbed midazolam. The washings 
were eliminated by a further centrifugation as described above. The purified 
nanoparticles suspension was freeze-dried (FreeZone 2.5 Benchtop Freeze Dry 
Systems, Labconco, Kansas City, USA) to obtain a fine powder of 
nanoparticles, which was stored in a -20ºC freezer.  
 
5.1.3 Characterisation of nanoparticles 
 
The size and zeta potential of the nanoparticles were determined in Mili-Q 
water suspension at 0.2 mg/ml by Zetasizer (Nano ZS, Malvern Instruments, 
Malvern, UK) based on dynamic light scattering technique. The analyses were 
performed at a scattering angle of 90º and at 25ºC. The polydispersity index 




distribution, having a value between 0 and 1 (0 being for monodispersed 
particles) was also obtained.  
 
The morphology of nanoparticles was observed by scanning electron 
microscopy (SEM) (JEOL JSM 6701F, Japan). The freeze-dried nanoparticle 
samples were coated with platinum under vacuum. Observations were 
performed at 5 kV.  
 
5.1.4 Simultaneous determination of midazolam and propofol by HPLC 
 
A Dionex UltiMate 3000 HPLC system and a Phenomenex Luna 3u C18 
column (50 × 2.0 mm; 3 m) were used. A gradient elution was used at 0.5 
ml/min. The determination wavelengths were 230 nm for midazolam and 272 
nm for propofol with the diode array detector which can detect simultaneously. 
The mobile phase consisted of solutions 1 (50 mmol ammonium acetate at pH 
6.0) and 2 (acetonitrile). The starting ratio was 70% v/v for solution 1 and 30% 
v/v for solution 2. At 8 min, the proportion of solution 2 increased to 50% for 5 
min, and then back to the initial composition, followed by an 8-min 
equilibration. The column temperature is 25°C. Mean peak area ratios of 
midazolam and propofol were linearly related to the drug concentrations for the 
samples containing 1 - 500 μg/ml of midazolam (r2 = 0.9999) and 1 - 5000 
μg/ml of propofol (r2 = 0.9998). 
 
5.1.5 Determination of drug loadings and entrapment efficiencies of 
nanoparticles 
 
Freeze-dried midazolam-loaded nanoparticles were carefully weighed and 
dissolved in 1 ml acetonitrile, and were vortexed for 5 min. After centrifugation 




method described in Section 5.1.4 to obtain midazolam amount in the 
nanoparticles.  
 
The drug loading (DL) of midazolam was the actual amount of midazolam 
incorporated into nanoparticles versus the total amount of the freeze-dried 
midazolam nanoparticles. The encapsulation efficiency (EE) of midazolam was 
calculated with the percent ratio of the actual amount of midazolam 
incorporated into nanoparticles to the total amount of midazolam used in the 
preparation of nanoparticles. The recovery rate of midazolam nanoparticles is 
the total amount of freeze-dried midazolam nanoparticles versus the total 
amount of raw materials used. Experiments were performed in triplicate.  
 
5.1.6 Optimisation of midazolam-loaded nanoparticulate preparation 
 
Different formulation parameters were tested with at least three levels to 
achieve the highest DL and EE. A set of parameters determined by preliminary 
studies was set as control. Only one parameter was changed at one time with all 
other parameters unchanged and conformed to the control. Parameters tested 
were: pH of aqueous phase, sonication time, PLGA amount, midazolam amount, 
PVA concentration, and oil/water ratio. Each level was tested in triplicate. 
 
5.1.7 Preparation of MNP organogel 
 
5.1.7.1 Heat stability of nanoparticles 
 
In order to determine if midazolam nanoparticles were stable at high 
temperature during the preparation process of organogel, midazolam 




change in size and particle number of nanoparticles stored at 90ºC for 30 min 
and 60 ºC for 30 min and 3 min in an oven. The particle number was 
characterised using derived count rate (in kilo counts per second (kcps)), which 
was a function of the particle concentration and an indirect indicator of the 
suspension stability over time. 
 
5.1.7.2 Preparation methods 
 
After determination of the heat stability of midazolam nanoparticles, they 
were carefully weighed and suspended in 1 ml of the solvent used for 
organogel matrix (PG or ISA), vortexed until homogenous suspension was 
formed. Organogels containing 5% w/v GP-1 in PG or 8% w/v GP-1 in ISA 
were mixed and placed in an oven at 90°C for 30 min for dissolution, after 
which the organogels were kept in an oven at 60°C and equilibrated for 30 
min. Three times of mild shake (5 sec per time) were performed to ensure the 
homogenous of the hot solution. Then, the organogels were taken out and 20% 
v/v propofol, 2.5% v/v limonene and 1 ml midazolam nanoparticle suspension 
were added. The resulting mixture was then stirred and cooled by tap water to 
room temperature, and a yellowish gel was formed.  
 
5.1.8 In vitro release study 
 
Release study of midazolam-loaded nanoparticles and MNP organogels were 
carried out according to in vitro release study (method described in Section 
2.1.5) except that Spectra/Por
®
 dialysis membrane (MWCO 6k-8k, Spectrum 





5.1.9 In vitro hairless mouse skin permeation study 
 
In vitro hairless mouse skin permeation of MNP organogels and midazolam 
(no nano) propofol organogels were carried out according to in vitro skin 
permeation study described in Section 2.1.4 except that hairless mouse dorsal 
skin was used with a flow rate of 0.65 ml/hr of the receptor solution. The skins 
were obtained from euthanised 12-week female hairless mice. All the skins 
were stored in -80°C freezer. The fat and connective tissues were removed 
carefully and checked for any broken skin before use. 
 
5.1.10 Characterisation of rheological parameters  
 
The rheometer (HAAKE RheoStress RS600, Thermo Electron Corporation, 
Waltham, Massachusetts, USA) was used to determine rheological parameters 
of fresh (48-hr-old) MNP organogel and midazolam propofol organogel. All 
measurements were performed at 32 ± 0.2ºC.  
 
5.1.11 Stability study 
 
With the formulation finalised, MNP organogels were prepared and tested with 
several parameters in 3 different temperatures: 4°C, room temperature (23°C ± 
2°C), and oven (40°C ± 2°C) in triplicate. Physical and chemical studies were 
performed on the gels at different time intervals and temperatures. 
 
5.1.11.1 Physical stability of MNP organogel 
 





Samples were observed and their homogeneity, surface and colour at 3 
different temperatures were photographed on Day 0, Month 1 and Month 6. 
 
5.1.11.1.2 SEM characterisation of freeze-dried MNP organogel 
 
An amount of 50 mg MNP organogel was spread onto a cover glass (d = 12mm) 
and freeze-dried for 8 hr. The morphology of MNP organogel was characterised 
by SEM as described in Section 5.1.3. The tests were carried out on Day 1, 
Month 1 and Month 6 for midazolam nanoparticulate organogels, stored at 
4°C in triplicate. 
 
5.1.11.1.3 Rheological behaviour of MNP organogels 
 
The organogels stored in 4°C were tested at predetermined time intervals by 
amplitude sweep tests using the Rheometer as described in Section 5.1.10 to 
obtained parameters, such as elastic modulus (G’), viscous modulus (G’’) and 
yield value. The tests were carried out at Day 0, Day 14, Month 1, Month 3 and 
Month 6 in triplicate. 
 
5.1.11.2 Chemical stability  
 
5.1.11.2.1 Chemical stability of midazolam nanoparticles in suspensions 
 
Midazolam nanoparticles (10 mg) were suspended into 3 ml PG or ISA. 
Midazolam nanoparticle suspension was centrifuged at 8000 rpm for 10 min. 
Fifty l of the supernatants were drawn for HPLC tests. The remaining 
suspension was vortexed and re-suspended and stored at 3 different 




14, Month 1, Month 2, Month 3 and Month 6. The chemical instability was 
considered to be a significant change of midazolam and propofol concentrations 
in the supernatant over ±5% of the concentrations at Day 0 according to USP. 
No further tests were done on formulations which were unstable. The studies 
were performed in triplicate. 
 
5.1.11.2.2 Chemical stability of MNP organogel 
 
The MNP organogels to be tested were final formulations kept at 4°C. Around 
100 mg organogel was carefully weighed and suspended with acetonitrile to 
form a 0.10 g/ml suspension. After vortex for 10 min and centrifugation at 
13000 rpm for 10 min, the supernatants were subjected to HPLC tests for 
simultaneous detection of propofol and midazolam contents. The tests were 
carried out at Day 0, Day 14, Month 1, Month 3 and Month 6. The chemical 
instability was considered to be a significant change of propofol or midazolam 
concentration in the supernatant over ±5% according to USP. The studies were 
performed in triplicate. 
 
5.1.12 Statistical analysis 
 
Statistical analysis was performed using Minitab software. One-way analysis of 
variance (ANOVA) with Tukey’s comparison was used in group comparisons. 
The level of significance was taken as p < 0.05. 
 





5.2 Results and discussion 
 
5.2.1 Effect of formulation parameters on characteristics of nanoparticles  
 
A variety of formulation parameters may influence the size, size distribution, 
encapsulation efficiency, drug loading and recovery rate of nanoparticles. 
Investigation of all these variables is limited by time and resources. However, 
based on some preliminary studies and the properties of drug (midazolam) and 
polymer (PLGA), some of the more important parameters, such as pH of 
aqueous phase, sonication time, PLGA amount, midazolam amount, PVA 
concentration and oil/water ratio were explored and optimised.  
 
5.2.1.1 pH of aqueous phase 
 
The aqueous phase pH may be a pivotal parameter in deciding the EE and DL of 
an ionisable compound as the solubility of the compound is pH-dependent. 
Midazolam has a pKa value of 6.08 (Andersin, 1991) thus is un-ionised in basic 
environment, which means basic environment of aqueous phase would 
probably decrease the likelihood of midazolam diffusing from the oil phase into 
the aqueous phase.  
 
Fig. 5.1 shows that EE reached a plateau when aqueous phase pH was above 8. 
From pH 8 to 11, no significant changes occurred. But EE dropped when pH 
decreased below 8. At pH 8, calculated from Henderson-Hasselbalch equation, 
98.8% w/v of midazolam is in un-ionised form. The results suggest that 
un-ionised form of midazolam may effectively increase the retention of 
midazolam in the oily droplets formed by sonication and prevent the leakage of 




improved the drug loading from 5.4% to 20.4% and increased the encapsulation 
efficiency from 28.2% to 84.3% by increasing the pH for a basic compound 
U-86983.  
 
Fig. 5.1. Effect of pH on encapsulation efficiency (EE) of midazolam 
nanoparticles (n = 3). 
 
 
As extreme pH values can affect the shape of the particles and the integrity of 
the polymer and the drug (Bodmeier and McGinity, 1987), and the hydrolytic 
erosion of PLGA was found to be specifically proton catalysed (Jain et al., 
2010a), a more neutral pH was preferred. Since the EE changes were 
insignificant from pH 8 to 11, pH 8 was chosen as the optimal pH in the 
following studies. 
 
5.2.1.2 Sonication time 
 
Sonication is the essential step of the single emulsion evaporation method since 
this is the decisive step in the formation of nano-sized droplets, which would 
















sonication are sonication time and power. Longer sonication time will generally 
bring about smaller size nanoparticles that can be obtained also by higher 
sonication power. So we chose sonication time only to test the sonication 
impact on nanoparticles with the output power set at 30 W, which is a 
commonly used value in literature. 
 
Fig. 5.2. Effect of sonication times on drug loading (DL) and encapsulation 
efficiency (EE) of midazolam nanoparticles (n = 3). 
 
 
Fig. 5.2 shows that as the sonication time increased, the average size, EE and 
DL decreased. The application of high energy in the system over prolonged 
period resulted in a rapid dispersion of polymeric organic phase as droplets of 
small size and homogeneous distribution. Therefore, the longer sonication time 
(3 min) yielded smaller nanoparticles with narrower size distribution (PdI = 
0.06 ± 0.02). However, sonication over prolonged period may cause more 
midazolam to diffuse into the aqueous phase instead of remaining as nano-sized 
droplets. During sonication the droplets may collapse and reform and larger 
droplets may shrink into smaller droplets. During the reforming of droplets, 



























were reduced as a result of the drug leakage. Our findings are in accordance 
with those reported by other authors (Mainardes and Evangelista, 2005; Kwon 
et al., 2001). 
 
5.2.1.3 PLGA amount 
 
The PLGA amount in the oil phase is a parameter to test the utilisation 
efficiency of the polymer in the single emulsion evaporation method. 
 
Fig. 5.3. Effects of PLGA amounts on drug loading (DL) and encapsulation 
efficiency (EE) of midazolam nanoparticles (n = 3). 
 
 
Fig 5.3 shows that more PLGA leads to increased nanoparticle size, increased 
EE and decreased DL. Increased PLGA in the oil phase led to increased 
viscosity, resulting in a decrease in the net shear stress and promoted the 
formation of larger droplets which formed larger nanoparticles after 
evaporation of the organic solvent. In addition, the increased viscosity could 
retard rapid dispersion of PLGA molecules from the oil phase into the aqueous 





























insufficient PVA available to completely cover the surface of droplets, which 
impaired the stabilising ability of PVA and caused the coalescence of droplets 
and aggregation of nanoparticles during and after the evaporation of organic 
solvent.  
 
The higher EE with the increasing PLGA amount may be attributed to the 
higher viscosity in the oil phase, resulting in less leakage of midazolam into the 
aqueous phase. As more PLGA was added, more midazolam could interact with 
the PLGA, but the increase of the entrapped amount of midazolam was not in 
proportion to the increase of total PLGA added. Therefore PLGA utilisation 
efficiency decreased with excessive PLGA added into the system, and a lower 
DL was also attributed to an increasing PLGA. Song et al. (2008) reported a 
similar trend when a lipophilic drug vincristine sulfate was encapsulated in 
PLGA using the single emulsion evaporation method. 
 
5.2.1.4 Midazolam amount 
 
The midazolam and PLGA were dissolved in the oil phase, and the variable 
drug/polymer ratio was commonly used as a testing parameter. However, the 
viscosity changes in the oil phase due to the different amounts of midazolam 
and PLGA, even though drug/polymer ratio stays the same, may influence the 
nanoparticle formulation process. Therefore, we chose to test midazolam and 
PLGA amount in the oil phase separately. 
 
Fig. 5.4 shows that 100 mg midazolam yielded a significant higher average size 
than 30 mg and 10 mg midazolam, and that 30 mg and 50 mg midazolam 
yielded the highest EE and 50 mg possessed the highest DL. More drug led to a 
more viscous oil phase. With the increasing difference in viscosity between oil 




the oil-in-water system. The high viscosity could have retarded the dispersion 




Fig. 5.4. Effects midazolam amounts on drug loading (DL) and encapsulation 
efficiency (EE) of midazolam nanoparticles (n = 3). 
 
 
With a high DL of 45.0% ± 2.6%, which means the nanoparticles are composed 
of 45% w/v midazolam and 55% w/v PLGA, it can be speculated that 
midazolam may have a good solid-state solubility in PLGA, i.e. midazolam 
may interact with PLGA and may form some kind of complex with PLGA. 
After washing 3 times, the solution from the last wash was analysed by HPLC to 
ensure that the unencapsulated drug was washed off from nanoparticles. The 
midazolam remaining on the surfaces of PLGA nanoparticles may interact in a 
loose manner with PLGA molecules. This could explain the high DL of 45.0% 
of the nanoparticles. Furthermore, a possible interaction between midazolam 
and PVA may exist as PVA covered most surfaces of the nanoparticles even 





























In the reported studies on nanoparticle formulation, researchers used excessive 
PLGA to raise the EE of the encapsulated drug while achieving a relative low 
DL at around 1%. However, nanoparticles with low DL will have little clinical 
significance since a large amount of nanoparticles are needed to deliver a 
therapeutic dose of drug. In this study, we proved that without adding excessive 
PLGA, a very high EE and DL can be achieved at the same time. The stability 
and release profile of these preparations will be discussed in later sections. 
 
5.2.1.5 PVA concentration 
 
Polyvinyl alcohol (PVA), a copolymer of vinyl acetate and vinyl alcohol, is the 
most commonly used emulsifier and stabiliser for the preparation of PLGA 
micro/nanoparticles due to its excellent interaction with PLGA surfaces 
(Wischke and Schwendeman, 2008). The most commonly used PVA 
concentration for preparing PLGA nanoparticles in the literature using single 
emulsion evaporation method is 1% w/v. A higher PVA concentration may 
favour drug loss to the continuous phase. Giunchedi et al. (1998) reported that 
the solubility of hydrocortisone increased from 0.28 mg/ml in water to 1.38 
mg/ml in the presence of 1.5% w/v PVA. Midazolam may possess a similar 
solubility increase as hydrocortisone since its water solubility is 0.24 mg/ml 
(Andersin 1991). And a leakage of midazolam into the aqueous phase would 
contribute to the decrease of EE and DL with a high concentration of PVA. 
Therefore, we chose 0.3%, 1% and 3% w/v PVA because 1% w/v is the most 
commonly used while 0.3% w/v and 3% w/v have also been considered in the 
relatively low concentration region (< 5% w/v). 
 
Fig. 5.5 shows that an increase of PVA concentration leads to an increase of 
average size and a decrease of EE and DL. Some reported studies showed 




concentration changed. For example, Zambaux and his colleagues (1998) found 
that the mean nanoparticle size decreased from 520 to 380 nm with an increase 
in the PVA concentration in the external aqueous phase from 0.5 to 5% w/v. 
Their study differs from ours as it was done using double emulsion evaporation 
method, and the PVA was in the secondary aqueous phase, while PVA was used 
in primary aqueous phase in our study. In their study, higher PVA concentration 
increased the viscosity of the aqueous phase thus reducing the net shear stress 
and decreased nanoparticle size. In our study, as discussed in Section 5.2.1.4, 
midazolam may have interacted with PLGA and formed a complex, which 
could become less sensitive to the increase of drug solubility in aqueous phase 
by increasing PVA. It can be postulated that at high PVA concentration, PVA 
molecules could have interacted with the midazolam-PLGA droplets and the 
nanoparticle components (midazolam and PLGA) acted as an adhesive agent to 
make the nanoparticles grow larger like snowballs. 
 
Fig. 5.5. Effect of PVA concentrations on drug loading (DL) and encapsulation 
efficiency (EE) of midazolam nanoparticles (n = 3). 
 
 


























5.2.1.2), PLGA amount (Section 5.2.1.3) and midazolam amount (Section 
5.2.1.4.), EE showed a positive correlation with the size. However, in the 
optimisation of PVA concentration, EE was negatively correlated with the size. 
Therefore, it can be concluded that a larger nanoparticle may not lead to a 
higher EE.  
 
Mainardes and Evangelista (2005) found that with the single emulsion method, 
when the PVA concentration dropped to 0.15% w/v, agglomeration appeared in 
SEM photos where some particles fused together. At this low concentration, 
PVA amount was not enough to stabilise PLGA nanoparticles. Therefore, there 
was a lower limit for the concentration of PVA because nanoparticle stability 
must not be neglected. As such, we chose 0.3% w/v PVA as the optimal PVA 
concentration. 
 
5.2.1.6 Oil/water ratio 
 
Oil/water ratio is also a commonly tested parameter in nanoparticle 
optimisation. In order to maintain the concentrations of midazolam and PLGA 
as well as the viscosity in oil phase, the oil/water ratio was changed by altering 
the volume of aqueous phase in our study. 
 
Fig. 5.6 demonstrates that as the volume of the aqueous phase increased, the 
average size increased and the DL and EE decreased. When the volume of the 
aqueous phase increased, the total amount of PVA in the aqueous phase 
increased. So the increasing volume of the aqueous phase essentially has the 
same influence on the system as the increasing concentration of PVA in the 
aqueous phase. Therefore, the changing trends of size, EE and DL are the same 
as the increase of PVA concentration described in Section 5.2.1.5. Furthermore, 




during diffusion into the aqueous phase, thereby forming larger nanoparticles. 
Song et al. (2008) and Mainardes and Evangelista (2005) reported similar trend 
of decreasing oil/water ratio while nanoparticle size increased with drugs 
encapsulated in PLGA using a single emulsion evaporation method. The large 
amount of aqueous phase may give rise to more midazolam leakage due to its 
water solubility, which further decreased EE and DL. 
 
Fig. 5.6. Effects oil/water ratio on drug loading (DL) and encapsulation 
efficiency (EE) of midazolam nanoparticles (n = 3). 
 
 
5.2.1.7 Optimisation of preparation method 
 
After studying the 6 parameters for the preparation of nanoparticles, the 
selected parameters were pH = 8, sonication time = 25 sec, PLGA amount = 50 
mg, midazolam amount = 50 mg, PVA concentration = 0.3% w/v, and oil/water 
ratio = 1/3. Using these optimal parameters, the midazolam nanoparticles had 
significantly improved drug loading of 45.4 ± 3.0% (n = 6) and encapsulation 





























Based on the optimisation results, there is no correlation among nanoparticle 
size, EE and DL. So by judging from nanoparticle size change, it is not possible 
to extrapolate EE or DL changing trends. Therefore, optimisation for each 
important parameter is needed to obtain the final optimisation of the preparation 
process of nanoparticles. 
 
The encapsulation efficiency ranged from 60 to 70 % for drugs such as estradiol 
or xanthones (Danhier et al., 2012). One of the major pitfalls of PLGA-based 
nanoparticles is the poor drug loading. While PLGA-based nanoparticles 
possessed high encapsulation efficiencies, drug loading was regarded to be 
generally poor (around 1%) which poses a major problem for clinical 
applications of PLGA-based nanoparticle formulations.  
 
To develop a successful nanoparticulate delivery system, sufficient drug 
loading is needed to reduce the quantity of the nanoparticles required for 
administration. The successful entrapment of drug within the nanoparticles 
depends on many factors: (1) low solubility of drug in the aqueous phase; (2) a 
fast rate of precipitation/solidification of the polymer in the organic phase 
which in turn depends on high aqueous phase solubility and high vapour 
pressure of solvent, and low viscosity of the internal phase; and (3) high 
solid-state solubility of drug in the polymer (Sahana et al., 2008; Panyam et al., 
2004). In this study, it was observed that midazolam could have interacted with 
PLGA with a high solid-state solubility in PLGA, which resulted in a high drug 
loading and encapsulation efficiency. Therefore, less midazolam nanoparticles 
were incorporated in the organogel vehicle to achieve a therapeutic plasma level 
in the transdermal drug delivery system compared to PLGA nanoparticles with 





5.2.2 Characterisation of the nanoparticles 
 
5.2.2.1 Characterisation by Zeta sizer 
 
The optimal midazolam-loaded nanoparticles were found to have size of 574.3 
± 22.9 nm, PdI of 0.427 ± 0.036, and zeta potential of -15.4 ± 0.61 mV. It is 
known that microparticles with zeta potentials more positive than +30 mV and 
more negative than -30 mV are considered stable for colloidal dispersion 
(Mukherjee et al., 2008). Much of the PLGA nanoparticles surfaces were 
covered with PVA and the high drug loading nanoparticles indicated that most 
of the midazolam molecules was on or near the surface of the nanoparticles. 
At physiological pH, positive charged protonated amino groups in midazolam 
molecules may neutralise some of the negative charged carboxylic acid end 
groups in PLGA molecules and vinyl hydroxyl end groups in PVA molecules 
(Garcia et al., 2011). This could explain the relatively low absolute value of 
zeta potential of the optimal midazolam-loaded nanoparticles. However, a zeta 
potential less negative than -30 mV may probably not lead to instability of 
nanoparticles after the nanoparticles are suspended into the organogel matrix 
because the high viscosity of organogel may hinder the aggregation of the 
nanoparticles if they are evenly dispersed. 
 
5.2.2.2 Characterisation by SEM 
 
Fig. 5.7 shows the SEM characterisation of the morphology and size of the 
freeze-dried optimised midazolam-loaded PLGA nanoparticles. The majority of 
the nanoparticles were spherical with a smooth surface at 10000 × 
magnification. However, at 20000 × magnification, some of the nanoparticles 
appeared to be irregular shaped. This is because the high voltage (5.0 kV) in the 




of nanoparticles and even melting of the nanoparticles. The phenomenon was 
more commonly seen in our samples at magnification greater than 20000 fold. 
Therefore, low voltage (0.5 kV) SEM should be applied to obtain reliable 
morphological data of PLGA nanoparticles if possible. 
 
Judging from the SEM images, the nanoparticles sizes fell in the range of 150 - 
300 nm. The average size of 574.3 ± 22.9 nm measured by zetasizer, which are 
larger than the average size observed from SEM images, could be due to the 
presence of a few large particles and aggregates of nanoparticles that increased 
the average size. Although several authors claimed that freeze-drying increased 
the size of PLGA nanoparticles without lyoprotectant by irreversibly 
aggregating nanoparticles, the size increasing effect of freeze-drying process 
was not obvious in our study, which could be due to the presence of a high 
percentage of midazolam in the nanoparticles (Jain et al., 2010b; D'Addio et al., 
2010; Bozdag et al., 2005). 
 
Fig. 5.7(b) showed that a corona covered the nanoparticles. The corona is 
thought to be composed of PVA that could not be eliminated even after three 
times of wash to the nanoparticles (De and Robinson, 2004; Sahoo et al., 2002). 
Remaining PVA associated with the nanoparticles despite repeated washing as 
PVA formed an interconnected network with PLGA at the interface. The 
hydrophobic segments of PVA penetrated into the organic phase and remained 
entrapped in the polymeric matrix of the nanoparticles. The binding of PVA on 
the nanoparticle surface could have happened when the organic solvent was 
evaporated from the interface in which interpenetration of PVA and PLGA took 
place (Boury et al., 1995). An increase in PVA concentration in the external 
aqueous phase resulted in the increase in the residual PVA amount associated 
with nanoparticles (Sahoo et al., 2002). The amount of residual PVA associated 




(Zambaux et al., 1998). 
 
Fig. 5.7. SEM images of freeze-dried optimised midazolam-loaded PLGA 
nanoparticles. Bar = 1 m.  









Nanoparticles can aggregate during freeze-drying process. One approach to 
alleviate aggregation is use of lyoprotectant which reduces the aggregation of 
nanoparticles during freeze-drying, but cannot eliminate it (Astete and Sabliov, 
2006). Possible mechanisms of stabilisation by lyoprotectants are the ability of 
lyoprotectants to form a glassy amorphous matrix around the particles, 
preventing the particles from sticking together during the removal of water or a 
formation of hydrogen bonds between lyoprotectants and the polar groups of 
nanoparticles at the end of the drying process based on water replacement 
hypothesis (Carpenter et al., 1997). The lyoprotectants preserve the native 
structures of nanoparticles by serving as water substitutes (Ford and Dawson, 
1993). However, it is laborious to decide the species and concentration of 
lyoprotectants used in the nanoparticle suspension before freeze-drying. 
Considering that our midazolam-loaded PLGA nanoparticles had no obvious 
aggregation after freeze-drying, lyoprotectant was not used. 
 
The midazolam-loaded PLGA nanoparticles were air-dried to compare with 
freeze-drying ones. The results in Fig. 5.8 showed that a large number of 
crystals co-existed with the nanoparticles. By using the energy-dispersive X-ray 
spectroscopy (EDS), an analytical technique used for the elemental analysis, 
crystals tested possessed an element F as shown in Fig. 5.8 (b). The spherical 
particles showed no trace of element F (data not shown) but the crystals 
containing element F were supposed to be midazolam crystals because only 
midazolam had element F among all the materials used in the preparation of the 
nanoparticles. The emergence of midazolam crystals in air-dried nanoparticle 
suspension, which did not exist in freeze-dried nanoparticle suspension, reflects 
the differences in the two drying processes. The major drying force of 
freeze-drying is sublimation, in which there is no transitional liquid state. While 
in the air-drying process, almost the whole sample is in liquid until fully dried at 





Fig. 5.8. SEM images of air-dried optimised midazolam-loaded  
PLGA nanoparticles. (a) SEM image; (b) Energy-dispersive X-ray 
spectroscopy (EDS) analysis on a crystal. 
 
 
becomes a solvent of midazolam and carries a large amount of midazolam out 
of the PLGA nanoparticles during the slow evaporation process. Because 
midazolam is a small molecule, and can easily be carried by dichloromethane 
rather than detained by the larger molecules and PVA, the efflux of 
dichloromethane will not destroy the structure of PLGA nanoparticles. 
However, we observed an increase in the size of nanoparticles in Fig. 5.8 (a) 
versus those of Fig. 5.7. This nanoparticle growth could be due to the partially 




existence of dichloromethane efflux as particles with larger size would have 
less surface area and were thermodynamically favoured. Therefore, 
freeze-drying is preferred for the preparation of midazolam-loaded PLGA 
nanoparticles. 
 
5.2.2.3 In vitro release study of nanoparticulate suspensions 
 
While the experimental set-up for release studies is specified in the 
pharmacopoeias (USP, Ph. Eur.) for conventional dosage forms, there is no 
such specification for long-acting release nanoparticles. Colloidal disperse 
systems such as liposomes, microemulsions or nanosuspensions, could either 
block the filter in USP apparatus 4 or pass through it (Bhardwaj and Burgess, 
2010). We adapted the modified flow-through cell method reported by Kaiser et 
al. (2003) and Zolnik et al. (2005) for determining the release profile of 
midazolam nanoparticles in PG and water suspensions. 
 






Fig. 5.9 shows the midazolam release profile from PLGA nanoparticles in water 
and PG. When suspended in water, the PLGA nanoparticles released 
midazolam in an almost zero-order manner. And in PG suspension, there was a 
burst release in the first 10 hr followed by an almost zero-order controlled 
release. 
 
There are five release mechanisms of micro/nanoparticles: desorption of the 
surface-bound/adsorbed drug, diffusion, erosion, osmotic-mediated release, and 
a combination of these mechanisms (Wischke and Schwendeman, 2008). 
Diffusion of small molecular weight drugs through the polymer can be expected 
to play an important role in drug release (Panyam et al., 2004). Moreover, 
several authors suggested that during the early phases of release profiling, 
release occurred mainly through diffusion in the polymer matrix (Sahana et al., 
2008; Mogi et al., 2000; Makino et al., 2000). PLGA degradation needs days to 
months but our release study for PLGA nanoparticles performed for only 72 hr, 
thus our release profile can be considered the early stage of the whole release 
profile. Therefore, the major release pattern in our study by midazolam-loaded 
PLGA nanoparticles may be considered as diffusion. Although degradation of 
PLGA could occur simultaneously, the erosion rate could be negligible in 72 hr. 
 
The most commonly reported PLGA nanoparticle release is a triphasic release 
pattern: an initial ‘burst’ phase, a lag phase followed by a second release phase 
(Corrigan et al., 2009). However, the triphasic profile usually needs a testing 
duration of at least 30 days. Considering that our nanoparticulate organogel 
may reside on skin surface for not more than 3 days, we performed the release 
studies for 72 hr, which would probably show the release profile of the PLGA 
nanoparticles. It can be seen from Fig. 5.9 that within the first 72-hr of release of 
midazolam, nanoparticles in water suspension showed a monophasic release 




There was an obvious burst release in the PG suspension in the first 10 hr. The 
burst release of nanoparticles was primarily due to adsorbed drug at the particle 
surface or in the suspension medium. As midazolam, made up 45% w/w of the 
nanoparticles being a substantial part of the nanoparticles, was located on and 
near the surface of nanoparticles, it could be easily solubilised by PG solvent. 
Matsumoto and his colleagues (2005) also suggested that a rapid release of 
lipophilic drugs from polyester nanoparticles after contact with a lipophilic 
solvent could be due to the partition of the drug between the lipophilic cores of 
the particles and the lipophilic solvent. However, PG is more lipophilic than 
water since it is a short chain alcohol and PLGA has been tested to show 
negligible solubility in PG. Therefore, the diffusion of midazolam from PLGA 
into PG would not be the main contributor to the burst release in the first 10 hr. 
The burst release could be probably due to midazolam adsorbed on the surface 
of PLGA nanoparticles. This extrapolation can be buttressed by the fact that the 
solubility of midazolam in PG was found to be over 100 mg/ml in our study, 
which was considered to be freely soluble. Thus, the high midazolam solubility 
in PG posed a crucial impact on the burst release of midazolam in PG 
suspension. For parenteral and oral applications of nanoparticles, burst release 
is a negative effect that should be avoided. Even for transdermal delivery of 
long-lasting effect drugs, burst release should also be minimised. However, as 
this clinical application of MNP organogel is for procedural sedation which 
needed to take effect within minutes, and considering the fact that the organogel 
reservoir and skin pose two restrictive barriers for the diffusion of midazolam 
into human blood stream, a minor burst release of the nanoparticles will 
probably not influence the pharmacokinetic profile of midazolam applied 
transdermally. The major concern for the transdermal release of midazolam is 
to achieve a steady and fast permeation of drug into the blood circulation. 
 




many approaches to increase the release of PLGA nanoparticles. Higher 
glycolide contents, e.g., PLGA 50/50 vs. 85/15 are considered to release faster 
in water (Liggins et al., 2000). An increase in the surface area/volume ratio, i.e., 
a decrease in the particle size, may probably lead to higher release for the drug. 
Since PLGA are linear polymers, the overall mobility of their chains will 
increase with decreasing molecular weight, thus a low molecular weight PLGA 
may allow the drug to diffuse faster through the particle matrix. An elevated 
temperature can also accelerate the release of PLGA particles (Agrawal et al., 
1997). 
 
5.2.3 Preparation of MNP organogel 
 
As far as we know, there is no report on incorporating PLGA nanoparticles into 
an organogel matrix. However, as the preparation method of small molecular 
gelling agent (SMGA) organogel needs a high temperature at 90°C for 30 min, 
and as the glass transitional temperature (Tg) of PLGA (50:50) is in the range of 
40-50°C (Rawat and Burgess, 2011; Wischke and Schwendeman, 2008), there 
is an urgent need to test the heat stability of nanoparticles before incorporating 
the PLGA nanoparticles into the organogel matrix. 
 
5.2.3.1 Heat stability of nanoparticles 
 
During organogel preparation, a heating process for 30 min at 90°C is needed. 
So we firstly tested 30 min stability at 90°C.  
 
Table 5.1 showed that after heating at 90°C for 30 min, the nanoparticle powder 
melted and became a plastic film. Nanoparticles in ISA suspension also melted 
to form irregular shaped plastic beads, but nanoparticles in PG suspensions 




size of the nanoparticles significantly increased and the counting rate 
significantly decreased with obvious aggregation of the nanoparticles. Some of 
the aggregates could not be re-suspended in the PG solution thus the countable 
particles in the suspension dropped significantly as they precipitated. Therefore, 
although nanoparticles in PG suspension remained after heating at 90°C, they 
were not stable. Thus it can be concluded that PLGA nanoparticles cannot be 
added into PG/ISA before the heating procedure at 90°C for 30 min in 
organogel preparation. Nanoparticles should avoid the high temperature and be 
incorporated into the organogel after the 90°C heating procedure. 
 
Table 5.1. Stability of PLGA nanoparticle suspensions at 90°C for 30 min. 
                Size 
Derived count rate 
At room 
temperature (23°C) 
At 90°C, 30 min 
Solid nanoparticles Flocculent powder Melted 
Suspension in water 475.1 ± 10.82 nm 
1798.3 ± 69.2 kcps 
459.5 ± 16.77 nm 
1500.7 ± 106.5 kcps 
Suspension in PG 603.1 ± 18.88 nm 
1777.6 ± 44.2 kcps 
643.8 ± 15.72 nm 
1149.5 ± 10.5 kcps 
Suspension in ISA 293.4 ± 5.811 nm 
833.7 ± 21.9 kcps 
Melted 
 
From Table 5.1 the nanoparticle water suspension shows an insignificant 
average size change and a slightly decrease in counting rate, which indicates 
that PLGA nanoparticles could be considered stable in water suspension. 
Comparing the data of 3 suspensions and 1 powder shown in Table 5.1, it can 
be postulated that solvents provided protection against heat for PLGA 
nanoparticles when they were in suspensions. When the nanoparticles were 
suspended in the solvents, each nanoparticle was separated from others and no 
agglomeration occurred in an ideal situation. The viscous solvent separating 
nanoparticles are pivotal for the nanoparticles to avoid coalesce or aggregation 
according to Stokes’ Law. The volumes of solvents are relatively larger than the 
bulk of nanoparticles. The high heat capacity of these solvents also alleviates 




glycol and water are 2.470 and 4.186 kJ/(kg•K) at 20°C, respectively (data from 
Dow Chemistry). The higher heat capacity of the solvent could bring about 
higher heat protection capacity for the nanoparticles. 
 
The organogel began to solidify at 60°C which means that it is the lowest 
temperature at which nanoparticles could be incorporated into organogel. 
 
Table 5.2. Stability of PLGA nanoparticle suspensions at 60°C for 30 min. 
                Size 
Derived count rate 
At room 
temperature (23°C) 
At 60°C, 30 min 
Solid nanoparticles Flocculent powder Coalesced 
Suspension in PG 606.2 ± 18.17 nm 
997.1 ± 16.8 kcps 
781.5 ± 7.912 nm 
1062.4 ± 57.2 kcps 
Suspension in ISA 293.4 ± 5.811 nm 
833.7 ± 21.9 kcps 
261.1 ± 10.92 nm 
789.9 ± 19.5 kcps 
 
Table 5.2 shows that when nanoparticle powder was heated at 60°C for 30 min, 
it formed a white film. PG and ISA suspensions showed significant changes in 
average size, which indicates that PLGA nanoparticles remained unstable at 
60°C for 30 min. 
 
Compared to air cooling in the usual preparation method of organogels, we used 
water cooling which shortened the cooling process of organogels to less than 3 
min before solidification at room temperature. Therefore, stability at 60°C for 3 
min was tested. 
 
Table 5.3. Stability of PLGA nanoparticle suspensions at 60°C for 3 min. 
                Size 
Derived count rate 
At room 
temperature (23°C) 
At 60°C, 3 min 
Suspension in PG 675.4 ± 10.14 nm 
1739.9 ± 104.4 kcps 
681.3 ± 20.22 nm 
1772.8 ± 40.8 kcps 
Suspension in ISA 304.7 ± 16.29 nm 
965.0 ± 14.1 kcps 
300.3 ± 7.184 nm 
985.3 ± 23.3 kcps 
 




ISA nanoparticle suspensions after storage at 60°C for 3 min did not change the 
physical properties of midazolam-loaded PLGA nanoparticles. 
 
In summary, the PLGA powder kept at 60°C and 90°C, above the glass 
transition temperature of 40 - 50°C, remained in the rubbery state, in which 
degradation was accelerated when compared to the glassy state. However, due 
to the heat capacities of ISA and PG, they could protect PLGA nanoparticles 
from heat for a short time (3 min) and they remained physically stable. 
Therefore, it is stable to keep PLGA nanoparticles in the suspension at 60°C for 
3 min thus the incorporation procedure is acceptable for the preparation of 
nanoparticulate organogel. 
 
5.2.3.2 Incorporating midazolam-loaded nanoparticles into organogel 
 
There is no published method for addition of nanoparticles into organogel 
matrix, besides a few reports on incorporating PLGA nanocarriers into hydrogel 
systems, either directly into the hydrogel matrix (Cascon et al., 2002; Kim and 
Martin, 2006) or suspended in aqueous solution and then the suspension was 
blended into the hydrogel matrix (Luengo et al., 2006). Based on the heat 
stability studies in Section 5.2.3.1, our incorporation method was designed to 
blend nanoparticle suspension to the organogel solution containing dissolved 
GP-1 equilibrated at 60°C. After addition of the nanoparticle suspension, water 
cooling lowered the temperature of the organogel to room temperature (23°C) 
within 3 min. The whole process would not cause deterioration to the 
midazolam-loaded nanoparticles. 
 
5.2.4 In vitro release study of MNP organogels 
 




MNP organogel in PG and MNP organogel in ISA, both of which followed 
Higuchi release pattern without obvious burst release, which is a commonly 
seen release pattern in nanomaterials and suspension systems (Kalia and Guy, 
2001). In Fig. 5.9, the cumulative amount of midazolam released from PLGA 
nanoparticle PG suspension at 48 hr is 433.3±17.4 g/cm2. In Fig. 5.10 (a), the 
cumulative amount of midazolam released from PLGA nanoparticle PG 
organogel at 48 hr is 41.5±4.0 g/cm2. The nanoparticles in suspension were 20 
mg/ml, while they were 6 mg/ml in organogels. If the midazolam release 
amount is proportional to the weight of midazolam-loaded PLGA nanoparticles, 
then with the same concentrations of midazolam-loaded PLGA nanoparticles, 
the cumulative amount of midazolam released from nanoparticle suspension is 
3.1 fold compared to midazolam released from nanoparticulate organogel. The 
slower release from the nanoparticulate organogel compared to suspension 
could be due to the fibre network in the organogel and the higher viscosity of 
the organogel which could have a retarding effect on the diffusion of 
midazolam from the surfaces of the nanoparticles to the organogel and then to 
the skin surface (Pénzes et al., 2004). The diffusion resistance posed by the 
organogel matrix may be a contributing factor to the reduced burst release of 
midazolam compared to that from PG nanoparticle suspension (Fig. 5.9). 
 
Fig. 5.10 (b) shows that the release of propofol from MNP organogel is a 
zero-order model, but there is a significant difference in the release rates 
between PG organogel and ISA organogel. As propofol consisted of 20% v/v of 
the organogel system, it can be considered an infinite reservoir which released 
propofol in a sustained release manner for a long time thereby showing the 
zero-order release profile. Regarding the difference between PG and ISA 
organogels, differences in release rates may be due to: (1) ISA, an alcohol with 
a long chain, is much more lipophilic than PG, thus propofol may interact with 
ISA by hydrophobic interaction thus slowing the release; (2) ISA organogel 




Fig. 5.10. In vitro release profile of drugs from MNP organogels:  






w/v, which probably retarded the release of propofol. However, the ISA 
organogel with propofol did not solidify with addition of GP-1 up to 7%. 




midazolam, which may be due to the different lipophilicities of propofol and 
midazolam. Propofol has a log P value of 4.16 (Hui et al., 2009) while 
midazolam is 3.0 (Dagenais et al., 2009). Therefore, propofol, being more 
lipophilic, would interact to a greater extent with GP-1 than midazolam. 
Therefore, the denser GP-1 network in ISA organogel could have retained more 
propofol in its matrix by decreasing its release rate but it showed less impact on 
midazolam release. 
 
5.2.5 In vitro hairless mouse skin permeation of MNP organogel and 
midazolam (nano-free) propofol organogel 
 
5.2.5.1 In vitro permeation study of MNP organogels 
 
The size of the prepared nanoparticles is more than 500 nm. They could not 
penetrate the skin barrier, but could only reside in hair follicles or on skin 
furrows, acting as a drug reservoir. The high local concentration reached by 
nanoparticles accumulated in skin furrows and hair follicles would favour the 
aggregation of denatured nanoparticles thus accelerating the release of 
midazolam (Prow et al., 2011; Cevc and Vierl, 2010). The midazolam 
molecules contained in the nanoparticles could also be at a higher 
thermodynamic activity relative to solution formulations, facilitating their 
partitioning into the skin (Alvarez-Roman et al., 2004). Moreover, in vivo 
polymer degradation was shown to be faster compared to in vitro assays in 
buffer solution, which was attributed to a plasticizing effect of biological 
substances such as lipids (Menei et al., 1993) and the acidic human skin surface 
at pH of 4.2-5.6 (Schmid-Wendtner and Korting, 2006). Furthermore, the 
accumulation of acidic hydrolytic products from the degradation of 
nanoparticles in the microenvironment on the skin surface may accelerate 




midazolam on the skin surface could lead to a high drug permeation rate. 
 
Fig. 5.11. In vitro permeation profile through hairless mouse skin from MNP 









Fig. 5.11 shows the permeation profile of the drugs through hairless mouse skin 
from MNP organogel. The two major differences between release and 
permeation studies shed light on the membrane differences between the 
cellulose dialysis membrane and the hairless mouse skin. 
 
Firstly, the cumulative amounts of midazolam released from PG and ISA 
organogels differed significantly in permeation study while they are almost the 
same in the release study. PG is a co-solvent type chemical penetration 
enhancer (CPE), and limonene is a terpene CPE. Both of them are effective 
CPEs for enhancing the permeation of propofol from organogel as reported. As 
both PG and limonene can enhance the permeation of lipophilic and hydrophilic 
drugs, permeation of midazolam was also significantly increased by altering the 
structure of stratum corneum in the hairless mouse skin. As there is no report on 
permeation enhancement by ISA, it is not considered as a CPE. Therefore, in 
ISA organogel, 2.5% v/v limonene could enhance the permeation of midazolam, 
but exerted less enhancement than that achieved by the combined enhancement 
effect of PG and limonene in the PG organogel. 
 
The second difference was the release pattern of the drugs. The release of 
midazolam from the organogels followed Higuchi model (Fig. 5.10 a) but 
changed to zero-order in permeation study (Fig. 5.11 a). The release of propofol 
was zero-order (Fig. 5.10 b) and changed to a typical in vitro transdermal 
permeation profile that was non-Fickian (Fig. 5.11 b). The changes of drug 
release patterns between release study and permeation study may be 
substantially attributed to the membrane properties of the dialysis membrane 
and hairless mouse skin. Assuming that the dialysis membrane did not change 
structurally during the 48-hr release studies, the decreased release rate of 
midazolam from nanoparticulate organogel was due to a finite amount of 




dense organogel network. However, in the 48-hr permeation study, the skin 
structure changed with time due to skin hydration and permeation enhancement 
by PG and limonene. The skin surface environment also influenced PLGA 
nanoparticles as PLGA are subjected to bulk erosion at acidic and neutral pH 
values (von Burkersroda et al., 2002), thus releasing more midazolam at the 
surface of the skin. As such, form the release patterns (Fig. 5.10) and the 
permeation pattern (Fig. 5.11) of midazolam and propofol, it would seem that 
drug release was more sustained in the permeation study. The midazolam 
reservoir on the skin furrows and in the hair follicles delivered sustained release 
of midazolam over 48 hr. Propofol release rate also increased through the skin 
compared to its zero-order release through the dialysis membrane.  
 
In order to check whether there is a possibility to further increase midazolam 
permeation amount by increasing the concentration of midazolam nanoparticles 
in organogel, permeation studies of nanoparticulate organogels containing 
different concentrations of midazolam nanoparticles were performed. 
 
Fig. 5.12 shows that increasing midazolam nanoparticle concentration in 
organogel yielded significant increase of drug permeation. With an increase in 
midazolam concentration of 2.67 fold, the flux of midazolam permeation 
increased 2.84 fold, indicating that the increase in nanoparticle concentration 
was proportional to, or at least positively correlated to, the increase in 
permeation flux. Therefore, addition of more midazolam nanoparticles into 
organogel could increase the permeation of midazolam but its stability would 






Fig. 5.12. In vitro permeation profile of midazolam through hairless mouse skin 




5.2.5.2 In vitro permeation of midazolam (free-drug) propofol organogels 
 
In order to justify the application of midazolam nanoparticles instead of directly 
incorporating free drug midazolam into the organogel, in vitro permeation study 
of organogel containing midazolam as free drug through hairless mouse skin 
was performed. The concentration of free drug midazolam added into organogel 
was the same concentration as contained in the midazolam nanoparticles. 
 
Fig. 5.13 shows the permeation profiles of midazolam propofol organogel 
which is absence of nanoparticles. It is demonstrated that between 
nanoparticulate organogels and nano-free organogels, propofol permeation 
profile shows insignificant difference (Fig. 5.13 b), while midazolam 
permeation profile shows significant variances in flux and release patterns. In 





Fig. 5.13. In vitro permeation of midazolam (nano-free) propofol organogels in 










nano-free organogel in midazolam release. In addition, the zero-order 
permeation of free midazolam changes to a Higuchi pattern. The differences in 
permeation of midazolam from nanoparticles and as free drug indicate 
improvement on sustained release and permeation profiles of the 
nanoparticulate organogel. This could be due to the accumulation of 
nanoparticles on skin furrows and in hair follicles which could cause high 
regional concentrations of midazolam and formation of many small drug 
reservoirs on the surface of the skin. High total surface area and high 
thermodynamic activity of nanoparticles could have also contributed to the 
increase in drug permeation (Joo et al., 2008). Alvarez-Roman and co-workers 
also (2004) found that PLGA nanoparticles significantly increased the in vitro 
permeation of a highly lipophilic compound octyl methoxycinnamate through 
porcine ear skin compared to a non-particulate formulation at the same 
concentration without detectable permeation. In conclusion, the novel MNP 
organogel provided an excellent release and permeation profile in in vitro 
model through dialysis membrane and hairless mouse skin with a potential to 
further increase midazolam permeation by adding more midazolam 
nanoparticles, which is promising in further in vivo study and clinical research. 
 
5.2.6 Characterisation of the rheological parameters of MNP organogels 
 
In any topical or transdermal formulation, there is a need to characterise and to 
modify the rheology of the system in order to achieve: (1) long-term physical 
stability by avoiding creaming or sedimentation and separation; and (2) ease 
of application, mainly bioadhesion and spreadability (Tardos 2010).  
 
Three parameters are essential for the determination and prediction of 
long-term physical stability: (1) elastic modulus (G’, Pa), characterising the 




system; (2) viscous modulus (G’’, Pa), characterising the viscous (plastic) 
behaviour, representing a quantity of irreversibly lost energy; and (3) yield 
value (Pa), which is the crossover point of G’ and G’’ curves in amplitude 
sweep profile, indicating the minimum shearing or normal stress required to 
produce continuous deformation in a semisolid (Dragicevic-Curic et al., 2010; 
Gašperlin et al., 1998). The yield value is an important indicator in the 
stability evaluation because a good correlation was established between the 
yield value and the elastic parameters (Tamburic and Craig, 1996). The three 
parameters can be obtained in one graph by the amplitude sweep analysis of 
the samples. A typical result of amplitude sweep analysis of MNP organogel is 
shown in Fig. 5.14. The G’ and G’’ values are stable in the range of 5 to 20 Pa 
for shear stress. So the G’ and G’’ values are estimated by the average values 
of points in this range. The yield value is the crossover point of G’ and G’’, 
which is calculated by the RheoWin
®
 software.  
 








A flow curve is crucial to provide the information of whether a semisolid has 
good spreadability. Fig. 5.15 is the flow curve of MNP organogel. It can be 
seen that when the shear rate increases, the viscosity drops significantly and 
rapidly, which is called “shear-thinning”. Shear-thinning is a desirable 
property of semisolid dosage forms for good spreadability and good “skin 
feel”, since they should be “thin” during application and “thick” otherwise. 
During storage, organogels can maintain their plastic behaviour, which is a 
desirable characteristic of the consistency of topical formulations. The flow 
curve also demonstrates a plastic behaviour of the MNP organogel, indicating 
that the nanoparticulate organogel network exhibited resistance to an external 
force before it started flowing. During storage, nanoparticulate organogels 
maintained plastic behaviour, which is a desirable characteristic of the 
consistency of topical formulations (Dragicevic-Curic et al., 2010).  
 







5.2.7 Stability of MNP organogel 
 
Drug-loaded nanoparticles exist in final products either in dry powder or 
suspension form. MNP organogel is essentially a semisolid nanoparticle 
suspension. Nanoparticles are thermodynamically unstable due to the large 
specific surface area and high surface energy. Many reported stability concerns 
of nanoparticle suspensions arise from drug-loaded nanoparticles that are 
dispersed in a medium with or without stabilisers. Stability issues associated 
with nanosuspensions have been widely investigated and can be categorized as 
physical and chemical stability.  
 
5.2.7.1 Physical stability 
 
The PLGA nanoparticles are reported to be physically unstable due to 
sedimentation/creaming, agglomeration, crystal growth and change of 
crystallinity state (Wu et al., 2011).  
 
The sedimentation rate can be described by Stokes’ Law, in which medium 
viscosity is inversely proportional to the sedimentation rate. The semisolid 
organogel medium possessing high viscosity makes the sedimentation rate 
probably negligible to nanoparticles.  
 
The large specific surface area of nanoparticles leads to high total surface 
energy, which is thermodynamically unfavourable. Therefore, the nanoparticles 
tend to agglomerate to minimise the surface energy. Agglomeration can cause a 
variety of issues for nanosuspensions including crystal growth, rapid 
settling/creaming and inconsistent dosing. The most common strategy to tackle 
this issue is to introduce stabilisers into the formulation. The two main 




and non-aqueous media are electrostatic repulsion and steric stabilisation (Wu 
et al., 2011). PVA is a stabiliser which can increase negative charges on the 
surface of PLGA nanoparticles via its numerous dissociated hydroxyl groups. 
Moreover, the branched network in the organogel could confer steric 
stabilisation as it can be seen from SEM that it is quite densely distributed and 
occupied most of the space in the organogel. However, the PLGA nanoparticles 
were likely to agglomerate when subjected to high temperature during the 
preparation of the nanoparticulate organogel. 
 
Crystal growth in colloidal suspensions is a thermodynamically-driven 
spontaneous process, which is known as Ostwald ripening and is responsible for 
changes in particle size and size distribution. Oswald ripening originates from 
the solubility dependence of particles on their size. Small particles have higher 
saturation solubility than larger ones according to Ostwald–Freundlich equation, 
creating a drug concentration gradient between the small and large particles. 
Ostwald ripening is essentially a process where smaller crystals or sol particles 
dissolve, and redeposit onto larger particles, leading to a shift in the particle size 
and size distribution of the colloidal suspension to a higher range (Wu et al., 
2011; Kabalnov, 2001; Taylor, 1998). A narrow particle size distribution, 
stabilisers and low temperature can help to inhibit Ostwald ripening (Madras 
and McCoy, 2003). Van Eerdenbrugh and teammates (2008) demonstrated that 
Ostwald ripening was highly dependent on temperature by exploring TPGS 
(D-α-tocopherol polyethylene glycol 1000 succinate) stabilised 
nanosuspensions of 9 drug candidates. Following 3-month storage at room 
temperature, Ostwald ripening occurred in 8 out of 9 nanosuspensions studied. 
Enhanced Ostwald ripening was observed at 40 °C storage, while lowering 
temperature to 4°C slowed down or even stopped Ostwald ripening effects. 
 




states. The high energy top-down manufacturing techniques tend to create 
partially amorphous nanosuspensions and some bottom-up techniques can 
create completely amorphous particles. The high energy amorphous particles 
are unstable and inclined to convert to low energy crystalline state over time. 
Usually amorphous nanoparticles become highly unstable in the presence of 
small amounts of crystalline particles, although a few amorphous 
nanosuspensions have been demonstrated to be stable over a certain period of 
time (Wu et al., 2011). However, further study on whether midazolam remains 
in a crystalline phase or an amorphous phase within the nanoparticles 
throughout the PLGA is needed. 
 
5.2.7.1.1 Visual inspection of MNP organogel 
 
Visual inspection is the most direct approach to check the physical changes of 
the formulations for the surface characteristics, the homogeneity phase 
separation and the colour of an organogel. 
 
ISA organogels at 4°C and 23°C showed unchanged appearance after 1 month 
storage, while ISA organogel at 40°C became drier on the surface with a less 
yellowish colour. PG organogel remained unchanged in physical appearance at 
4°C after 1 month, while PG organogels at 23°C and 40°C showed drier 
surfaces with a less yellowish colour. Therefore, after 1 month, ISA organogels 
at 4°C and 23°C and PG organogels at 4°C showed no change in physical 
appearance. The surface drying could be the loss of the solvent in organogels 
due to evaporation. The change in colour to a lighter yellow could also indicate 
loss of propofol from organogels by evaporation. After storage at 4°C for 6 
months, both ISA and PG organogels showed no sedimentation or phase 
separation. The appearances were the same as those at Month 1. Therefore, it 




months without any significant change in physical appearance. 
 
5.2.7.1.2 SEM images of MNP organogel 
 
In Fig. 5.16 (a), big particles (3 - 5 m in diameter) appeared in ISA organogel 
after storage at 23°C for a month and a large number of big particles existed at 
40°C. No significant size and morphology changes were observed for samples 
stored at 4°C. These big particles could be formed by Ostwald ripening. In Fig. 
5.16 (b), big particles with a severe aggregation of nanoparticles appeared in 
PG organogel after a month at 40°C. Slight particle size increase can be 
observed for samples stored at 23°C for 1 month. Particles stored at 4°C 
showed insignificant changes after 1 month. 
 
Fig. 5.16. SEM images of freeze-dried MNP organogels. (a) ISA organogels 
after 1-month storage at 3 temperatures; (b) PG organogels after 1-month 












In Fig. 5.16 (c), nanoparticles in ISA and PG organogels showed insignificant 
changes of size and morphology after 6-month aging at 4°C. The emergence of 
big particles at 40°C was also reported by Van Eerdenbrugh et al. (2008) 
compared to stable samples stored at 4°C. PVA may not have caused the 
aggregation of nanoparticles (De and Robinson, 2004; Sahoo et al., 2002). 
From our study, high temperature caused aggregation of nanoparticles. De and 
Robinson (2004) also reported that the average size monitored by SEM of 




with temperature from 266.9 ± 2.8 nm to 1865.9 ± 67.0 nm. They suggested that 
PLGA nanospheres should be stored at 4°C. Therefore, midazolam 
nanoparticles in ISA and PG organogels did not change in size and morphology 
after 6-month storage at 4°C. 
 
5.2.7.1.3 Rheological behaviour of MNP organogel 
 
As discussed in Section 5.2.6, changes in the rheological behaviour of the gel 
can indicate the kinds of instability in the semisolid system that may not be 
noticeable by visual observation. G’, G’’ and yield value are used as three 
parameters to indicate the physical stability of the semisolid system. As shown 
in Fig. 5.17, it is obvious that after 6-month storage at 4°C, the 3 parameters of 
MNP organogel remained stable. Together with the visual observation and 
SEM data, we postulate that the formulation of MNP organogel in PG solvent 
would be physically stable over 6 months when kept at 4°C. 
 





5.2.7.2 Chemical stability 
 
While physical stability is a common concern for nanosuspensions and 
semisolids, chemical stability is drug specific. As midazolam nanoparticles are 
dispersed in the organogel system, chemical reaction is less likely compared to 
solution-based formulations. Therefore, MNP organogel would be more stable 
than MNP suspension.  
 
5.2.7.2.1 Chemical stability of midazolam nanoparticles in suspensions  
 
The midazolam-loaded nanoparticles were suspended in ISA/PG. Drug was 
released into the solvent at Day 0 because of burst release from dissolution of 
drug absorbed on the surface of nanoparticles. During storage, midazolam in 
the nanoparticles could have diffused into the solvent or be released by 
degradation and bulk erosion of the nanoparticles, which would transform the 
MNP organogel into a midazolam propofol organogel, thereby lowering the 
release rate of midazolam (as discussed in Section 5.2.5.2).  
 
 
It is indicated in ICH: Guidance for Industry Q1A(R2) Stability Testing of New 
Drug Substances and Products (2003), ± 5% in drug content variation is the 
limit of drug stability test. It is demonstrated in Fig. 5.18 that midazolam 
content changed more than 5% when stored for 7 days at 40°C and 28 days at 
23°C in both ISA and PG. But there was no significant drug release into the 
solvents when kept at 4°C for 6 months. The results indicate that there was a 
continuing release of midazolam into the solvent due to diffusion as well as 
possible nanoparticle degradation and erosion. And the release rates increased 
with temperature, which is the same trend with some studies (Rawat and 
Burgess; 2011; Wischke and Schwendeman, 2008). It was reported that, at 




diffusion coefficient may increase by as much as three orders of magnitude 
(Agrawal et al., 1997), which explain the high drug release after 7 days at 40°C. 
The degradation of PLGA increased with increasing storage temperature and 
water content. The hydrolysis of PLGA may be accelerated in the presence of 
hydrogen-bond donating functional groups. Dong and colleagues (2006) 
reported that PLGA was stable in oily suspensions at 4°C and degraded only 
slightly faster than solid powder at 25°C. PLGA underwent a slight degradation 
at 4°C after 150 days in water and saturated sodium chloride solution. These 
findings agree with our results that PLGA nanoparticles were stable in 
non-aqueous suspensions at 4°C. 
 
Fig. 5.18. Midazolam release from midazolam nanoparticles in PG and ISA 
suspension in the presence of limonene and propofol. Each point on the curve 
represents the ratio of midazolam released from specific storage time over 








5.2.7.2.2 Chemical stability of MNP organogel 
 
As discussed in Section 5.2.7.2.1, the midazolam from the midazolam-loaded 
nanoparticles are unlikely to diffuse into the organogel matrix at 4°C within 6 
months. However, it needs further investigation to check the variations of drug 
contents of midazolam and propofol during storage.  
 
Fig. 5.19. Drug contents of midazolam (MID) and propofol (PRO) in MNP 
organogel when stored at 4°C for 6 months. Each point on the curve represents 
the ratio of drug released from specific storage time over drug released in Day 0 
(n = 3). 
    
 
Fig. 5.19 shows that after 180-day storage at 4°C, the midazolam and propofol 
contents were insignificantly changed in the nanoparticulate organogel. No 
new peak appeared in the HPLC analysis graphs when compared with the Day 
1 analysis. Therefore, it can be concluded that MNP organogel was chemically 
stable at 4°C over 6 months. 
 
5.2.7.3 Summary of MNP organogel stability study 
 
The results of stability tests of the two organogel vehicles at different 
temperatures are collected in Table 5.4. After comparing 3 parameters, only 




are considered unstable. As the PG organogel provide better permeation 
enhancement and less greasy appearance compared to ISA organogel, the 
MNP organogel in PG matrix was selected as the preferred formulation. 
 
Table 5.4. Summary of 6-month stability tests of MNP organogel. 
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This study reports for the first time a formulation of nanoparticulate organogel, 
which is a novel vehicle for transdermal drug delivery. Two drugs with 
synergistic effect on sedation were incorporated into the MNP organogel. 
Midazolam nanoparticles were first prepared and optimised, attaining a high 
encapsulation efficiency of 91.9 ± 1.7% and a very high drug loading of 45.4 
± 3.0%, which could be due to interactions between the drug and the polymer. 
These nanoparticles have an average size of 574.3 ± 22.9 nm, with a moderate 
size distribution. Freeze-drying was shown to facilitate the formation of 
nanoparticles compared to air-drying. To avoid degradation of midazolam 
nanoparticles by heat, they were incorporated into the organogel at 60°C 
followed by rapid water cooling. The nanoparticulate organogels were 




drug release of both midazolam and propofol. PLGA nanoparticles may 
interact with the skin to facilitate the release of midazolam. PG organogel 
yielded better drug release profile than ISA organogel. After physical and 
chemical stability studies of MNP organogels at 3 temperatures over 6 months, 






6. Isothermal Titration Calorimetry (ITC) study 
 
Farnesol is shown to be a suitable terpene penetration enhancer. Many studies 
have been carried out on penetration enhancement mechanisms, but few 
reported the application of ITC to unravel the interactions between small 
molecules, especially interactions between stratum corneum lipids and CPEs. 
This chapter demonstrates the mechanism of interaction between farnesol and 
human skin lipids. 
 




Propylene glycol (PG) (99.5%), palmitic acid, lignoceric acid, eicosanoic acid, 
and cholesterol were purchased from Sigma Aldrich (Steinheim, Germany) 
(Purity 99%). Ceramide [EOS] (CER[EOS]), ceramide [NP] (CER[NP]), 
ceramide [AP] (CER[AP]) were obtained as gifts from Cosmoferm BV (Delft, 
The Netherlands). Farnesol (95%) was purchased from SAFC Supply Solutions 
(St Louis, MO). Isopropyl alcohol (IPA) (99.8%) was purchased from Tedia 
(Ohio, USA). All the materials were used as supplied. 
 
6.1.2 Solubility tests of stratum corneum lipids in PG solution 
 
The solubilities of the lipids in PG were determined via trial and error. The 
lipids were weighed and transferred into a 10 ml volumetric flask. The solvent 
(propylene glycol) was filled in and a magnetic stirrer was added into the 






Plastic, Chicago) to avoid evaporation. The flask was then placed in a water 
bath at 37°C, keeping the water level above the meniscus of the liquid inside the 
flask. The magnetic stirrer was operated at 1200 rpm for 3 days. 
 
After every 6 - 8 hr, the sample was observed with the naked eyes under light to 
determine if the lipids were completely dissolved. The flask was flipped 
backward and forward a few times a day to make sure that any particle residing 
on the wall of the flask would be completely dissolved. The concentration at 
which the lipid particles cannot be detected by the naked eyes was taken as its 
solubility. Tests were performed in triplicate. 
 
6.1.3 Isothermal titration calorimetry experiments 
 
Isothermal titration calorimetry was performed using Thermal Activity Monitor 
2277 calorimeter (Thermometric AB, Sweden) equipped with 4-ml stainless 
steel ampoules. Two reactions were first conducted to validate isothermal 
titration calorimetry: the reaction between barium chloride and 
18-crown-6-ether and the reaction between HEPES 
(2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid) buffer and sulphuric 
acid (Wadsö et al., 2001).  
 
Table 6.1. ITC experiment sets. 
Set FAR as titrant Titrand Solvent 
A 183.62 mM  5.17 mM cholesterol PG 
B 276.86 mM  7.80 mM palmitic acid PG 
C 2.27 mM 64.00 mM eicosanoic acid IPA 
D 259.45 mM   7.31 mM CER[AP] IPA 
 
ITC experiments were conducted according to Table 6.1. In all cases, farnesol 
solution was formulated at a molar ratio of 71:2 to the respective lipid solution. 




thus to increase the reproducibility of the ITC tests as both are very slightly 
soluble in PG (less than 0.1 mg/ml).  
 
A 0.12 ml of farnesol solution was titrated consecutively into 2.7 ml of lipid 
solutions by 15 aliquots. The lipid solution was stirred at 60 rpm and the 
system’s temperature was maintained at 36.94°C. Two control experiments 
were done by titrating farnesol solution into the solvent and titrating the solvent 
into the lipid solution. The titration heat changes were then analysed using the 
Digitam
®
 software (Scitech Software, Sweden).  
 
The control experiments account for the dilution heats of farnesol and lipid as 
well as other non-specific heat. Hence, binding heat between farnesol and the 
stratum corneum lipid could be derived from the subtraction of the measured 
heat with that of the control experiment. The area under each peak is 
proportional to the fraction of reacted lipid. The binding stoichiometry (n), 
binding constant (K), and enthalpy change (ΔH) are estimated using Digitam®’s 
non-linear regression analysis on the calorimetric titration curve of the 
corrected heat effect. The standard Gibbs free energy (ΔG) and entropy change 
(ΔS) are then derived using the following equations: 
ΔG = -RTlnK              (6.1)  
ΔG = ΔH-TΔS             (6.2) 
 
6.2 Results and discussion 
 
6.2.1 Enhancement of lipid solubility with addition of farnesol 
 
Figure 6.1 shows the solubilities of stratum corneum lipids in PG with/without 5% 




soluble among all tested lipids without farnesol. A decrease in solubility was 
observed with the increase of carbon chain length of the fatty acids. Ceramides 
are generally very slightly soluble in propylene glycol. This correlates well with 
the reported characteristics of ceramides towards the skin barrier properties. 
After adding 5% v/v farnesol, the solubilities of stratum corneum lipids 
increased, particularly that of palmitic acid which exhibited an increase of 
nearly 641%. The increment in solubilities decreased as the carbon chain 
lengths of the fatty acids increased such that lignoceric acid displayed a small 
increase of 23%. Enhancement of the solubility of ceramide was observed but it 
was not as significant as those of the fatty acids. The solubility of cholesterol in 
propylene glycol increased approximately two fold with the addition of 
farnesol.  
 
Fig. 6.1. Solubility of lipids in propylene glycol and propylene glycol with 5% 
v/v farnesol. C16 = palmitic acid [C16:0], C20 = eicosanoic acid [C20:0], C24 = 
lignoceric acid [C24:0], CHO=cholesterol. Tests were done in triplicates. 
 
 
Kang and co-workers (2005) presented in their study that farnesol could 
increase permeation of haloperidol by 12 fold. Considering our research, it 
appears that the loss of short-chain lipids enhanced skin permeability while the 




remained intact as part of the skin barrier. As free fatty acids, also one category 
of CPEs, are known to retain the lipid organisation and increase the lipid density 
of the stratum corneum lipid lamella, they may also increase stratum corneum 
permeability by inducing a phase transition and/or loosening the lipid lamella. 
Since a change in the molar ratio of cholesterol to ceramide may affect the skin 
barrier function (Bouwstra et al., 2003) and solubility of cholesterol in PG was 
higher than that of ceramides in PG, the solubilisation of cholesterol by PG 
could have contributed to the phase transitions of the stratum corneum lipids. 
 
6.2.2 Isothermal titration calorimetry experiments 
 
Figure 6.2 shows the non-linear regression analysis of the isothermal titration of 
farnesol into various stratum corneum lipid solutions. The Digitam
®
 software 
results showed that two farnesol molecules bind to one palmitic acid molecule 
while two eicosanoic acid molecules bind to one farnesol molecule. No 
interactions were observed between farnesol and cholesterol or CER[AP]. The 
binding between palmitic acid and farnesol and the binding between farnesol 
and eicosanoic acid were spontaneous processes with a negative Gibbs free 
energy change at 37°C. Moreover, both displayed positive enthalpy and entropy 
changes upon titration of farnesol, indicating that they were enthalpically 
opposed (endothermic) but entropically favoured. Formation of hydrogen 
bonds between the molecules may be the main mechanism of interactions 
between farnesol and the free fatty acids, as palmitic acid and eicosanoic acid 
both possess carboxyl groups that could interact with farnesol molecules via 
hydrogen bonding. 
 
Combining the results of solubility tests and ITC experiments, it was found that 
both palmitic acid and eicosanoic acid displayed solubility enhancement and 




Fig. 6.2. Non-linear regression analyses to estimate the binding stoichiometry 
(N), the binding constant (K), and the enthalpy change (ΔH) with software 
Digitam
®
. (a) Titration of farnesol into cholesterol using propylene glycol as 
solvent. Tests were done in duplicate. (b) Titration of farnesol into eicosanoic 
acid using isopropyl alcohol as solvent N = 2, K = 779.64 m
-2, ΔH = 1.49 kJ/mol, 
ΔG = -17.16 kJ/mol, ΔS = 60.15 J/mol. Tests were done in triplicates. (c) 
Titration of farnesol into palmitic acid using propylene glycol as solvent. N = 2, 
K = 1.20 × 10
3
 m
-2, ΔH = 6.91 kJ/mol, ΔG = -18.28 kJ/mol, ΔS = 36.69 J/mol. 
Tests were done in duplicates. (d) Titration of farnesol into CER[AP] using 













formed were more disorderly and had higher solubilities in PG with addition of 
farnesol, suggesting that farnesol gave rise to lipid extraction and/or triggered 
lipid phase transition of the stratum corneum lamella, where the lipid molecules 
are in crystalline or liquid crystalline phase. Although farnesol enhances the 








ITC is a useful technique to investigate the interactions between small 
molecules. Our study revealed the possible penetration enhancement 
mechanism of farnesol, which is a commonly used terpene CPE. Farnesol in PG 
exerted its penetration enhancement effects by interacting mainly with the free 
fatty acids, leaving the cholesterol and ceramides less disturbed. The 
elucidation of this mechanism explained the lower irritancy of farnesol as it 
leaves the barrier function of the stratum corneum comprising mainly of 







7. Conclusion  
 
The thesis focused on the incorporation of CPEs into novel topical and 
transdermal formulations to achieve enhancement of percutaneous permeation 
of existing sedative, analgesic and anaesthetic drugs with possible 
improvements for unmet medical needs. 
 
7.1 Amitriptyline hydrogel 
 
The amitriptyline hydrogel has the potential to treat peripheral neuropathic 
pain. Menthol was found to be an efficacious enhancer for the in vitro 
permeation of amitriptyline through the human epidermis and 2% w/v menthol 
was sufficient to achieve the needed flux. Limonene and Tween 80 were also 
suitable penetration enhancers for amitriptyline. The amitriptyline hydrogel 
was found to be stable using an accelerated test over 30 days. From the ITC 
study, the permeation enhancement mechanism of menthol showed that 
menthol formed a complex with amitriptyline by hydrophobic interactions. 
 
7.2 Amitriptyline and ketamine hydrogel 
 
This is the first reported formulation development of amitriptyline and 
ketamine hydrogel with the incorporation of CPEs for the local treatment of 
peripheral neuropathic pain. Farnesol 0.5% v/v yielded the highest drug 
permeation enhancement when incorporated in the hydrogel. The amitriptyline 
and ketamine hydrogel was stable after 6-month storage at 4°C. The 
LC/MS/MS assay was established and validated for simultaneous detection of 
amitriptyline and ketamine. The pharmacokinetic and tissue distribution 
studies demonstrated that topical application of the hydrogel resulted in 




high drug concentrations in the surrounding skin and muscle tissues, which are 
the target sites for neuropathic pain.  
 
7.3 Propofol organogel 
 
PG significantly enhanced in vitro permeation of propofol both in PG-propofol 
solution and PG-propofol organogel. Limonene, farnesol, and carvone also 
provided effective enhancement of the formulation developed. The most 
promising propofol organogel contained 2.5% v/v limonene. It achieved 
approximately 34-fold permeation enhancement of propofol, compared to the 
dermal application of 100% propofol.  
 
7.4 Midazolam nanoparticulate propofol (MNP) organogel 
 
This study reports for the first time a formulation of nanoparticulate organogel, 
which is a novel vehicle for transdermal drug delivery. Midazolam and 
propofol with synergistic effect on sedation were incorporated into the MNP 
organogel. Midazolam nanoparticles attained a high encapsulation efficiency 
of 91.9 ± 1.7% and a high drug loading of 45.4 ± 3.0%. These nanoparticles 
have an average size of 574.3 ± 22.9 nm, with a moderate size distribution. 
Freeze-drying was shown to facilitate the formation of nanoparticles compared 
to air-drying. Midazolam nanoparticles were incorporated into the organogel 
at 60°C followed by rapid water cooling to avoid degradation. The in vitro 
release and permeation studies of MNP organogels showed controlled release 
of both drugs as the PLGA nanoparticles could have formed depots on the skin 
surface to facilitate the release of midazolam. After physical and chemical 
stability studies of MNP organogels at 3 temperatures over 6 months, MNP 





7.5 Isothermal Titration Calorimetry (ITC) study 
 
The ITC study of farnesol with human skin lipids revealed that farnesol 
interacted mainly with the free fatty acids, leaving the cholesterol and 
ceramides less disturbed, which explained the reports on the comparatively 
low dermal irritancy and higher permeation enhancing effect of farnesol 




This thesis has contributed new knowledge on the following aspects: (1) 
Alternative route of administration via the skin to treat peripheral neuropathic 
pain and procedural sedation; (2) Selection of CPEs to improve the in vitro 
percutaneous permeation of amitriptyline, ketamine, propofol and midazolam; 
(3) Novel amitriptyline and ketamine hydrogel containing CPE that was tested 
on in vitro and in vivo models and found to be stable; (4) First reported 
pharmacokinetic and tissue distribution profiles of topical delivery of 
amitriptyline and ketamine; (5) Novel midazolam nanoparticulate propofol 
organogel containing CPE that was tested on in vitro permeation model and 
found to be stable; and (6) Elucidation of the molecular mechanisms of 








8. Future work 
 
The possible synergistic effect of amitriptyline on the absorption of ketamine 
will be tested in vitro for the deeper investigation of the permeation 
mechanism enhancement in the amitriptyline and ketamine hydrogel. 
 
Pharmacodynamic study using the common neuropathic pain rat model is 
needed to evaluate the in vivo efficacy of the amitriptyline and ketamine 
hydrogel (Feng et al., 2009). Behavioural tests can be performed to 
quantitatively investigate thermal and mechanical hypersensitivity and 
allodynia which indicate the efficacy of the formulation. 
 
A comparison of commonly used marketed products EMLA cream, capsicin 
cream and our amitriptyline and ketamine hydrogel will be performed both in 
vitro and in vivo to test the possible superiority of the incorporation of CPEs. 
 
Due to the insufficient permeation flux of propofol from the midazolam 
nanoparticulate propofol organogel, other delivery enhancing techniques 
besides the use of chemical penetration enhancers, such as microneedles and 
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